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1.1 Synopsis of Thesis 
Cardiovascular disease remains a major cause of mortality and morbidity and is underpinned 
by Oxidative stress, within which, inactivation of nitric oxide (NO) by superoxide (SO) and 
other reactive oxygen species is characteristic. Two major enzyme systems are implicated 
within oxidative stress; NAD(P)H oxidase and endothelial nitric oxide synthase (eNOS). eNOS 
generates NO while at the same time, and within the same cells, NAD(P)H plays a powerful 
role in the generation of SO. Evidence is accumulating that polymorphisms of the genes 
encoding these enzyme systems may play an important role in the pathophysiology of CAD. 
Additionally there has been much recent interest in both biochemical markers of oxidative 
stress and low grade chronic inflammation as well as a non invasive vascular phenotype, pulse 
wave analysis. This thesis reports a series of studies (utilising the techniques described in 
chapter 2) which aimed to ascertain:- 
  The reproducibility of pulse contour analysis as a non invasive intermediate 
cardiovascular phenotype (Chapter 3). 
  Whether common single nucleotide polymorphisms of the p22phox gene CYBA and  
the endothelial nitric oxide synthase gene, NOS3, have an effect upon arterial compliance in 
patients with coronary artery disease (Chapters 4,5 and 6). 
  In healthy volunteers, free of cardiovascular disease whether a relationship existed 
between markers of low grade inflammation and arterial stiffness (Chapter 7). 
 
Chapter 3: The reproducibility of diastolic pulse wave contour analysis and its relation to 
systolic pulse contour analysis. 
This clinical study demonstrated that both large (C1) and small artery (C2) compliance values 
were reproducible and that there was a significant correlation between both Augmentation 
Index (AIx) and C1and AIx and C2 in healthy volunteers and though there was no association   3 
between AIx and C1 in patients with coronary artery disease AIx did correlate with C2 in this 
population. 
 
Chapter 4: The effect of the G894T SNP of the NOS3 gene upon arterial stiffness in 
patients with coronary artery disease. 
There was no association observed between this polymorphism and blood pressure or large 
artery compliance however ANOVA revealed a statistically significant association for TT 
homozygosity and small artery compliance. The highest small artery compliance was seen in 
the patients homozygous for the G allele, an intermediate value observed in heterozygotes and 
the lowest value demonstrated in patients homozygous for the T allele. Multiple regression 
analysis, examining the possible contribution of confounders showed that only small artery 
compliance was significant when NOS3 G894T genotype was assigned as the dependent 
variable. 
 
Chapter 5: The C242T single nucleotide polymorphism of the CYBA gene and blood 
pressure and arterial compliance in patients with coronary artery disease. 
We sought to examine the influence of the C242T SNP of CYBA upon vascular compliance and 
blood pressure using the dominant allele model. The presence of the 242T allele was associated 
with significantly higher systolic blood pressure. Patients homozygous for the C allele had 
lower systolic blood pressure than heterozygotes and patients homozygous for the T allele. 
There was no statistically significant effect upon diastolic blood pressure but there was 
however a significant association observed between the 242T allele and pulse pressure.  
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Chapter 6: Combined analysis of NOS3 G894T and CYBA C242T genotypes upon 
arterial stiffness. 
In order to contrast the arterial stiffness between the favourable versus the non-favourable 
genotypes patients homozygous for the NOS3 G allele and homozygous for the CYBA C allele 
were compared with those homozygous for the NOS3T allele and possessing the CYBA 242T 
allele. The former displayed higher large and small artery compliance than the latter group. 
Multiple regression analysis, examining the possible contribution of confounders showed that 
only the large and small artery compliance values contributed significantly when genotype was 
assigned as the dependent variable. 
 
Chapter 7 Chronic low grade inflammation and insulin resistance and arterial 
compliance in healthy volunteers. 
Within healthy volunteers multiple regression analysis showed that small artery compliance 
was significantly associated with IL 6, CRP and ICAM. Augmentation index showed only an 
association with ICAM1. There was no significant correlation between Adiponectin levels and 
either of the arterial stiffness parameters studied. 
 
Conclusions 
Diastolic pulse wave contour analysis is a reproducible assessment of arterial stiffness with the 
potential to represent a high fidelity non invasive vascular phenotype. 
 
Small artery compliance is correlated with Augmentation Index and although the 
measurements are not analogous they both represent useful means of acquiring quantitative 
data concerning arterial stiffness. 
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The 242T allele of the p22phox gene, CYBA, is associated with decreased large but not small 
artery compliance and increased systolic and pulse pressure. 
 
Homozygosity for a common NOS3 polymorphism (894 G T) was associated with decreased 
small artery compliance but not with large artery compliance or blood pressure. 
 
The markers of chronic inflammation Interleukin 6, ICAM and hsCRP but not Adiponectin, a 
marker of Insulin resistance, predict small artery compliance in healthy individuals apparently 
free of vascular disease. 
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C2       Small Artery Compliance 
CHD      Coronary Heart Disease 
CRP      C Reactive Protein 
CVD      Cardiovascular disease 
DBP      Diastolic Blood Pressure 
DPCA     Diastolic Pulse Contour Analysis 
eNOS      Endothelial Nitric Oxide Synthase 
HDL      High Density Lipoprotein 
IL-6      Interleukin 6 
L-NMMA    L-N
G-monomethyl arginine  
LDL       Low Density Lipoprotein 
MAP      Mean Arterial Pressure 
NADH/NAD(P)H   Nicotinamide Adenine Dinucleotide (phosphate) Oxidases 
NO      Nitric Oxide 
•O2
-        Superoxide 
PP       Pulse Pressure 
PWA      Pulse Wave Analysis 
PWV       Pulse Wave Velocity 
SBP      Systolic Blood Pressure 
sICAM-1    Soluble Intracellular Adhesion Molecule 1.   26 
SD      Standard Deviation 
SEM      Standard Error of the Mean 
SNP      Single Nucleotide Polymorphism 
SPCA      Systolic Pulse Contour Analysis 
UK       United Kingdom 
VNTR     Variable Number of Tandem repeats 
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1 Introduction 
 
Cardiovascular disease (CVD) is a designation for multiple pathologies underscored by 
atherosclerosis of which there are multiple clinical phenotypes. CVD is the main cause of death 
in the United Kingdom (UK) accounting for approximately 238,000 deaths per year: 39% of all 
deaths (BHF statistics at www.heartstats.org). The principle forms of CVD are Coronary Heart 
Disease (CHD) and stroke. CHD itself causes over 117,000 deaths per year in the UK: 
approximately 1 in 5 deaths in men and 1 in 6 deaths in women. It is the most common cause 
of premature death in the UK: 22% of premature deaths in men and 13% of premature deaths 
in women are from CHD. Over 1.2 million people in the UK have had a myocardial infarction 
and it is estimated that 2 million people are suffering from angina (www.heartstats.org). The 
aim of this thesis is to investigate non invasive intermediate vascular phenotypes that have a 
potential to be useful in the assessment of cardiovascular disease; namely pulse wave contour 
analysis and biochemical markers of inflammation. 
 
Conventionally risk stratification has rested upon traditional, established risk factors including 
smoking, poor diet, lack of physical activity, obesity, hypertension, hypercholesterolemia and 
diabetes mellitus. Genetic factors are increasingly recognised to predispose to CVD from 
studies that have provided long standing evidence that CVD clusters in families (Rose 1964). 
The advent of pulse wave analysis (PWA) as a non invasive vascular phenotype and increasing 
understanding of the importance of new surrogate markers of cardiovascular disease has 
introduced the capability of new ways of risk stratification and new methods of investigating 
the effect of genotype in CVD. It had previously been calculated that traditional risk factors per 
se may only explain approximately between 50%(Manson 1992) of the CHD risk but more 
recently this figure has been more accurately calculated as 80-90% (Khot 2003). A portion of   28 
risk however remains unexplained and it is timely to examine the association between genetic 
factors, biochemical surrogate markers as well as non invasive vascular phenotypes with CHD. 
 
The purpose of this thesis is to describe the relationship of genotypes of common oxidative 
stress gene polymorphisms upon these new vascular phenotypes. The introduction will seek to 
depict PWA as a useful non invasive cardiovascular phenotype, describe the common oxidative 
stress gene single nucleotide polymorphisms and their role in cardiovascular physiology and 
pathophysiology and clarify the potential function of biochemical markers of low grade 
inflammation and insulin resistance in CVD. 
1.1 Pulse Wave Analysis and Pulse Wave Velocity: Non-invasive vascular intermediate 
phenotypes. 
 
1.1.1 Introduction and historical perspective. 
Cardiovascular research has long searched for the holy grail of a non-invasive, high fidelity, 
reproducible technique to function as an intermediate phenotype facilitating mechanistic basic 
physiology, intervention and outcome studies. Returning to techniques first utilised over 100 
years ago has led to the development of methodology which may end this search. 
 
The arterial pulse waveform has been interesting clinical scientists since the end of the 19th 
century and the assessment of the arterial pulse remains a bedrock of basic clinical 
examination. Following the invention of the sphygmograph by Marey (Roy 1880) clinicians 
like Osler and Mohamed relied upon it heavily as a diagnostic tool (Sharpey 1866). Ultimately 
however the sphygmograph was superseded by the sphygmomanometer which was invented 
for recording blood pressure and used widely thereafter for clinical purposes. Technological   29 
advances now allow non-invasive acquisition of pressure pulse waveforms in a repeatable and 
reproducible manner. Early and consistent changes in the pulse contour occur with aging and 
cardiovascular risk factors and therefore descriptive analysis of the pulse contour may 
ultimately hold the potential to refine cardiovascular risk stratification and guide therapeutic 
interventions (McVeigh 2003). 
1.1.2 Why move beyond blood pressure? 
 
The Framingham Heart Study has generated important data on how systolic blood pressure 
(SBP) diastolic blood pressure (DBP) and pulse pressure (PP, the difference between SBP and 
DBP) change with advancing age (Franklin 1997). DBP is determined classically by peripheral 
arterial resistance and increases until middle age when it then tends to fall. SBP and PP, 
however, are influenced by the stiffness of large arteries, the peripheral pulse wave reflection 
and the pattern of left ventricular ejection and increase persistently with age. Changes in large 
artery (i.e. aorta or its major branches) stiffness accounts for the changes in SBP, DBP and PP 
observed from 50 years of age. The link between blood pressure and cardiovascular disease has 
been clearly established (Goldberg 1996), and SBP has been identified as having a greater 
predictive value for CHD than DBP in those aged over 60years (Kannel 1971, Franklin 2001a). 
Isolated systolic hypertension (ISH) where SBP is >140mmHG 140mmHg and DBP is <90 
mmHg is the most commonly observed form of hypertension in the elderly (Franklin 2001b) 
and is a major risk factor for stroke (Nielson 1995), coronary heart disease (Franklin 2001a) 
and total cardiovascular mortality (Antikainen 1998). Also recently the brachial artery PP, the 
chief determinant of which in the elderly is large artery stiffness, has emerged, albeit 
controversially (Prospective studies collaboration Lancet 2002), as an even more powerful 
predictor of CHD (Franklin 1999). 
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Hence with the integral part that altering arterial stiffness plays, not only in the ageing process 
but also, as will be discussed, with other risk factors for cardiovascular disease there is a 
growing appreciation that a better understanding of the mechanisms involved in generation of 
arterial stiffness will improve the treatment of hypertension and cardiovascular disease than 
that offered by simply measuring brachial BP. The ability to measure and monitor arterial 
stiffness would confer not only a useful research tool but also a clinical tool that will aid all 
levels of practitioners and physicians in diagnosis, treatment and possibly risk stratification. 
 
1.1.3 Arterial properties and arterial stiffness. 
 
Risk factors for cardiovascular disease mediate their effects by altering the structure, 
properties, and function of wall and endothelial components of arterial blood vessels (Gibbons 
1994).The ability to detect and monitor change in the physical properties of arteries, 
representative of the cumulative and integrated influence of heamodynamic, metabolic and 
inflammatory stimuli in impairing arterial wall integrity, holds potential to intervene at a 
preclinical stage to prevent or attenuate disease progression (McVeigh 2003).  
 
The elasticity of the arteries is not uniform and varies throughout different sites within the 
arterial tree. The elasticity of the proximal large arteries is the result of the high elastin to 
collagen ratio in their walls which steadily diminishes toward the periphery. The increase in 
arterial stiffness that occurs with increasing age (Hallock 1937) is largely due to progressive 
elastic fibre degeneration (Avolio 1998). The elasticity of a given arterial segment is not 
constant but depends on the distending pressure (Greenfield 1962). As distending pressure 
increases, there is greater recruitment of relatively inelastic collagen fibres (Roach 1957, Apter   31 
1967, Bank 1996) and consequently, a reduction in elasticity. The background level of 
distending pressure in the circulation is determined by mean arterial pressure (Oliver 2003).  
 
Elasticity is not only dependent on collagen and elastin but the endothelium (Kinlay 2001, 
McVeigh 2001, Wilkinson 2002a) and arterial wall smooth muscle bulk and tone (Bank 1996, 
Bank 1999) also contribute to elasticity. The latter is under control from the endothelium and 
the balance between the vascular smooth muscle cell derived free radical and superoxide (SO) 
and the endothelium derived nitric oxide (NO) will be discussed later in more detail. 
 
1.1.4 Genetics and arterial stiffness. 
 
Polymorphisms within genes that generate the components that define arterial structure and 
function have been related to arterial stiffness. Polymorphic variation in the fibrillin (Medley 
2002), angiotensin II type I receptor (Lajemi 2001a), and endothelin receptor genes (Lajemi 
2001b) have been associated with altered arterial stiffness. Additionally the angiotensin 
converting enzyme (ACE) I/D polymorphism has been associated, albeit inconsistently with 
vascular stiffness (Lajemi 2001a, Balkestein 2001). Thus putatively as eluded to above and to 
be discussed in more detail later in the introduction logically it could be hypothesised that 
allelic polymorphisms amongst genes involved in the oxidative stress pathway, whose products 
influence the relative bioactivity of NO and consequently vascular tone, may also influence 
vascular stiffness. 
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1.1.5 Generation of the arterial pulse wave and pulse pressure amplification. 
 
Left ventricular ejection pumps blood into the arterial tree but simultaneously creates a pulse 
pressure wave that travels in the arterial wall in an anterograde fashion until it reaches areas of 
bifurcation or other areas of impedance mismatch, mainly at high resistance arterioles, where a 
retrograde (reflected) waveform is initiated (Nichols & O‟Rourke 1998). The shapes of the 
arterial pulse waveforms vary at different sites, attributable to both varying elastic qualities 
along the arterial tree and to wave reflection. In healthy, young subjects without vascular 
disease mean arterial pressure (MAP) declines in the peripheral circulation but SBP and PP are 
amplified (Kroeker 1955), amplification which is accentuated during exercise and diminishes 
with increasing age (Rowell 1968, Wilkinson 2001). The wave form at the proximal aorta is 
critical as it is the BP profile here rather than the typically measured peripheral BP which 
determines left ventricular afterload and coronary blood flow. The contour and amplitude of 
the pressure waveform are influenced by large artery pulse wave velocity (PWV) as pressure 
waves of higher velocity arrive and are reflected from the peripheral circulation earlier. With 
compliant arteries and slow PWV, reflected waves return to the central aorta in diastole, 
augmenting DBP and subsequently coronary blood flow which occurs in diastole. On the 
contrary when arteries are less complaint and PWV fast, the reflected waves return earlier and 
augment central SBP, increasing left ventricular workload and compromising coronary blood 
flow (Bogren 1989, Ohtsuka 1994, Oliver 2003). 
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1.1.6 Definitions of parameters used to describe the static and dynamic qualities of the 
arterial tree. 
 
One of the problems in studying or discussing arterial stiffness is that it is a term which is 
imprecise and has been applied to a wide variety of different vascular parameters. These 
include arterial compliance, arterial distensibility (change in area or diameter of an artery 
resultant from a given change in pressure), elastic modulus (the change in stress for a given 
change in strain of the wall materials), volume elastic modulus, Young‟s modulus, PWV, 
characteristic impedance (the ratio of pressure and flow in an artery when pressure and flow 
waves are not influenced by wave reflection), stiffness index (β), capacitive compliance and 
oscillatory compliance as measures representative of the mechanical properties of arteries 
(O‟Rourke 1999, McVeigh 2002). Table 1.1 outlines definitions of commonly used indices that 
are used to generate quantitative estimates of arterial wall properties.   34 
Table .1.1 Definitions of the commonly measured indices of arterial stiffness. 
Parameter  Definition  Formula & Units 
Arterial Compliance 
 
Absolute diameter or area change for 
a given pressure step at fixed vessel 
length. 
ʔD/ ʔP(cm/mmHg or 
cm
2/mmHg) 
Arterial Distensibility 
 
Relative diameter or area change for a 
given pressure increment; the inverse 
of elastic modulus. 
ʔD/ ʔP x D (mmHg 
-1) 
Volume Elastic Modulus 
 
Pressure step required for a theoretical 
100% increase in volume where there 
is no change in length. 
ʔP/(ʔV/V) (mmHg)= 
ʔP(ʔD/D)(mmHg) 
Elastic Modulus 
 
Pressure step required for a theoretical 
100% increase in stretch from resting 
diameter at fixed vessel length. 
(ʔP x D/ʔD) (mmHg)· 
Young‟s Modulus 
 
Elastic modulus per unit area; the 
pressure step required per square 
centimetre for a theoretical 100% 
stretch from resting length (accounts 
for wall thickness).  
ʔP x D/(ʔD x h) 
(mmHg/cm)· 
Pulse Wave Velocity 
 
The speed at which the pulse wave 
travels along a defined arterial 
segment. 
Distance/ʔt (m/second) 
Pressure Augmentation 
 
Increase in aortic or carotid pressure 
after the peak of blood flow in the 
vessel. 
mmHg or % of pulse 
pressure 
Characteristic Impedance. 
 
Relationship between pressure change 
and flow velocity in the absence of 
wave reflections. 
(ʔP/ʔV)[(mmHg/cm)s] 
Stiffness Index. 
ʒ 
Ratio of logarithm (systolic/diastolic 
pressures) to (relative change in 
diameter). 
ʒ = In (Ps/Pd)/ [(Ds-
Dd)/Ds] 
(non dimensional) 
C1 Large Artery Elasticity 
Index/ Capacitative. 
 
Relationship between the decline in 
pressure and decline in volume in the 
arterial tree during the exponential 
component of diastolic pressure 
decay. 
(ʔV/ʔP) 
ml/mmHg x 10  
C2 Small Artery Elasticity 
Index/ Oscillatory or 
Reflective. 
Relationship between oscillating 
pressure change and oscillating 
volume change around the exponential 
component of diastolic pressure 
decay. 
(ʔP/ʔV) 
ml/mmHg x 100 
 
P = pressure, D = diameter, V = volume, h = wall thickness, t = time, s = systolic, d = diastolic. 
Adapted from Oliver 2003 & O‟Rourke 2002.   35 
1.2 Applanation tonometry, pulse wave velocity and pulse contour analysis. 
 
The technique of applanation tonometry detects the pressure pulse wave at a distinct 
anatomical site, for example the radial artery at the wrist by using a micromanometer tipped 
probe. The artery is compressed between the sensor and the underlying structures, and 
therefore the intra-arterial pulse pressure is transmitted through the arterial wall to the sensor. 
The recorded pressure waveform is then digitalized such that it can then be viewed upon a 
computer screen. The waveform that is recorded as stated above varies in different vessels in 
the same individual and is dependent on  
1)  The viscoelastic properties of the artery. 
2)  The viscosity of the blood. 
3)  Wave reflection. 
4)  Wave dispersion. 
 
As will be discussed below the computer software then utilises the recorded peripheral wave to 
either analyse the recorded pulse pressure wave in terms of a modified Windkessel model to 
generate arbitrarily labelled large and small artery compliance values (Diastolic Pulse Contour 
Analysis (DPCA)) or to use a mathematical generalised transfer function to construct the 
corresponding central aortic pressure and waveforms (Systolic Pulse Contour Analysis 
(SPCA)).  
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1.2.1 Pulse Wave Velocity 
Pulse Wave Velocity is simply a function of distance and time. 
  Velocity = Distance (m)/Time (seconds) 
 
To calculate the PWV, the time delay between the pulse pressure waves at two distinct sites 
has to be calculated by either placing probes simultaneously over two sites or by recording the 
waveforms at two sites independently and comparing the time delay at both sites against a 
simultaneously recorded QRS complex. Examples of sites where PWV is commonly recorded 
include carotid and radial arteries, or carotid and femoral arteries. Distance is measured simply 
with a suitable device. Calculating the time from the foot of the pressure wave at the first point 
to the foot of the pressure wave as it arrives at the next point is more complicated as it can be 
difficult to ascertain where the foot of the wave is, in particular identifying and defining the 
carotid pulse wave shape can be technically very difficult (Schram 2004). There are four 
recognised methods for calculating the location of the foot of the wave (Davies 2003a). The 
method using the point at which the second derivative of the pressure wave is maximal and the 
method looking at the point yielded by the intersection of a line tangent to the initial systolic 
upstroke of the pressure tracing and a horizontal line through the minimal point are the most 
reproducible. These are known as the second derivative method and the intersecting tangent 
method respectively (Chiu 1991). Comparison of studies utilising PWV as the means of 
assessing the arterial tree is must take into account the anatomy measured as there is no 
uniformity to the arterial tree segment that is being studied (i.e. carotid-femoral or carotid-
radial) and there are differences in arterial elasticity and tendency to atherosclerosis at different 
sites. 
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The strength of this technique is that it is simple to perform, no mathematical transformation is 
required and there is good published inter- and intra-operator reproducibility (Wilkinson 1998). 
Liang and colleagues report good repeatability of measurements preformed on two separate 
occasions (Liang 1998). Another group, however, reported a 16% variation in PWV on 
separate study days (Chiu 1991) which they suggest could be caused by changes in blood 
pressure, respiratory changes in arterial pressure or movement of the transducer on the skin 
overlying the arterial measuring site.  
 
PWV is sensitive to changes in heart rate and blood pressure (Quick 1998, Mitchell 1997, 
McVeigh 2002a) and small changes in arterial wall properties may not be detected between 
individuals, as data generated can often show considerable scatter for a given age range 
(Avolio 1983). Stewart et al (Stewart 2003) have demonstrated that inhibiting basal NO release 
caused an in increase in PWV, due to changes in MAP. 
 
Probably the most important facet of the literature pertaining to PWV is that it has been shown 
to be an independent predictor of outcome in high risk populations (Blacher 1999a, Blacher 
1999b, Blacher 2003, Guerin 2001). The utility of further refining risk stratification in patients 
already designated as being high risk, who should be receiving optimal therapy for risk 
reduction, has been suggested to be of limited clinical value (McVeigh 2002a).  
 
1.2.2 Systolic pulse contour analysis. 
 
SPCA is generated from pulse pressure waveforms recorded by applanation tonometry. When 
recorded at the radial artery at the wrist the waveform is calibrated to the brachial BP measured 
conventionally by arm/cuff oscillometric means. This has recently come under scrutiny and the   38 
inaccuracy of oscillometric cuff method for measuring arm blood pressure was identified as the 
limiting factor in predicting potentially clinically useful, non-invasive aortic pressures 
(Smulyan 2003). 
 
SPCA uses a generalised transfer function to derive central aortic waveforms from those 
acquired from the peripherally acquired arterial waveform – most commonly from the radial 
artery. From the generated central aortic waveform central BP values and the augmentation 
index (AIx) can then be calculated. The AIx is the proportion of central PP that results from 
arterial reflection and is a commonly, and successfully, used measure of arterial stiffness 
(Figure 1.1).  
 
 
Figure 1.1: Augmentation Index. 
Aix, the ratio of pressure augmentation to local pulse pressure (PP), can be defined for both the 
aortic and radial pulse waveforms. It depends on the relative amplitude and timing of the direct 
and reflected waves that summate to produce the overall waveform (from Oliver 2003). 
 
The timing of arrival of the reflected wave at the proximal aorta is determined chiefly by large 
artery PWV. AIx is not, however simply a surrogate or a different way of measuring PWV. 
Simultaneous measurement of AIx using the generalised transfer function and PWV, used as an 
PP 
Aortic AIx = ʔP/PP 
Reflected pressure 
Waveform. 
Aortic pressure 
pulse 
PP 
 
Reflected pressure 
Waveform. 
Radial pressure 
pulse 
P2 
Radial AIx = P2/P1 
ΔP 
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estimate of arterial stiffness revealed a positive (r=0.29) but modest correlation (Yasmin 1999). 
In this study only 9% of the variation of PWV was explained or accounted by variation in AIx.  
 
The Aortic AIx increases with age and blood pressure (Nichols & O‟Rourke 1998) and is 
elevated in subjects with other risk factors for cardiovascular disease namely diabetes 
(Wilkinson 2000) and hypercholesterolemia (Wilkinson 2002b). In patients with end stage 
renal failure (a group with high cardiovascular mortality) AIx is a highly predicative indicator 
of cardiovascular mortality (London 2001). As with the other vascular parameters derived 
using applanation tonometry AIx is sensitive to modulations of NO bioactivity. Inhibition of 
basal NO synthesis, with intra-arterial infusion of L-N
G-monomethyl arginine (L-NMMA), has 
been shown to lead to a dose dependent increase in MAP, peripheral vascular resistance, and 
aortic and systemic arterial stiffness (Wilkinson 2002a).  
 
There have been a number of criticisms levelled at the use of a generalised rather than an 
individualised transfer function and moreover at the use of any transfer function whatsoever. 
The use of a generalised transfer function can show bias and a significant amount of the 
variation in predicting the centrally obtained AIx (Glasser 1997, Chen 1997, Stergioplus 1998). 
SPCA has recently been used increasingly in healthy volunteer studies and it merits stressing 
that the generalized transfer function has never been validated in young healthy volunteers 
(Oliver 2003). Millasseau and colleagues have recently suggested that similar information on 
central pressure wave reflection can be obtained directly from the radial pulse and a radial AIx 
without use of a generalised transfer function (Millasseau 2003). 
 
The unequivocal association of increased Aix with arterial stiffness in recent publications 
(Wilkinson 2000, Wilkinson 1999, Brooks 1999) has been criticised (McVeigh 2002a).   40 
Although in some circumstances this may indeed be the scenario this supposition is to some 
degree speculative as it is based solely on a descriptive change in waveform morphology.  
 
The prognostic value of AIx has been shown in that carotid AIx is an independent predictor of 
cardiac ischaemic threshold during exercise in patients with CHD (Kingwell 2002). 
Additionally Aix is also a predictor of all cause and cardiovascular mortality in patients with 
end stage renal failure, even in those with normal PWV (London 2001). 
 
1.2.3 Diastolic pulse contour analysis. 
 
Cohn and McVeigh have pioneered DCPA as a useful research methodology for the early 
detection of vascular disease. Again the technology utilises applanation tonometry of the radial 
artery at the wrist and measures a waveform that is calibrated against the brachial BP.  
 
The modified Windkessel model (figure 1.2) is employed to interpret the consistent and 
predictable changes in the pulse pressure wave shape in diastole in terms of compliance, 
inertance and resistance in the arterial system (McVeigh 2002a). The Windkessel concept 
represents a lumped parameter non-propagative approach to interpret changes in the arterial 
mechanical properties that doesn‟t account for wave travel in the arterial system.  
 
The Windkessel model was first described, in 1769, by Stephen Hales. The Windkessel was the 
air filled dome in early fire engines which acted as a cushion to absorb fluctuations in water 
pressure delivered directly to the engine reservoir, hence allowing a smooth delivery of water 
to the fire hose. (O‟Rourke 1992). The physiological analogy is obvious with the pulsatile 
pump representing the heart, the Windkessel reservoir the central elastic arteries into which the   41 
heart pumps and the fire hose as the peripheral resistance (i.e. relatively non –elastic conduits 
of the peripheral arteries. The problem with this model is the assumption of uniformity 
throughout the arterial tree and as arteries differ in compliance and elasticity to smaller, and 
more muscular arteries such as the brachial and radial vessels. Additionally compliance varies 
throughout the length of each artery around junctions, curves and bifurcations (Kawasaki 1987, 
Van Merode 1991). This model cannot therefore account for wave amplification or the 
secondary diastolic wave that results from wave reflection in the arterial system. 
 
 
 
 
 
Figure 1.2: The modified Windkessel model of the arterial system. C1, proximal 
compliance; C2, Distal compliance; I, systemic inflow; L, inertance; R systemic vascular 
resistance. 
 
The energy contracts between all the elements in a modified Windkessel model can account for 
distortions in pressure-pulse contour produced by wave reflection, interpreting these changes in 
terms of altered compliance, resistance and inertance elements in the model (McVeigh 2002a). 
This non-invasive approach generates the cardiac output from an algorithm incorporating the 
radial pulse pressure waveform (McVeigh 1999). Two components of the diastolic waveform 
i 
L 
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are distinguished in DCPA. An exponential decay curve represents large artery compliance 
(C1). Oscillatory or reflective compliance (C2) consists of peripheral wave reflections that are 
superimposed upon the basic waveform and provide a measure of small artery compliance 
(Watt 1976).  
 
Values obtained by this non-invasive technique have been compared with those obtained from 
waveforms generated invasively (Cohn 1995). Non-invasively derived waveforms from the 
tonometer were found to underestimate, but were tightly correlated to, pressure wave forms 
obtained invasively. Compliance values calculated from invasive and non-invasive methods 
were correlated statistically, though more strongly for C1 than for C2, with non-invasive 
measures tending to overestimate.  
 
Again, as with SPCA, the derived model based parameters change in a consistent and 
predictable manner with ageing and with disease states associated with vascular disease (Cohn 
1995, Finkelstein 1982, McVeigh 1999, Watt 1976).  
 
Utilising both brachial artery waveforms obtained invasively and radial artery waveforms 
obtained non-invasively with tonometry increased age was associated with lower C1 and C2, 
whether assessed invasively or non-invasively (McVeigh 1999). SBP was associated, in this 
study with C1 but not C2, which was not associated with any BP parameter. In an earlier study 
McVeigh (McVeigh 1991) demonstrated reduced C2 in patients with hypertension compared to 
age matched controls. In this study, moreover, C2 was reduced to a greater extent in young 
hypertensives than C1, whereas C2 was reduced to a similar extent in older hypertensives and 
healthy controls. C2 but not C1 was also reduced in postmenopausal women with CAD (Cohn   43 
1995) and smoking and diabetes have also been associated with lower C2 than C1 (McVeigh 
1997, McVeigh 1993). 
 
Additionally inhibition of endothelial nitric oxide synthesis with L-NAME was associated with 
progressive diminution in the amplitude and frequency of the oscillatory diastolic waveform, 
identified as a decrease in C2 in the model analysis, with resolution to baseline with the 
addition of L-Arginine. This shows that, dynamically, the C2 is a sensitive means of 
identifying NO modulation of blood vessel tone (McVeigh 2001).  
 
Thus reduction in the small artery compliance value (C2), which reflects a diminished 
amplitude, frequency and duration of the secondary diastolic wave has been presented as a 
putative marker for the early detection of vascular disease. 
 
As for SPCA there has been criticism of this method and in particular debate as to whether 
SPCA or DPCA represents the most useful non invasive vascular phenotype. Rietzschel et al 
(Rietzschel 2001) preformed the first comparative study showing that, within 100 healthy 
individuals, the coefficients of variation were 32.8% for C1, 33.3% for C2 and 6.7% for Aix 
suggesting that in terms of reproducibility at least, SCPA was more robust. In this study, 
however, C2 was significantly and inversely correlated to AIx (r=-0.487). This was 
corroborated by a further study by Segers (r=-0.36) (Segers 2001). There is still some dubiety 
as to what C2 actually represents in terms of an anatomical site and though theoretically, the 
site measured should not affect measurements of overall proximal and distal compliance there 
was no correlation between values of C1 and C2 measured at the radial artery as compared to 
those measured at the posterior tibial artery (Manning 2002). Moreover in this study, despite   44 
good quality tonometry recordings, application of the model yielded non interpretable results in 
some subjects (Manning 2002). 
 
1.3 Oxidative stress, the NAD(P)H oxidase system and & vascular disease. 
 
The principal pathological lesion of coronary artery disease is atherosclerosis. The nidus for the 
lesion would appear to be transfer of oxidized low density lipoprotein (LDL) across the 
endothelium to the artery wall (Navab 1996). The transfer is reported to be due either directly 
to the oxidized LDL or physical, chemical or infective stimulation (Ross 1999). Endothelial 
cells, vascular smooth muscle cells, and macrophages are the sources of oxidants for the 
oxidative modification of phospholipids. Oxidised LDL may damage endothelial cells which 
subsequently produce adhesion molecules and chemotactic factors that induce monocyte and T 
lymphocytes recruitment (McEver 1992,Madamanchi 2005). Thereafter monocytes migrate to 
the sub endothelial space and, ingesting lipoproteins, become macrophages which generate 
reactive oxygen species which convert oxidized LDL to highly oxidized LDL. Upon taking up 
highly oxidized LDL the macrophages become foam cells which combine with leucocytes to 
become the fatty streak. Foam cells themselves generate growth factors that facilitate smooth 
muscle cell migration into the intima. As the process persists and progresses the fatty streaks 
become more complex lesions which protrude into the vessel lumen and may undergo fibrosis 
and calcification. Ultimately the rupture of this complex with release of thrombi may lead to 
vessel occlusion and the acute coronary syndrome (Madamanchi 2005). 
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1.3.1 Introduction to oxidative stress 
 
Oxidative stress describes the injury caused to cells by the oxidising of macromolecules 
resulting from increased formation of reactive oxygen species and/or diminished anti oxidant 
reserves (Zalba 2001b). Recent work has demonstrated that all types of vascular cells generate 
reactive oxygen species and a growing number of reports have depicted a pivotal role for 
oxidative stress in the pathogenesis of cardiovascular disease (Cahilly 2000). Almost all 
cardiovascular disease states including hypertension, hyperlipidaemia, diabetes, 
arteriosclerosis, unstable angina, vasculitis and myocarditis, restenosis as well as 
ischaemia/reperfusion have been linked to an enhanced generation of oxygen derived free 
radicals (Kojda 1999). Oxidative stress has a prognostic role for cardiovascular morbidity and 
mortality. Coupled with endothelial dysfunction increased oxidative stress has been 
demonstrated to predict the risk of cardiovascular disease in patients with coronary artery 
disease (Heitzer 2001). 
 
The molecule oxygen is usually quiescent as although a radical, it is sparingly reactive as its 
two unpaired electrons are situated in different molecular orbitals and demonstrate parallel 
spins. Molecular oxygen thus undergoes univalent reduction to form •O
2- by means of several 
enzyme systems; nicotinamide adenine dinucleotide (phosphate) (NADH/NAD(P) oxidases, 
xanthine oxidase and endothelial nitric oxide synthase (eNOS)in the absence of sufficient co 
factor or substrate. The perilous balance between oxidation and reduction is maintained by a 
series of pro and anti oxidant enzymes and molecules. The best studied of these is the 
NAD(P)H oxidase system. 
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1.3.2 NAD(P)H Oxidase 
 
NAD(P)H oxidase is the major inducible source of •O
2- within phagocytes for which it plays a 
bactericidal role and produces •O
2-  in response to pathogens (Cross 1991). The oxidase is a 
membrane bound enzyme that catalyses a single electron reduction of molecular oxygen to 
form •O
2-. The components of this enzyme system are highly conserved across mammalian 
species (Hitt 1996, Davis 1998). The enzyme system comprises several components:- a 
membrane bound portion the cytochrome b558, two cytosolic components p
47phox and p
67phox 
as well as the small GTPase protein rac2 (Leusen 1996, DeLeo 1996). The membrane bound 
heterodimeric protein referred to as the flavocytochrome b558 is the final electron transporter 
from NAD(P)H to molecular oxygen and consists of the larger gp91phox and the smaller 
p22phox (Parkos 1987). It is regarded as the redox centre of the NAD(P)H oxidase (Knoller 
1991). The NAD(P)H oxidase is ubiquitous to all vascular cells and is the chief source of 
vascular •O
2- (Greindling 2000). 
 
1.3.3 NAD(P)H Oxidase associated •O
2- and atherosclerotic vascular disease. 
 
The oxidative stress hypothesis of atherosclerosis posits that it is an inflammatory disease 
triggered, as described above, by subendothelial accumulation of LDL particles modulated by 
reactive oxygen species (Sorescu 2002). Furthermore reactive oxygen species mediate several 
additional pathological processes in the vessel wall including endothelial dysfunction and 
smooth muscle cell migration, growth and apoptosis (Griendling 2000).  
 
The evidence base linking •O
2-with vascular disease is substantial. Levels of NAD(P)H 
stimulated •O
2- have been reported to be elevated in hyperinsulineamic rats (Kashiwagi 1999),   47 
hypercholesterolaemic rabbits (Warnholtz 1999) as well as being positively correlated with 
endothelial dysfunction and clinical risk factors for atherosclerosis (Guzik 2000a). 
Hypertension and aging have been shown to be associated with increased •O
2- levels and 
consequently diminished NO levels (Hamilton 2001). Furthermore increased •O
2- production 
has been illustrated in coronary arteries from rats with methionine diet induced 
hyperhomocysteinemia, an independent risk factor for coronary artery disease (Ungvari 2003). 
•O
2- has also been implicated in the pathogenesis of vein graft intimal hyperplasia (West 2001). 
1.3.4 p22phox  
 
As described above the p22phox molecule is the smaller component of the flavo cytochrome 
b558 moiety of the NAD(P)H oxidase system. It has been implicated in the pathophysiology of 
vascular disease including atherosclerosis, diabetes and hypertension. 
 
The first investigation of p22phox and its difference in expression between non atherosclerotic 
and atherosclerotic human coronary arteries emanated from Azumi and co workers (Azumi 
1999). Utilising autopsied cases they demonstrated that in non atherosclerotic arteries p22phox 
was weakly expressed mainly in the adventitia. In contrast in atherosclerotic human arteries 
p22phox expression was more pronounced and was present in adventitial fibroblasts, smooth 
muscle cells, macrophages in the neointima and media and endothelial cells. As atherosclerosis 
progressed the expression of p22phox increased through the vessel wall (Azumi 1999). In their 
study examining O2
-production in experimental venous bypass graft intimal hyperplasia West 
demonstrated increased p22phox protein expression in vein grafts as compared with control 
jugular veins (West 2001). In coronary arteries from 20 patients undergoing heart 
transplantation Sorescu and colleagues sought to localize the cellular sources of intracellular 
O2
- production in atherosclerotic and non atherosclerotic human coronary arteries and   48 
characterise the cellular distribution of the Nox proteins –novel gp91phox homologues 
(Sorescu 2002). They found, in accordance with work by others detailed above, that O2
- was 
produced by all cell types in the vessel wall but specifically that O2
- was especially high in the 
shoulder regions of the plaque. Moreover gp91phox and Nox 4 were abundant in human 
coronary arteries, whereas Nox 1 expression is very low. p22phox co-localized with gp91phox 
and additionally the severity of atherosclerosis correlates with NAD(P)H oxidase subunit 
mRNA expression (Sorescu 2002).  
 
The p22phox protein was found to be significantly increased in diabetic arteries and veins 
compared to non diabetic patients undergoing coronary artery bypass graft surgery (Guzik 
2002a). Further association of the pathological role of this molecule in diabetes mellitus was 
recently produced which found that in decompensated type 2 diabetes p22phox expression was 
increased in circulating monocytes (Avogaro 2003). In terms of a role of the p22phox protein 
in hypertension the p22phox mRNA is elevated in spontaneously hypertensive rats (Fukui 
1997), can be induced in rats with a ligated renal artery (Ushio-Fukai 1996) and recently 
increased expression of p22phox has been documented in hypertensive lymphoblasts (Pettit 
2002). 
  Endothelial cells  Fibroblasts  Vascular Smooth 
Muscle Cells 
p22phox  +  +  + 
gp91phox  +  +  - 
p67phox  +  +  - 
p47phox  +  +  + 
Rac  +  +  + 
Table 1.2: Expression of NAD(P)H oxidase Components in vascular cells ( From Zalba 
2001 b).   49 
1.3.5 Modulation of vascular NAD(P)H oxidase. 
 
The best characterized stimulus for NAD(P)H oxidase activation and induction is angiotensin 
II from studies in animals and man. Animal studies have documented that not only is the 
NAD(P)H oxidase system modulated by Angiotensin II but, in turn the •O
2-  anion may play a 
role in the physiological and pathophysiological actions of this peptide. Angiotensin II 
increases vascular smooth muscle cell •O
2-  production by activation of a membrane bound 
NAD(P)H oxidase (Griendling 1994). Berry et al characterized cellular and enzymatic sources 
of •O
2-  production in human blood vessels showing that •O
2-  production was greater in human 
internal mammary arteries than in saphenous veins and that the prime sources were the 
NAD(P)H oxidase and xanthine oxidase enzyme systems (Berry 2000). Jacobson et al reported 
that inhibition of vascular NAD(P)H oxidases, using the chimeric peptide inhibitor, gp91ds-tat, 
suppressed angioplasty induced neointimal hyperplasia in the carotid artery of the rat (Jacobson 
2003). This finding therefore linked NAD(P)H oxidase dependent free radical production and 
neointimal formation. Within human blood vessels NAD(P)H oxidase inhibition has been 
shown to improve endothelial function (Hamilton 2002). The reduction in NO bioactivity is 
thus not related to diminished NO production per se but to increased •O
2- production.
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Figure 1.3: The functional consequence of NAD(P)H oxidase activation in hypertension. 
Ang II = Angiotensin II, PDGF platelet derived growth factor, TNF α Tumour Necrosis Factor 
α. Adapted from Zalba 2001 b. 
 
1.3.6 The p22 phox gene, CYBA. 
 
The gene coding for the p22phox gene, CYBA, is located on chromosome 16q24 (Cahilly 2000) 
and has several allelic variants (Cahilly 2000, Gardemann 1999, San José 2004). The 
association of three of these and vascular pathophysiology, C242T, A640G and -930 A/G, shall 
be discussed in detail. 
 
1.4 The CYBA C242T single nucleotide polymorphism and vascular disease. 
 
The CYBA C242T SNP within exon 4 of the gene induces a replacement of histidine by 
tyrosine at amino acid position 72 which is a potential heme binding site (Parkos 1988). This is 
Humoral factors 
(Ang II, PDGF, TNF-α) 
Heamodynamic factors 
(sheer stress) 
Genetic factors 
(SNPs of oxidative 
 stress genes) 
↑ NAD(P)H Oxidase 
↑•O2-  
↑ ONOO-, ↓NO  ↑ H2O2 
Endothelial Dysfunction  Media Hypertrophy   51 
the best investigated of the three allelic variants of the CYBA and hence will be discussed in the 
most detail. 
 
The mechanism by which this SNP is functional is contentious. Most authors speculate that the 
C242T SNP may alter the structure of the heme binding site of the NAD(P)H oxidase and 
thereby lead to a reduced activity of the enzyme and thus modulate oxidative stress within the 
vasculature (Guzik 2000b). However, spectral analysis of the membrane fractions from 
transfected COS7 cell lines, expressing either gp91phox alone or gp91 and p22phox, indicated 
that the gp91 phox is the sole heme-binding component of flavocytochrome b558 (Yu 1998). 
The link with atherosclerosis and NAD(P)H oxidase mediated oxidative stress is well 
established as oxidation of LDL, a key step in the genesis of atherosclerotic lesions, is 
associated with the NAD(P)H oxidase system. Aviram and co workers established that 
NAD(P)H-cytochrome P450 reductase is able to oxidize LDL in vitro (Aviram 1999). 
 
1.4.1 Coronary Artery Disease. 
 
The first series of data associating this SNP with coronary atherosclerosis was generated by a 
number of case control studies. Inoue et al compared the distribution of C242T genotypes in 
201 Japanese patients with CAD compared to 201 controls (Inoue 1998). At odds with findings 
from other, and notably European and American populations (Cai 1999, Cahilly 2000) they 
found that the presence of the T allele was more prevalent in controls rather than patients thus 
suggesting that the T allele conferred a protection against atherosclerosis. The presence of the 
T allele has been reported, within an Italian study of 237 patients with coronary stenosis, to be 
associated with a reduced recurrence of cardiovascular deaths, non fatal myocardial infarction 
and new revascularization procedures (Arca 2008). In contrast Cai and co workers documented   52 
that the T allele was a modest risk factor for the development of CAD in younger patients (less 
than 45 years) but not in the overall population (Cai 1999). Opposed to both these studies was 
an American study which failed to find a difference in prevalence of the C242T allele in 140 
patients with angiographically documented CAD or 103 patients with normal coronary arteries 
(Li 1999). Neither did they elicit any significant difference in coronary epicardial or 
microvascular responses to intracoronary acetylcholine or sodium nitroprusside (Li 1999). 
Further negative studies emanated from Saha and co workers who did not find that the C242T 
SNP was associated with coronary heart disease risk in Asian Indians and Chinese (Saha 1999) 
and Zafari et al who, in American population of 216 patients referred for coronary angiography 
did not find any association of this SNP with CAD (Zafari 2002). Additionally a study by 
Stanger et al in 108 male Caucasians with coronary artery disease and 65 controls failed to 
associate any relation of this SNP with the generation of malondialdehyde, a sensitive and 
specific marker of lipid peroxidation as biochemical end-product (Stanger 2001). 
 
In contrast to these reports a prospective study was done by Cahilly and co workers who 
determined the association of the C242T variants with the severity, progression and regression 
of CAD with serial quantitave coronary angiography (Cahilly 2000). They elicited that the T 
allele was associated with progression of CAD. In detail they documented that the presence of 
the T allele was linked with greater losses in mean lumen diameter and greater lesion specific 
mean lumen diameter and was associated with progression and also less regression of 
angiographically documented lesions over the 2.5 years of follow up (Cahilly 2000). There was 
no difference in characteristics at baseline suggesting self selection but the distribution of the 
genotypes was according to that expected under Hardy Weinberg equilibrium hence suggesting 
otherwise. A Polish case control study of 172 patients with angiographically documented   53 
coronary artery disease versus 169 healthy controls found a cumulative effect of the 242T 
allele carrier state and cigarette smoking and hypercholesterolemia (Niemiec 2007). 
 
Schächinger and colleagues examined whether this SNP was associated with differences in 
coronary endothelial vasodilator function (Schächinger 2001). In accordance with Inoue they 
found that the CC homozygote was deleterious and was associated with a significantly blunted 
endothelium dependent dilator response. Guzik et al, in an elegant study measuring •O2
- with 
lucigenin-enhanced chemiluminescence in human saphenous veins from patients undergoing 
coronary artery bypass graft surgery found that the presence of the T allele was associated with 
decreased •O2
- production (Guzik 2000b). Not all results have been in parallel and most 
recently the 242T allele has been found to be a predictor of lower risk of cardiovascular events 
in high risk patients (Arca 2008). 
 
1.4.2 Cerberovascular Disease. 
 
Ito et al studied 226 Japanese patients with ischaemic (rather than cardioembolic or 
haemorrhagic) stroke and 301 control subjects from Tokyo (Ito 2000). They found that the T 
allele was associated with ischemic stroke with an odds ratio of 1.81. The T allele was also 
recently associated with an enhanced risk for ischaemic stroke in a German population based 
case control study of patients below the age of 50 (Genius 2008) 
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1.4.3 Diabetic Nephropathy. 
 
Hodgkinson et al found that there was a marked increase of the TT homozygous genotype in 
patients with type 1 diabetes mellitus and nephropathy compared with long term uncomplicated 
subjects and those with retinopathy alone (Hodgkinson 2003). This suggested that the T allele 
contributes to the susceptibility to diabetic nephropathy. The further findings from this study 
are discussed below with the A640G SNP. 
 
1.4.4 Carotid Atherosclerosis. 
 
The p22phox protein is significantly increased in human diabetic veins and arteries (Guzik 
2002a). Within a Japanese population of 200 subjects with type 2 diabetes mellitus and 215 
healthy non-diabetic controls the effect of this SNP with carotid intima media thickness was 
studied (Hayaishi-Okano 2003). In accordance with other studies by Inoue (Inoue 1998), 
Schächinger (Schächinger 2001) and also Guzik (Guzik 2000b) they found that the presence of 
the T allele conferred upon patients a protective, anti atherogenic effect with a smaller intima 
media thickness observed in this group (Hayaishi-Okano 2003). 
 
1.4.5 Peripheral Vascular Disease. 
 
Given the association of this SNP with CAD, Renner and co workers attempted to document 
whether there was any similar relationship with peripheral atherosclerosis (Renner 2000). In 
341 patients with peripheral vascular disease ranging from intermittent claudication to   55 
gangrene compared to 295 control subjects they failed to ascertain any association with the 
C242T SNP with this phenotype. 
 
1.4.6 Pre Eclampsia. 
 
As the p22phox gene variants had been linked to other oxidative stress implicated disease 
phenotypes Raijmakers et al, within a Dutch population, compared normotensive pregnancies 
with pregnancies complicated by pre-eclampsia or the haemolysis elevated liver enzymes and 
low platelets syndrome (Raijmakers 2002). They found no difference in prevalence of C242T 
alleles between cases or controls concluding that the C242T SNP of CYBA was not associated 
with pre-eclampsia. 
 
1.4.7 Endothelial Function. 
 
There is some evidence that this SNP is implicated in endothelial function. Fan and co-workers 
noted that CC homozygotes had a lower flow mediated vasodilatation at the brachial artery 
than TT homozygotes – a relationship evident in subjects who smoked or were obese (Fan 
2007). Schneider et al sought to ascertain whether this SNP was associated with endothelial 
function as measured by endothelium dependent vasodilatation of the forearm vasculature 
utilising forearm plethysmography in 90 subjects with elevated cholesterol levels (Schneider 
2003). They found no association of the CYBA C242T and endothelial function. 
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1.4.8 Insulin Resistance. 
 
A link with insulin resistance was documented by Hayaishi-Okano within the non diabetic 
control group of the study into carotid atherogenesis (Hayaishi-Okano 2003). They found that 
fasting insulin levels and the insulin resistance index of homeostasis model assessment was 
significantly lower in patients with the T allele (Hayaishi-Okano 2003). 
 
In conclusion there have been multiple studies that have identified associations between CYBA 
gene polymorphism and cardiovascular diseases although there have not been consistent 
results. This is perhaps because these variants may identify a particular high-oxidative-stress 
risk subgroup within the healthy population and the population exhibiting cardiovascular risk 
factors, including hypertension and diabetes. Hence this points toward the importance of 
multiple polymorphism assessment in functional and association studies of complex disease 
traits (San José 2008). 
 
1.5 The CYBA A640G and CYBA 930A/G single nucleotide polymorphisms and vascular 
disease. 
 
The A640G SNP is situated within the 3‟ untranslated region of CYBA. This gene variation 
may modify messenger RNA processing and stability and therefore modulate p22phox protein 
biosynthesis (Gardemann 1999). The first study examining this SNP was in the context of 
CAD in a Japanese population (Inoue 1998). In the 402 participants analysed the T allele of the 
C242T gene polymorphism but neither the A allele nor the G allele of the CYBA A640G gene 
variation was associated with a reduced or an increased risk of coronary artery disease (Inoue 
1998). This association was further studied in a German population of 2205 male caucasians   57 
(Gardemann 1999). On the contrary they found that the G allele of the A640G SNP was 
significantly more frequent in controls without CAD than in patients with CAD. 
Correspondingly the AA genotype of the A640G SNP was preferentially found in patients with 
CAD. They also found that the association of the A640G gene variation with the presence and 
extent of CAD was not only evident in the entire population but was even stronger in high risk 
(e.g. those with hypertension),younger individuals (Gardemann 1999). They found no relation 
with CAD when assessing potential influence of the C242T SNP. In contrast no association 
was found by Zafari et al when examining the effect of the A640G SNP in an American 
population (Zafari 2002). 
 
Hodgkinson et al found that there was not only a contribution of the C242T SNP upon the 
contribution to risk of nephropathy in patients with type 1 diabetes but also demonstrated that 
the entire CYBA haplotype – including the G640 allele -was important and that there was also a 
significant contribution of the aldose reductase (AKR1B1) gene (Hodgkinson 2003).  
 
The 930A/G SNP, within the promoter of CYBA was recently described by Moreno et al 
(Moreno 2003). They screened the promoter, which they found to contain TATA and CCAC 
boxes as well as Sp1, γ interferon and NFκB binding sites for new mutations. Moreno and co 
workers identified this SNP, localised at position -930 from the ATG codon, which was 
associated with hypertension in a Spanish population (Moreno 2003). In comparing 88 patients 
with hypertension and 68 normotensive controls they found that the presence of the G allele 
was associated with hypertension. Mutagenesis experiments suggested that the G allele had a 
higher promoter activity than the A allele by approximately 30% thus signifying the potential 
functional nature of this SNP. In a multi-factorial chronic disease such as hypertension a 
discrepancy in activity of 30% may well be significant. The same group went on to show that   58 
hypertensive GG homozygotes displayed a variety of phenotypes linked with oxidative stress, 
i.e. higher NAD(P)H oxidase activity as assessed by chemiluminescence, higher levels of 
p
22phox mRNA and protein expression as well as lower NO production as assessed by 
quantification of NO metabolites (San José 2004). Both these studies found functionality that 
was confined to hypertensives only. Why this should be is not clear but the presence of the G 
allele may modulate the transcription of the p22phox gene. Furthermore the -930 polymorphic 
site lies on a potential binding site for C/EBP transcription factors which may be relevant to the 
pathophysiology of hypertension (San José 2004). The G allele of this SNP has also been 
implicated within insulin resistance (Ochoa 2008).  
 
1.6 Nitric Oxide 
 
Initially NO was considered to be a noxious pollutant in exhaust fumes, cigarette smoke and 
responsible for acid rain and degradation of the ozone layer. Since the endothelium derived 
relaxing factor, proposed by Furchgott and Zawadski in 1980 (Furchgott 1980), was identified 
by Palmer and co workers (Palmer 1987) to represent NO there has been considerable attention 
to the multiple functions of this ubiquitous messenger molecule in human physiology and 
pathology. Under normal conditions eNOS generates NO which is multifunctional and in 
addition to its vasorelaxant role also inhibits platelet aggregation, leukocyte adhesion to the 
endothelium, vascular smooth muscle cell migration and growth and also the oxidation of low-
density lipoprotein (Cooke 1997). As stated earlier the latter is a key stage in the evolution of 
atherosclerosis, the means of a structural and functional change within the arterial wall,  
potentially identified by PWA. NO is synthesised from L-arginine by the NOS family of 
oxidoreductases via the L-arginine nitric oxide pathway (Palmer 1988). There are three known   59 
isoforms of NOS which are the products of three distinct genes and summarised in table 1.3 
(Hecker 1990, Bredt 1991, Xie 1992).  
Gene  Enzyme  Calcium 
dependent? 
Chromosome Location  Protein (kDa) 
NOS1  NOSI 
(neuronal) 
Yes  12q24.2-24.31  155 
NOS2  NOSII 
(inducible) 
No  17cen-q11.2  125-135 
NOS3  NOSIII 
(endothelial) 
Yes  7q35-36  135 
 
Table 1.3: The characteristics of the three human nitric oxide synthase isoforms. 
 
 
 
1.6.1 Endothelial nitric oxide synthase 
 
This constitutively expressed 135 KDa protein is predominantly associated with the 
particulated specific structures in the plasmalemmal membrane, caveolae, of vascular 
endothelial cells (McDonald 1997, Sakoda 1995). Endothelial nitric oxide synthase is 
responsible for the conversion of L-arginine to L-citruline and NO in the endothelium 
(Moncada 1991) and loss of endothelium derived nitric oxide is plays a pivotal role in 
atherogenesis (Ross 1993). Moreover experimental inhibition of NO synthesis is associated 
with acceleration of formation of early atherosclerotic lesions (Cayette 1994). 
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1.6.2 The eNOS gene, NOS3: position and background. 
 
The human eNOS gene, NOS3, is situated on the long arm of chromosome 7(7q 35-26) and 
comprises a total of 26 exons spanning 21 kb (Marsden 1993). Due to the importance of eNOS 
in terms of cardiovascular function in man many investigators have sought to elucidate whether 
mutations or polymorphisms of the NOS3 gene correlate with either an altered physiological 
response or increased risk of cardiovascular disease. 
 
1.8 The NOS3 G894T single nucleotide polymorphism and human physiology. 
 
Given the centrality of NO in the regulation of numerous essential physiological processes 
including maintenance of vascular tone, inhibiting platelet and leukocyte adhesion to vascular 
endothelium, inhibiting vascular smooth muscle cell migration and growth as well as anti-
apoptotic and antioxidant functions SNPs within the NOS3 gene have been the subject of 
several studies which have associated common allelic polymorphism of this gene with human 
physiology (Loscalzo 1995a, Hingorani 1999, Vanhoute 1997, Lowenstein 1994, Karvonen 
2002). 
 
The importance of these studies is in that while the studies detailed in subsequent sections 
detail the importance of genetic variation within established disease phenotype these studies 
are preformed in the preclinical stage, prior to the potentially confounding lifetime of 
environmental risk and also when future strategies may seek to modify the initiation and 
progression of atherosclerosis. The G894T SNP has been examined in most detailed and 
further studies within are central to this thesis hence although other SNPs will be discussed the   61 
importance of the G894T SNP in both human physiology, and later, in human pathology will 
be discussed in detail. 
 
1.8.1 Endothelial function: Interaction with environmental and dietary factors. 
 
Utilising flow-mediated arterial dilation, a nitric oxide dependent endothelial response, Leeson 
and co workers (Leeson 2002) investigated the influence of this polymorphism upon 
environmental risk factors, namely pro-atherogenic cigarette smoking and anti-atherogenic n-3 
fatty acid intake, in a young cohort (aged 20-28). They found, even at this age, within males 
the number of aspartate
298  alleles dictated the degree as to which endothelial function was 
impaired by smoking and, within both sexes the degree upon n-3 fatty acid status augmented 
endothelial function. They postulated that the steady state of the eNOS enzyme may be lower 
in the asp
298 variant with a consequent diminution in NO production which, though sufficient 
to maintain vascular homeostasis in the absence of risk factors, is more amenable to further 
attenuation in the presence of risk factors (Leeson 2002). A lager study generated conflicting 
results. Kathiresan and co workers took advantage of the Framing Heart Study Offspring 
cohort which has almost 2500 subjects that have had vascular phenotyping with brachial artery 
flow-mediated vasodilatation or hyperaemic flow velocity measurements (Kathiresan 2005). 
They found no association of the G894T SNP and either of these NO mediated phenotypes. 
Recently however analysis of this SNP within the Prospective Study of the Vasculature in 
Uppsala Seniors Study of 959 subjects aged 70 found that of 23 SNPs analysed only this SNP 
was related to flow mediated vasodilatation (Ingelsson 2008). Furthermore recent work from 
Dundee has shown that within 68 healthy volunteers aged 18-44 the T allele was associated 
with blunted endothelial dependent vasodilatation assessed by forearm venous occlusion 
plethysmography (Godfrey 2007).   62 
 
1.8.2 Maternal vascular adaptation to normal healthy pregnancy. 
 
Flow mediated dilatation was also employed to study 139 women at 12 weeks gestation during 
an early, complication free, singleton pregnancy (Savvidou 2001). At this point in pregnancy it 
is recognised that the eNOS enzyme is physiologically up regulated (Weiner 1994). There was 
an inverse and highly statistically significant relation between brachial artery flow mediated 
dilation and the number of maternal eNOS asp
298 alleles (Savvidou 2001). Not only is this a 
fascinating insight into the pathophysiology of normal healthy pregnancy but moreover it 
implicates a role in genetic variation of the NOS3 gene in modulating risk of pre-eclampsia. 
 
1.8.3 Carotid intima-media thickness. 
 
An Italian study undertook to examine the effect of this SNP as well as the T
-786→C SNP of the 
NOS3 gene upon not only upon flow mediated dilatation but also carotid intima-media 
thickness, a marker of early atherosclerosis, in 118 subjects aged 21-45 (Pardossi 2004). They 
found that the TT genotype (asp
298/ asp
298 variant) was significantly and independently 
associated with decreased brachial artery flow mediated dilatation and increased carotid 
intima-media thickness in this group of young healthy individuals free of traditional 
cardiovascular risk factors. On the contrary they found no evidence of an effect of the T
-786→C 
SNP on this measurement of endothelial function or upon carotid thickening. This parallels the 
findings of Rossi et al who found that the T
-786→C altered forearm blood flow in patients who 
were hypertensive but not normotensive (Rossi 2003b). The extrapolation of this being that this   63 
is a „disease-modifying allele‟ and in itself insufficient to account for enhanced susceptibility 
to vascular dysfunction. 
1.8.4 Baseline production of nitric oxide. 
 
Veldman et al examined the differences in basal NO production between the different NOS3 
G894T genotypes but quantifying the vasoconstrictor response to eNOS inhibition by infusion 
of N
G-monmethyl-L- arginine (L-NMMA) (Veldman 2002). The absolute and relative decrease 
in forearm blood flow during infusion of L-NMMA was attenuated in the asp
298 variant 
concluding that basal NO production was attenuated in healthy subjects heterozygous or 
homozygous for the T allele of this substitution. 
 
1.8.5 Blood pressure response to endurance training. 
 
Four hundred and eighty four subjects were studied by Rankinen et al to elicit the association 
between this polymorphism and endurance training in previously sedentary normotensive white 
subjects (Rankinen 2000). They found that the TT homozygote had a blunted responsiveness of 
sub maximal exercise diastolic blood pressure and rate pressure product (an index of 
myocardial workload) than heterozygotes or GG homozygotes. 
 
1.8.6 Heamodynamic reactivity to stress. 
 
Malhotra and colleagues examined the effect of the G894T SNP upon heamodynamic response 
to stress whilst also taking into account possible confounding factors such as adipocity and 
ethnic background (Malhotra 2004). They showed that European Americans exhibited lower   64 
diastolic blood pressure reactivity unless they were obese Asp allele carriers. African American 
non obese asp carriers exhibited the greatest total peripheral resistance reactivity. Obese asp 
allele carriers exhibited the greatest increases in cardiac output and the largest decrease in NO 
metabolites to a stress response. 
 
1.8.7 Inflammatory and oxidative stress markers. 
 
The association of the G894T SNP and elevated levels of inflammatory and oxidative stress 
markers comes from a group from Greece who studied 595 from the greater Athens area 
(Chrysohoou 2004). They found that there was TT homozygotes had higher levels of oxidised 
low density lipoprotein, white cell count and fibrinogen. They found a non significant 
association with homocysteine (p=0.08) but Brown et al, looking at 2 different populations 
found that the TT homozygote was associated with significantly higher levels of homocysteine 
in non smokers with low folate levels (Brown 2003). 
 
1.8.8 Post challenge insulin levels. 
 
Finally, in terms of human physiology a recent study by Maruyama and colleagues from Japan 
found no difference in insulin sensitivity between 247 non diabetic controls but post standard 
75g oral glucose tolerance elevated levels of Insulin were noted in carriers of the T allele as 
compared to GG homozygotes (Maruyama 2003). 
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1.9 The NOS3 G894T single nucleotide polymorphism and human pathology. 
 
As detailed thus several studies have documented the effect of this SNP upon human 
physiology. Likewise, although some studies have been negative a substantial amount of the 
available literature links this functional polymorphism with an important role in human 
pathology. 
 
1.9.1 Ischaemic heart disease. 
 
The first report emanated from Japan in 1998 when Hibi and associates investigated the role of 
this SNP in 226 patients at first presentation of acute myocardial infarction with comparison to 
482 control subjects (Hibi 1998). They found that those homozygous for the TT allele were at 
increased risk of acute myocardial infarction. Moreover they noted that lack of an association 
with the heterozygotes for this SNP suggested that the 894T allele was not dominant and that 
the increased risk posed by this SNP was confined to the TT homozygote. Evidence associating 
this SNP with coronary artery disease in a European population was subsequently published in 
1999 by Hignorani and co workers (Hignorani 1999). They compared 249 white individuals 
with acute myocardial infarction with healthy control subjects from East Anglia. Again the 
increased risk was confined to individuals homozygous for the TT allele and they quantified 
the increased risk as lying between 2.5 to 4 times that of individuals homozygous for the GG 
allele. A subsequent study, the ECTIM study, genotyping patients from France and Northern 
Ireland failed to corroborate this finding failing to elicit a significant association between this 
SNP and Ischaemic heart disease. A further positive association came again from a Japanese 
population of 285 patients with an acute myocardial infarction and 607 age matched controls 
which demonstrated that the missense G894T NOS3 variant (heterozygote and TT   66 
homozygote) was associated with acute myocardial infarction (Shimasaki 1998). Guzik et al 
(Guzik 2001) did not show any association between this variant, however, and endothelium 
dependent vasorelaxation to different agonists in human saphenous veins from patients with 
coronary artery disease. Further negative studies between this polymorphism and ischaemic 
heart disease were generated by Jeeroburkhan in the United Kingdom and Schmoelzer from 
Austria (Jeeroburkhan 2001, Schmoelzer 2003).  
 
The overwhelming balance of evidence does, however, implicate this SNP as being a risk 
factor for ischaemic heart disease. Further corroboratory evidence was provided by Gardemann 
from a German population of 2717 individuals undergoing coronary angiography who 
associated, in younger individuals, an association between T allele carriers and an increased 
risk of coronary artery disease or myocardial infarction and also by Colombo from an Italian 
population of 201 patients with coronary artery disease where the T allele was associated with 
not only the presence of coronary artery disease but also the extent and severity of the 
atherosclerotic lesions (Gardemann 2003, Colombo 2002). 
 
Perhaps the most compelling evidence comes from a recent meta-analysis of 26 studies 
involving 23 028 subjects that sought to clarify the role of this SNP and the -786T/C SNP as 
well as the intron 4 SNP that are discussed below (Casas 2004). The strength of this study is 
that by sheer weight of numbers throughout a variety of populations they were able to 
overcome the potential criticism of smaller, possibly underpowered case-control allele 
association studies. This study concluded that the summary odds ratio under a fixed-effect 
model showed that individuals homozygous for the T allele were 1.31 times more likely to 
develop ischaemic heart disease. Even when the study with the largest influence upon this odds 
ratio was removed (Hignorani 1999), the overall estimate remained similar. Also interestingly   67 
despite racial differences between the frequency of the 894T allele between Asian and non-
Asian populations, a meta-regression analysis showed that ethnic background as well as 
smoking, age and gender were not significant sources of heterogeneity (Casas 2004). A 
subsequent larger meta-analysis however suggests that that a potentially deleterious effect of 
the T allele may infact be markedly reduced (Odds Ratio 1.17) (Casas 2006). Furthermore the 
association is not without contention as in a prospective multi centre study Andrikopoulos and 
co workers did not, within a Greek population, show any association of the Asp298 variant 
with risk of further myocardial infarction, extent of coronary artery disease or in hospital 
mortality after acute myocardial infarction (Andrikopoulos 2008). 
 
1.9.2 Cerebrovascular disease 
 
Following the finding that the G894T SNP had proven to be putatively a strong risk factor for 
atherosclerosis within the coronary circulation (Hignorani 1999) several investigators sought to 
elucidate as to whether this finding potentially translated to the cerebral circulation (Markus 
1998, MacLeod 1999, Elbaz 2000, Akar 2000). Markus and co workers studied 361 
consecutive white patients recruited to a London teaching hospital comparing the allelic 
frequencies with 236 normal controls. They found no relationship between this SNP in exon 7 
of NOS3 (Markus 1998). A larger study from Paris, by Elbaz et al on behalf of the GÉNIC 
investigators, recruited 460 cases and 460 controls that were recruited among individuals 
recruited at the same individuals hospitalized at the same institutions and individually matched 
on age, sex and centre (Elbaz 2000). They found, counter-intuitively that homozygosity for the 
G allele was associated with cerebral infarction, especially with lacunar stroke. Other studies 
from Aberdeen (MacLeod 1999) and Ankara, Turkey (Akar 2000) failed to find any significant 
association between the G894T SNP and ischaemic stroke.   68 
 
1.9.3 Coronary in-stent stenosis 
 
The genetic contribution to coronary in-stent restenosis was recently examined within London 
teaching hospitals (Gomma 2002). A total of 226 patients that underwent elective or 
emergency coronary artery stenting were recruited and carriers of the T allele exhibited a 
significantly higher frequency of restenosis (Odds Ratio 1.88) when compared to GG 
homozygotes (Gomma 2002). Moreover the -786T/C SNP was also found to have an 
association with the carriers of the -786C allele showing a higher risk of restenosis with an 
odds ratio of 2.06. These effects were found essentially to be additive and independent of other 
classical risk factors (Gomma 2002). 
 
1.9.4 Survival in patients with congestive cardiac failure. 
 
The role of the T allele variant of this common SNP was recently reported in a study from the 
USA (McNamara 2003). 469 patients with an ejection fraction of less than 45% were recruited 
and the investigators demonstrated that event free survival was influenced by the presence or 
absence of the T allele. Interestingly, in subset analysis the adverse impact of the T allele was 
evident primarily in patients with non ischaemic cardiomyopathy (McNamara 2003). This is 
surprising given the evidence linking this SNP with risk of ischaemic heart disease as listed 
above. 
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1.9.5 Coronary artery spasm and an enhanced vascular response to phenylephrine. 
 
Philip et al (Philip 1999) injected the alpha adrenergic agonist, phenylephrine into patients 
undergoing cardiac surgery and found the enhanced response to alpha adrenergic stimulation in 
patients with the 894T allele. This finding highlights the potential modulation of a vascular 
response to vasoconstricting hormones by this SNP. This finding did not extend however to α2 
adrenoceptor-induced coronary vasoconstriction, which appeared exclusively associated to the 
825T allele of GNB3, the gene which encodes the G protein β3 subunit, previously associated 
with an enhanced coronary blood flow reduction in response to α2 adrenoceptor activation 
(Naber 2003). Within a Japanese population where variant angina tends to be associated with 
diffuse coronary artery spasm the role of this polymorphism was examined (Chang 2003). 
They found, further implicating this SNP in cardiovascular pathophysiology, that the T allele 
was associated with diffuse, rather than focal spasm (usually associated with an area of 
atherosclerosis) of the coronary arteries (Chang 2003). 
 
1.9.6 Renal Disease 
 
Noiri et al compared 185 patients with end stage renal disease with 304 unrelated healthy 
individuals. They demonstrated an accumulation of T alleles, especially in patients with 
diabetes mellitus as the cause of their end stage renal disease (Noiri 2002). They postulated that 
diminished NO production in individuals with the T allele may augment the proinflammatory 
leukocyte adhesion to endothelial cells consequently decreasing the vasodilatory capability and 
further exacerbating atherosclerotic lesions in end stage renal disease. 
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1.9.7 Pre Eclampsia 
 
Pre eclampsia, hypertension and proteinuria in pregnancy, is a transient endotheliosis in other 
wise healthy young women. Serrano and colleagues postulated that the NOS3  gene was a 
candidate gene for pre eclampsia as physiologically there is considerable evidence that NO 
plays a role in pregnancy induced uterine vasodilatation (Serrano 2004). Acetylcholine is more 
potent and efficacious in producing dilatation of isolated uterine arteries from pregnant than 
from non-pregnant patients, an effect blocked by NOS inhibitors (Nelson 1995, Nelson 1998). 
Furthermore, in human uterine arteries there is a pregnancy associated increase in calcium 
dependent NOS activity and eNOS protein expression (Nelson 2000). 
 
Therefore Serrano et al studied 322 pregnancies with pre-eclampsia with comparison to 522 
controls (Serrano 2004). They analysed the effect of all 3 SNPs discussed in this introduction 
but found no increase in the risk of pre-eclampsia for the intron 4 or the -786T/C 
polymorphisms. They did however find a significant association in women homozygous for the 
T allele who had an adjusted odds ratio for pre-eclampsia of 4.6 (Serrano 2004). Furthermore 
after a multivariate analysis, carriage of the 894T-786C-intron 4b haplotype was associated 
with an increased risk of pre-eclampsia (odds ratio 2.11) compared to the 894G-786T-intron 4b 
haplotype. This corroborates earlier evidence associating the 894T allele with severe pre-
eclampsia in a Japanese population (Yoshimura 2000).  
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1.9.8 Cognitive Function 
 
A Spanish study recently reported on mild cognitive impairment and the G894T SNP (Solé-
Padullés 2004). Though no direct association was observed between this NOS3gene variation 
and mild cognitive impairment in 62 subjects studied those carriers of the 894T allele with 
mild cognitive impairment preformed worse in the Mini Mental State Examination, Wechsler 
Memory Scale (Revised),  long term visual memory and the phonetic verbal fluency tests 
(Solé-Padullés 2004). Thus the T allele represents a genetic risk factor for cognitive 
impairment in the elderly. 
 
1.9.9 Hypertension 
 
The first study linking this SNP and hypertension was published by Miyamoto and co workers 
(Miyamoto 1998). They examined the association of several SNPs of the NOS  gene and 
hypertension including the G894T SNP and the VNTR Intron 4 SNP in 2 different geographic 
sites in Japan, comparing hypertensives and normotensive controls. The odds ratio was similar 
in both places (2.3%) associating the 894T allele, but not the Intron 4 SNP, with hypertension 
(Miyamoto 1998). Though these findings in an were not substantiated in Australian (Benjafield 
2000) or a Scandinavian (Karvonen 2002) populations further evidence of an association of the 
894T allele, and with essential hypertension resistant to conventional treatment, came from a 
Czech population (Jáchymová 2001).  
 
Following the conflicting results generated from these association studies an elegant 
examination of the association of all three di-allelic SNPs (G894T, -786T/C and Intron 4   72 
VNTR) and also another SNP, within Intron 13 of NOS3, was recently published by Persu 
(Persu 2005). They genotyped 110 dizygotic white twin pairs from Flanders, Belgium and 
examined blood pressure as a continuous trait using ambulatory blood pressure recorders. 
Although sib-pair analysis failed to show any significant association of any specific SNP with 
blood pressure, haplotype analysis disclosed a significant association between NOS3 
haplotypes and daytime systolic blood pressure (Persu 2005). Ultimately as this approach is 
more informative further studies, and specifically functional studies within a given phenotype 
would be most informative. 
 
1.9.10 Insulin resistance 
 
Hyperinsulinaemia and insulin resistance are cofactors in the pathophysiology of essential 
hypertension with the association of impaired endothelial with decreased nitric oxide 
production shared by insulin resistance and essential hypertension (Cleland 2000). Hence Chen 
and colleagues examined, in an American population, a community based sample of 1021 
unrelated African American and white young adults aged 19 to 38 years (Chen 2001). They 
sought to obtain information on the combined effects of the NOS3 G894T SNP and Insulin 
resistance status (using the homeostasis model assessment of insulin resistance utilising fasting 
insulin and glucose) on blood pressure. After adjusting for sex, age, body mass index, carriers 
of the T allele displayed higher systolic, diastolic and mean arterial blood pressure and was not 
race specific (Chen 2001). This association was modulated by insulin resistance status. 
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1.9.11 Aortic Stiffness: Pulse Wave Velocity. 
 
Given the association described above between SNPs of the NOS3 gene and hypertension 
Lacolley and colleagues sought to ascertain whether this SNP had an association with a 
surrogate marker of arterial stiffness, PWV (Lacolley 1998). They measured carotid-femoral 
pulse wave velocity in 309 untreated hypertensive and 123 normotensive controls. They failed 
to show any association with either blood pressure or pulse wave velocity in this French 
population (Lacolley 1998). 
 
1.9.12 How may the G894T single nucleotide polymorphism of the NOS3 gene  be 
functional? 
 
The G894T SNP of the NOS3 gene has, therefore been widely implicated in both human 
physiology as well as the pathogenesis of vascular disease in man. The key question pertains as 
to if this SNP is itself functional and thus an important potentially modifiable target in the 
treatment of vascular disease or whether not this is merely a marker of another significant loci 
that heralds a functional effect that has so far eluded discovery. 
 
Several groups have undertaken painstaking research upon the structure, localization and 
putative effects of this SNP upon the biology of NO. This exon 7 polymorphism (894G→T) 
which determines the location of either a glutamate or an aspartate residue at position 298 has 
been associated with altered vascular biology but with several reservations. 
 
Firstly both glutamate and aspartate are conservative substitutions hence it is unlikely that they 
themselves produce functional affects. This SNP is of special interest as this conservative   74 
amino acid substitution within the oxygenase domain of the eNOS may influence eNOS 
function. Additionally analysis of the crystal structure of eNOS indicates that residue 298 is 
situated externally, distant from the active catalytic site and cofactor binding domains, and thus 
aspartate substitution would theoretically have minimal effect upon enzymatic activity 
(Fischmann 1999).  
 
Initial evidence was provided by Tesauro and co-workers who, utilising transfected cells, 
primary human endothelial cells and human hearts, demonstrated that eNOS with aspartate but 
not glutamate at position 298 was cleaved generating 100 KDa and 35 KDa products (Tesauro 
1999). The altered cleavage was postulated to alter NO generation. Additionally they noted, 
using Chou-Fasman secondary structure predictions that this seemingly conservative 
replacement generated significant structural changes. This contention was ultimately 
challenged by Fairchild et al who showed that the intracellular cleavage discovered in cells 
harbouring the Asp298 NOS3 substitution was an  in vivo artefact due to the acidic pH used in 
the study (Fairchild 2001).  
 
Gosler et al performed a detailed characterization of the G894T SNP with respect to its effect 
upon enzyme kinetic parameters, bound cofactors, uncoupled NADPH oxidase activity and 
binding affinities for calcium calmodulin and tetrahydrobiopterin. They showed no difference 
between the Glu/Glu or the Asp/Asp variants (Gosler 2003). 
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1.10 The NOS3 -786T/C SNP and human pathophysiology. 
 
The -786T/C SNP of the NOS3 gene has also been studied with respective to human 
pathophysiology. This variant results in a cytosine instead of thymidine substitution at 
nucleotide -786 (Nakayama 1999). This SNP has been shown to reduce the promoter activity 
(Nakayama 1999) and consequently reduce eNOS protein expression and eNOS activity (Wang 
2000a).  
 
1.10.1 Ischaemic heart Disease and coronary in-stent stenosis.  
 
The first evidence of the putative role of this SNP in ischaemic heart disease was produced by 
Álvarez who not only found that the frequency of patients homozygous for the C allele were 
significantly increased in patients compared to controls but also observed a synergistic effect 
between the NOS3 CC and the ACE DD genotypes in the risk of developing early coronary 
artery disease (Álvarez 2001). Colombo et al (Colombo 2003) in a study of 415 unrelated 
individuals from Italy with coronary artery disease described significant linkage disequilibrium 
between the G894T SNP and the -786T/C SNP. Both variants, they found, were significantly 
associated with the occurrence and severity of coronary artery disease and that the risk of CAD 
was increased amongst individuals homozygous for the C allele of the -786T/C SNP when 
compared to individuals homozygous for the T allele. Moreover individuals who were 
homozygous for the T allele of the G894T allele of the G894T SNP and who had at least one C 
allele of the -786T/C SNP were at greatest risk of coronary artery disease. As detailed above 
carriers of the -786C allele were found to be at higher risk of coronary instent stenosis (Gomma 
2002). Not all studies have been congruous as Jeerooburkhan did not show any association 
between this SNP and risk of ischaemic heart disease in the UK (Jeeroburkhan 2001). In a   76 
large study of 1225 individuals, however, Rossi et al for the GENICA study performed 
multiple logistic regression analysis for the effect of this SNP and the G894T SNP on two and 
three vessel coronary artery disease. They found that the -786T/C SNP, but not the G894T 
SNP, was associated with coronary artery disease with subjects harbouring a -786C allele 
having an increased risk of tow or three vessel coronary artery disease (Rossi 2003b). 
 
Again, as with the G894T SNP, the meta analysis described above examined the role of the -
786 T/C SNP upon risk of ischaemic heart disease (Casas 2004). While examining for both the 
dominant or recessive models of genetic association the authors failed to ascertain any 
association between this SNP and risk of ischaemic heart disease (Casas 2004). The subsequent 
updated meta analysis from the same group in 2006 also did not assocaite this SNP with 
coronary heart disease (Casas 2006). 
 
1.10.2 Insulin resistance. 
 
Altered eNOS activity has been associated not only with hypertension but also glucose 
homeostasis and insulin resistance (Duplain 2001). Ohtoshi et al examined the relationship 
between the G894T and -786T/C SNPs, common eNOS gene variants and insulin resistance 
(Ohtoshi 2002). While they observed no relationship with the former several fascinating 
findings were observed with the latter. Non diabetic subjects with the -786C allele had higher 
fasting glucose and homeostasis model assessment of insulin resistance than -786 TT 
homozygotes; diabetic subjects with the T allele had higher HbA1c levels and utilising the 
euglyceamic hyperinsulineamic clamp diabetic patients with the C allele demonstrated a lower 
glucose infusion rate than those without (Ohtoshi 2002). Moreover diabetic patients with the C 
allele had lower levels of NO metabolites. Further association associating this SNP with insulin   77 
resistance was produced by Fernandez et al (Fernandez 2004) who observed that the -786C 
homozygote was significantly more frequent in hypertensive patients with metabolic syndrome 
than in those without the syndrome. When they combined analysis of this SNP with the G894T 
SNP they identified the 786C894G as the risk haplotype for metabolic syndrome susceptibility. 
Lastly -786T/C genotype has been associated with AIx in children with type1 diabetes mellitus 
(Zineh 2007).  
 
 
1.10.3 Coronary artery spasm. 
 
Similar to the G894T mutation this SNP is associated with increased susceptibility for the risk 
of coronary artery spasm (Nakayama 1999). Subjects homozygous for the C allele were at a 3 
times elevated risk for coronary artery spasm as compared to heterozygotes or TT 
homozygotes. Moreover this group subsequently showed that this polymorphism combines 
with smoking to increase the risk of coronary artery spasm (Nakayama 2003). 
 
1.10.4 Internal carotid artery stenosis. 
 
Further evidence of the role of this SNP in the atherosclerotic process was recently published 
by an Italian group who observed that patients homozygous for the C allele were at higher risk 
of moderate to severe internal carotid artery stenosis, especially ulcerative lesions (Ghilardi 
2002). 
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1.10.5 Cerebral blood flow. 
 
The effect of this SNP upon cerebral blood flow parallels that of coronary artery spasm in 
regards to there being no recognised association between cerebral blood flow within non 
smokers but in smokers CC homozygotes had a significant decrease in cerebral blood flow 
(Nasreen 2002). 
1.10.6 Hypertension. 
 
Hyndman and colleagues, in a Canadian population of 705 healthy individuals, examined the 
effect of this polymorphism upon hypertension and documented that subject homozygous for 
the C allele had significantly higher systolic blood pressure and approximately 2 times more 
likely to be hypertensive (Hyndman 2002). 
 
1.11 The NOS3 Intron 4 variable number of tandem repeat and human pathophysiology. 
 
Several variable number of tandem repeats (VNTR) have been described in the NOS3 gene 
(Marsden 1993) including a polymorphism which represents 4 or 5 times the 27 base pair 
variable number of tandem repeats in intron 4 (NOS3 4a/b) (Wang 1996). Considerable 
interplay appears to exist between this SNP and the -786T/C SNP. Wang demonstrated that the 
27-bp repeat from the NOS3 intron 4 has a cis-regulating effect on the eNOS promoter (Wang 
2002a). Furthermore this regulation appeared to be haplotype dependent on both the eNOS 
promoter and intron 4 DNA sequence variants. 
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1.11.1 Ischaemic heart disease. 
 
The vast majority of the associations of this SNP with cardiovascular pathology centre upon 
ischaemic heart disease 
 
The first report associating this SNP with ischaemic heart diseased was published in 1996 by 
Wang et al (Wang 1996). They associated homozygosity for the NOS3a allele as a risk factor 
for coronary artery disease only in smokers. A further study, larger study with 455 patients 
with ischaemic heart disease and 550 controls, also from Japan confirmed the findings of Wang 
(Wang 1996) but found that the association of homozygosity for the NOS3 extended to both 
smokers and non-smokers (Ichihara 1998).  Furthermore these results were reproduced within a 
Turkish population where Hatemi found that the presence of an intron 4a allele was observed 
more frequently in patients with myocardial infarction than in controls (Hatemi 2002).  
 
Not all the literature is congruous, however, and Hibi et al, though they associated the TT 
homozygote of the G894T SNP with risk of acute myocardial infarction showed, within this 
Japanese population, no association between homozygosity of this SNP and ischaemic heart 
disease (Hibi 1998). Similar findings were elicited from a German population who, in 2717 
individuals undergoing coronary angiography compared to 533 healthy controls, failed to find 
an association between this SNP and risk of coronary artery disease and acute myocardial 
infarction (Gardemann 2002). Again as with all 3 SNPs Jeerooburkhan failed to ascertain any 
relationship between NOS3  genotype and either risk of ischaemic heart disease or plasma NO 
metabolites in a sample of middle aged white men in the United Kingdom. 
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In combining the 16 studies available examining the contribution of the intron 4a allele to 
ischaemic heart disease Casas concluded that, with a probable recessive genetic model of 
inheritance, the aa allele was associated with ischaemic heart disease (Casas 2004). 
 
1.11.2 Hypertension and correlation between blood pressure and physical activity. 
 
Kimura et al found a significant association between the intron4 VNTR genotype and physical 
activity level on systolic blood pressure (Kimura 2003). The association was only confined to 
those in the lowest tertile of physical activity level who had at least one a allele but 
nevertheless facilitates a better understanding of the mechanism of exercise to reduce 
hypertension and modulate cardiovascular risk.  
 
1.11.3 Pre-Eclampsia 
 
For the same reasons detailed above the Intron 4a/b had been investigated with regard to pre-
eclampsia. Although as previously described the influence of this SNP was found in one study 
to only extend as part of the 894T-786C-intron 4b haplotype in multiple regression analysis 
(Serrano 2004) others have associated this SNP with Pre-eclampsia (Tempfer 2001). Indeed the 
latter study elucidated a striking association odds ratio of developing pre-eclampsia when one 
of the shorter a alleles was present, 6.5 (Tempfer 2001). 
 
Other important reports that failed to find a significant association between this SNP and 
vascular disease includes negative studies pertaining to diabetic nephropathy (Rippin 2003) 
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1.12 Biochemical indices as markers of cardiovascular disease 
 
Markers of Inflammation have received widespread attention within the medical literature over 
recent years as the link between low grade inflammation and cardiovascular disease gains 
rising precedence (de Maat 2004). Inflammation would appear to play a crucial role in all steps 
in the development of atherosclerosis from the nascent lesion to a full blown acute coronary 
syndrome (Libby 2002). Some of the markers extensively studied in relation to their putative 
roles are C-reactive protein (CRP), interleukin 6 (IL 6), Adiponectin and Intracellular adhesion 
Molecule 1 (ICAM1). 
 
1.12.1 C-reactive protein. 
 
CRP is a plasma protein which is produced by the liver and is an acute phase protein. It 
belongs to the pentraxin family of proteins and was initially discovered by Tillett and Francis 
in 1930 as a substance in the serum of patients with acute inflammation that reacted with the C 
polysaccharide of pneumococcus (Tillett 1930). CRP is a prototypic marker of inflammation 
and as will be described has been denoted to predict cardiovascular events in apparently 
healthy subjects, and a poor prognosis following acute coronary syndromes. 
 
Basal levels of CRP are associated with an increased risk of diabetes, hypertension and 
cardiovascular disease. Raised levels of CRP indicate that atherosclerosis is a chronic 
inflammatory process (Hirschfield 2003). Moreover several large scale prospective 
epidemiological studies have shown that plasma levels of CRP are strong independent 
predictors of atherosclerotic events in apparently healthy women and men (Ridker 1997, 
Ridker 1998a). Elevated CRP is a surrogate marker for sub clinical atherosclerosis (Wang   82 
2002b) and is involved in development and progression of atherosclerosis (Pasceri 2000). 
Elevated baseline CRP was found to portend heightened risk of 30 day death or myocardial 
infarction in 727 patients prior to percutaneous coronary intervention (Chew 2001). Increases 
in pulse pressure in a large stuffy of almost 10,000 were associated with elevated CRP levels 
amongst healthy adults from the United States, independent of SBP and DBP (Abramson 
2002). Low grade inflammation has also been associated with the insulin resistance syndrome 
(Yudkin 1999, Festa 2000) and markers of low grade chronic inflammation have been shown 
prospectively to independently predict those at high risk for type 2 diabetes mellitus(Schmidt 
2000, Freeman  2001). Leinonen and co workers demonstrated that fasting levels of sICAM-1, 
IL-6 as well as CRP were associated with Insulin resistance and adiposity in 239 female 
patients with type 2 diabetes (Leinonen 2003). Additionally women with poly cystic ovarian 
syndrome have significantly increased CRP levels compared to healthy controls (Kelly 2001).   
 
There has been some dubiety regarding the strength of the association between CRP and CVD 
and a large study by Danesh and colleagues suggested that CRP may only be a modest risk 
factor for CVD (Danesh 2004). Furthermore Timpson and co workers examined associations 
between serum CRP concentrations and metabolic syndrome phenotypes in the British 
Women‟s Heart and Health Study then comparing these estimates with those derived from a 
randomized framework with common CRP gene haplotypes (Timpson 2005). While they found 
that CRP haplotypes were associated with plasma CRP concentration they noted disparity 
between estimates of the association between plasma CRP and phenotypes comprising the 
metabolic syndrome derived from conventional analysis and comparing those from a 
Mendelian randomization approach. Thus they suggested that there was no causal association 
between CRP and the metabolic syndrome phenotypes (Timpson 2005).   83 
There thus remains contention as to whether CRP levels are merely a marker or whether there 
is a pathophysiological role for CRP within the vascular diseases described (de Maat 2004, 
Schunkert 2008). A statistical association is not analogous to clinical or pathophysiological 
causality (Schunkert 2008).  
 
CRP has been associated with arterial stiffness. Yasmin et al found that, even after controlling 
for confounding factors such as blood pressure, age, gender and smoking, aortic and brachial 
PWV were both associated CRP in 427 healthy individuals (Yasmin 2004). This group did not 
find any association with Aix and CRP. On the contrary another group from Estonia, in a 
smaller cohort of healthy individuals (158) found significantly higher Aix in subjects with CRP 
levels above 1mg/ml and in multiple regression analysis Aix correlated positively with age, 
female gender, short stature, mean arterial pressure and CRP (Kampus 2004).  
 
1.12.2 Interleukin 6  
 
IL-6 is a cytokine with both pro inflammatory and anti inflammatory effects on many cell 
types, affecting both B cell immunoglobulin production and T cell cytotoxic activity (Barton 
1996). IL-6 also modulates platelet function as well as endothelial function and is the only 
substance known to induce synthesis of all of the acute phase proteins by the liver (Lindmark 
2001). Il-6 itself is produced by many cellular elements such as activated macrophages, 
lymphocytes, endothelial cells and vascular smooth muscle cells (Rattazzi 2004).  
 
A series of studies have revealed the association of Il-6 and „traditional‟ vascular risk factors. 
Il-6 levels rise with age and are significantly associated with high blood pressure, smoking and 
insulin sensitivity (Bermudez 2002, Fernandez- Real JM 2001,Ridker 2000). Furthermore   84 
production of IL-6 increases at increasing levels of adiposity in healthy men and women 
(Mohammed-Ali 1997). A circadian variation exists with increased cytokine levels during the 
night exists (Sothern 1995). 
 
Chae and co workers documented significant graded relationships between blood pressure and 
IL-6 and sICAM-1 in 508 apparently healthy men (Chae 2001). Il-6 plasma levels are elevated 
in patients with unstable angina compared to those with stable angina or healthy subjects 
(Biasucci 1996, Biasucci 1999). Large scale prospective studies have shown that IL-6 plasma 
levels in the upper quartile of the considered normal range are independently predictive of an 
increased risk of premature death or further myocardial infarction (Harris 1999, Ridker 2000). 
The idea that IL-6 is involved in progression of CAD is further substantiated by a Swedish 
study which identified circulating levels of IL-6 as a strong independent risk factor of increased 
mortality in unstable CAD and identifies patients, with high IL 6 levels (>5ng/l), who benefit 
most from a strategy of early invasive management (Lindmark 2001).  
 
1.12.3 Adiponectin 
 
Adiponectin is a protein hormone which regulates a variety of metabolic processes including 
glucose regulation and fatty acid catabolism. It is a 244 amino acid long polypeptide with 4 
distinct regions (Whitehead 2006). The gene for Adiponectin has been identified and is situated 
on chromosome 3p27 and has been highlighted as affecting genetic susceptibility to obesity 
and type 2 diabetes mellitus (Ukkola 2005). It is solely secreted from adipocytes and plasma 
levels are inversely and paradoxically proportional to body mass index, unlike leptin, another 
adipose tissue specific secretory product which is known to increase with body mass index 
(Takahashi 1996). Hence patients who have the highest BMI and highest quantity of adipose   85 
tissue have the lowest levels of Adiponectin. There is also a sexual dimorphism with females 
displaying higher levels than males as well as circadian (Gavrila 2003).  
 
This hormone has been described as playing a key role in type 2 diabetes mellitus, obesity and 
atherosclerosis. Patients with diabetes have lower Adiponectin levels than control subjects and 
moreover those with macroangiopathy have lower levels than those without (Hotta 2000). 
Moreover plasma levels of Adiponectin were lower in Pima Indians, a unique cohort where the 
high prevalence of obesity aggregates with diabetes (Lindsay 2002). Additionally plasma levels 
of Adiponectin strongly correlate with insulin sensitivity (Stefan 2002). Thus Adiponectin has 
a key role in insulin action and low levels may result in insulin resistance and diabetes mellitus 
(Matsuzawa 2004). Adiponectin has also been found to predict Insulin resistance but not 
endothelial function in 294 adolescents (aged 13 to 16 years) (Singhal 2005). Patients with 
hypertension and ischemic heart disease have also been found to have lower levels of 
Adiponectin (Mallamaci 2002, Kumada 2003). Interestingly, whereas there is no adiponectin 
present in untreated normal vascular walls in rabbit models when balloon injury is introduced 
to vascular walls, a markedly positive immunohistochemical stain was found with anti 
adiponectin antibody (Okamoto 2000).  Therefore the presence of adiponectin may be a key 
pathological event in the development of CAD. The importance of adiponectin as a potential 
risk factor in vascular disease is further corroborated by Kaplan-Meyer analysis of patients 
with chronic renal insufficiency which demonstrated that subjects with lower levels died of 
cardiac events more frequently during a 4 year observation period (Zoccali 2002). The high 
molecular weight form of adiponectin is more strongly associated with insulin sensitivity (Hara 
2006), is more strongly associated with incident risk of diabetes (Nakashima 2006) and is also 
more strongly associated with protection against endothelial cell apoptosis (Kobayashi 2004) 
and hence is perhaps a more sensitive marker of coronary heart disease then Adiponectin per   86 
se. It was not, however associated with incident coronary heart disease in women from the 
British Women‟s Health and Heart Study (Sattar 2008). It is unclear whether adiponectin is a 
key mediator or bystander in cardiovascular disease (Antoiniades 2009). It is therefore too 
early to nominate adiponectin as the origin of vascular disease. 
 
1.12.4 Intracellular adhesion molecules 
 
Cellular adhesion molecules in part mediate adhesion of circulating leucocytes to the 
endothelial cell (Springer1994, Adams 1994). Subsequent transendothelial migration is 
putatively an important step in the initiation of atherosclerosis (Ross 1993). ICAM1 is 
constitutively expressed on endothelial cells in most regional vascular beds (Granger 2004). 
Pathological studies have shown increase cellular adhesion molecule expression in several 
components of the atherosclerotic plaque (Poston 1992, O‟Brien 1996). There is a potential 
role for adhesion molecules in acute atherothrombotic syndromes (Jang 1994). Furthermore 
plasma concentrations may be higher among patients with atherosclerosis (Peter 1997, Blann 
1994) and dyslipidaemia (Hackman 1996). As noted above Chae et al described in healthy men 
a graded relationship between blood pressure and levels of ICAM 1 (Chae 2001). Ridker 
defined the importance of ICAM1 in CHD by showing in a large prospective cohort of 
apparently healthy men that increasing concentration of ICAM1 is associated with risk of 
future myocardial infarction (Ridker 1998b). The risk of future myocardial infarction was 80% 
higher in patients with baseline ICAM1 concentrations in the highest quartile (Ridker 1998b).  
 
In summary inflammatory activation, in part mediated by the molecules detailed above, in 
reaction to an atherogenic stimuli may, in the arterial wall, cause alterations in vascular   87 
stiffness. We therefore sought to examine the putative relationship between these inflammatory 
markers and arterial stiffness in healthy volunteers. 
 
 
1.13 Diminished nitric oxide bioactivity: A potential link between non invasive vascular 
compliance as an intermediate phenotype and low grade inflammation. 
 
As described earlier in sections 1.2.2 and 1.2.3 both augmentation index and small artery 
compliance are sensitive to pharmacological manipulation in NO bioactivity with LNMMA 
(Wilkinson 2002a. McVeigh 2001). A growing body of evidence suggests that in the arterial 
wall low grade inflammation per se parallels the presence of poor NO bioactivity. 
 
eNOS is present within endothelial cells as stated the derived NO stimulates arterial 
vasodilatation and inhibits smooth muscle cell proliferation, LDL oxidation, platelet adhesion 
and aggregation and  monocyte adhesion to the endothelium (Wever 1998, Loscalzo 1995b, 
Boger 1996). Endothelial dysfunction which is complicit with impaired NO bioactivity occurs 
early in atherosclerosis. CRP has been shown to cause a direct reduction in eNOS expression 
and bioactivity in human endothelial cells with a simultaneous decrease in cyclic GMP and an 
increase in adhesion to monocytes to the endothelium – an early stage in atherosclerosis, with a 
rise in sICAM-1 levels (Venugopal 2002). Furthermore patients with angiographically 
documented coronary artery disease with high levels of CRP had diminished endothelial 
vasoreactivity (r=-0.46, Fichtlscherer 2000) and Cleland et al have shown a relationship 
between CRP levels and percentage decrease in forearm blood flow during infusion of the 
eNOS inhibitor L-NMMA (Clelland 2000b).    88 
Aims 
The aims of the current study were: 
1) To assess the reproducibility of diastolic pulse contour analysis as a non invasive 
intermediate cardiovascular phenotype. 
 
2) To determine whether the C242T single nucleotide polymorphism of the p22phox gene, 
CYBA, has an effect upon arterial compliance in patients with coronary artery disease. 
 
3) To determine whether the G894T (Glu298Asp) single nucleotide polymorphism of the 
endothelial nitric oxide synthase gene, NOS3, has an effect upon arterial compliance in patients 
with coronary artery disease. 
 
4) To determine whether there is an interaction between the NOS3 G894T single nucleotide 
polymorphism and the CYBA C242T single nucleotide polymorphism in patients with coronary 
artery disease. 
 
5) To determine, in healthy volunteers, free of cardiovascular disease whether a relationship 
existed between markers of low grade inflammation and arterial stiffness. 
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Chapter 2 Methods. 
2.0 Summary  
 
This chapter provides a description of the general protocols of the clinical techniques used in 
the studies described in this thesis.  
2.1 Healthy volunteers and patients. 
 
All the studies described within this thesis were performed in the Clinical Investigation and 
research Unit (CIRU), British Heart Foundation Glasgow Cardiovascular Research Centre, 
Western Infirmary Glasgow. 
 
Twenty four healthy volunteers (Chapter 3) were recruited for validation studies. Each subject 
attended twice, at the same time of day for non invasive vascular phenotyping as described 
below. Volunteers were all in good health with no past or current medical history, aged 19-65 
and taking no regular mediation. Two were smokers. All subjects gave a full clinical history 
and underwent a full examination to confirm health prior to the study. 
 
Fifty three healthy normotensive volunteers were recruited via advertisements within the 
University, Glasgow Herald newspaper offices and local newspapers for the work described in 
chapter 6. No subjects were taking any medication and all abstained from alcohol, nicotine, 
tobacco, food and strenuous activity overnight before the study day. Physical health was 
confirmed by screening with history, a full physical examination, ECG and supine blood 
pressure measurement in triplicate. Ninety volunteers were screened and those with raised 
blood pressure, an antecedent history of vascular disease or abnormal ECG excluded.   90 
 
The studies comparing oxidative stress genotype upon vascular compliance described in 
chapters 4 and 5 were performed in 103 individuals attending the Western Infirmary, Glasgow 
for coronary artery bypass grafting. Each individual previously underwent coronary 
angiography which had documented coronary artery disease and attended the BHF Glasgow 
Cardiovascular Research Unit in the University of Glasgow the week prior to surgery fasted 
and abstinent from tobacco, alcohol, tea or coffee from midnight the previous night. Each 
patient had their height and weight recorded as described below and a detailed drug and past 
medical history taken as well as a full physical examination and electrocardiogram. We 
excluded those who had a history of endocrine, hepatic, renal or valvular heart disease or atrial 
fibrillation. The latter two in themselves can alter the pulse pressure wave shape. All 
participants were asked to defer taking their normal medication on the day of the study until 
after the protocol was completed.  410 patients were screened and those withdrawn who did not 
manage to comply with fasting or due to an episode of anginal pain during the preceding 24 
hours, or upon documented valvular heart lesion or audible murmur or arrhythmia discovered 
during clinical examination or electrocardiogram. Clinical details obtained from the patients 
were corroborated from case sheet examination. A history of current cigarette smoking, 
hypertension (defined as either current anti-hypertensive treatment or a blood pressure > 
140/90 mmHg), diabetes mellitus and hypercholesterolaemia (plasma cholesterol >5.4 mmol/or 
on treatment) were considered as risk factors. Each patient brought with them an up to date 
repeat prescription sheet from their general practitioner to ensure that an accurate drug history 
was obtained. 
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2.2 General Clinical Protocol. 
 
The study protocols were individually approved by the Ethics Committee of the West Glasgow 
Hospitals University NHS trust. All underwent the pre study procedure above following full 
informed consent. On each study day the healthy volunteers or patients with coronary artery 
disease were transported to the CIRU between 0700 hours and 0900 hours after an overnight 
fast from 2200hrs. After the clinical and morphometric measurements were taken the patients 
lay supine, at rest in a quiet room which was temperature controlled, at 24-25ºC, where the 
clinical studies were undertaken. Following each study a light meal was provided for subjects 
prior to transportation home. 
 
2.3 Clinical and morphometric measurements.  
 
2.3.1 Body Mass Index 
 
Body weight and height were measured with subjects in light clothes and without shoes to the 
nearest 0.5kg of weight and the nearest 0.5cm of height. Exactly the same equipment was used 
throughout the studies, and the weighing scales (Seca, Germany) were calibrated regularly. The 
same observer preformed all the measurements (RSD). Body mass index (BMI, kg/m
2) was 
calculated as:  
BMI= Body weight (kg )/(height (m))
2 
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2.3.2 Blood Pressure and heart rate. 
 
Throughout each study the technique utilised to record blood pressure and heart rate remained 
uniform. Systolic and diastolic blood pressure and heart rate were measured, after 1 hours 
supine rest, by an oscillometric technique using a Dinamap Critikon (Johnson and Johnson 
Professional Products Ltd., UK) semi automatic sphygmomanometer, maintained and 
calibrated at regular intervals by the Department of Physics, Western Infirmary.  
 
2.3 Pulse Wave Analysis. 
 
Systolic and diastolic pulse wave analysis was carried out by a single investigator (RSD) in a 
dedicated investigation room as described. Subjects were placed in the supine position and 
right radial artery waveforms acquired as detailed below.  
2.3.1 Diastolic pulse contour analysis.  
 
Subjects were placed in the supine position and right radial artery waveforms were acquired 
with the use of a calibrated proprietary tonometer (model CR 2000 Hypertension Diagnostics 
Inc) and used according to manufacturers specifications. The tonometer consists of a 1.27cm 
diameter stainless steel canister with a 0.15mm thick stainless steel diaphragm connected to a 
double plated ceramic piezoelectric element used to amplify the waveform signal. The 
subject‟s arm is stabilised in an angulated wrist support and radial artery waveforms analysed 
for a 30 second period. The CR 2000 device then utilises the 4 element modified Windkessel 
model to generate C1 and C2 as described previously (Cohn 1995, McVeigh 1991, McVeigh 
1993, McVeigh 1999). A description of the mathematical model used within the Windkessel is   93 
described in the introduction in section 1.2.3. Four recordings were taken and the mean used 
for analysis. The procedure was well tolerated by each subject. 
 
2.3.2 Systolic pulse contour analysis 
 
For systolic pulse contour analysis the SphygmoCor Arterial Tonometry system (Atcor 
Medical Inc) was utilised. Central pressure waveforms are derived and analysed as described 
by Wilkinson et al (Wilkinson 1998). A high fidelity micromanometer probe (SPC-301; Millar 
Instruments) was used by one observer (RSD). The probe is placed on the right radial artery at 
the wrist. The wrist is extended and held within a support to ensure that the artery is kept in one 
position and to facilitate reproducibility. The probe is placed upon the wrist with sufficient 
pressure to flatten but not occlude the radial artery at the wrist. The probe is connected to a lap 
top computer upon which data was collected directly. After a waveform recording was 
established 20 sequential waveforms are collected and software integral to the system generates 
an impression of an average peripheral waveform. A generalised transfer function, the 
methodology of which is described in the introduction in section 1.2.2, then constructs a 
derived central waveform. Recordings were excluded as per standard procedures of other 
groups which have utilised this technique (Wilkinson 2000). In this way recordings were 
excluded if the systolic or diastolic variability of the waveforms exceeded 5%, or the amplitude 
of the waveform, a measure of the quality of the tracing exceeded 100mV. The derived central 
waveform was then analysed, again using the integrated software to generate the AIx, the 
difference between the first and second peaks of the central pressure waveforms as described in 
section 1.2.2 and figure 1.1 .The AIx is expressed as a percentage of the pulse pressure and is a 
measure of systemic arterial stiffness and wave reflection. All measurements were made four 
times and again the mean values utilised.    94 
 
2.4 Genotyping. 
 
Following non-invasive vascular measurements a sample of blood was taken and DNA 
extracted using the Wizard Genomic DNA Purification kit (Promega). Genotyping of the 
CYBA C242T and NOS3 G894T SNPs was performed by investigators Dr Nick Brain and Mrs 
Koh-Tan who were unaware of the patients‟ phenotypes.  
 
Genotyping of the C242T polymorphism was performed by restriction enzyme treatment and 
agarose gel resolution. Primers for polymerase chain reaction (PCR) were designed around the 
polymorphism.  Sequences of these were TGCTTGTGGGTAAACCAAGG (Fwd), 
GGAAAAACACTGAGGTAAGTG (Rev).  PCR was performed with 1U of Taq DNA 
polymerase (Promega) in a 20  l reaction volume containing 25 ng of genomic DNA; 1X PCR 
buffer; 1.5 mM Mg
2+; 200  M each dNTP and 20 pmol of primer. PCRs were cycled on PCT-
225 thermal cyclers (MJ Research) as follows: 95 C for 5 min; then 30 cycles of 95 C for 1 
min, 55 C for 1 min, and 72 C for 1 min; followed by 72 C for 10 min.  PCRs were run on 
1.5% Ultrapure Agarose gels (Invitrogen) to confirm amplification. Restriction reactions 
consisted of 20 U of RsaI, 16  l of PCR product and 2  l of buffer. Reactions were incubated 
at 37 C for 2 hours, before resolution on 2% Ultrapure Agarose gels.  Genotype was 
determined from fragment patterns as follows: CC: 353 bp; TT: 160 bp and 193 bp; CT: 160, 
193 and 353 bp (Ito 2000).  Genotyping was checked by two individuals.  Fourteen 
representative samples were sequenced in forward and reverse directions, using PCR primers, 
to confirm fidelity of restriction genotyping.  
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The G894T polymorphism was genotyped by sequencing.  PCR primers were designed with 
the following sequences: AAGGCAGGAGACAGTGGATGGA (Fwd), 
CCCAGTCAATCCCTTTGGTGCTCA (Rev).  PCR was performed with 0.2U of HotStar Taq 
(Qiagen) in a 20  l reaction volume containing 25 ng of genomic DNA, 1X PCR buffer (with 
1.5 mM Mg
2+), 200  M of each dNTP and 20 pmol of primer, and cycled on PCT-225 thermal 
cyclers (MJ Research).  The following program was used: 95 C for 15 min followed by 30 
cycles of 94 C for 1 min; 58 C for 1 min; 72 C for 1 min; followed by 60 C for 30 min.  PCR 
products were purified using Nucleofast-96 plates (Macherey-Nagel) and the manufacturer‟s 
protocol.  Products were sequenced using BigDye Terminator v3.1 kits (Applied Biosystems) 
and a modified 20  l reaction protocol such that 0.5  l of Ready Reaction mix and 3.75  l of 
5x sequencing buffer were used per reaction.  The reverse PCR primer was used for 
sequencing.  Sequencing reaction products were purified using genCLEAN plates (Genetix) 
before being resolved on an ABI 3730 capillary sequencer (Applied Biosystems) using 
standard sequencing run conditions. Genotyping of the sequencing data was performed using 
SeqScape (Applied Biosystems) software and two individuals checked all genotypes. 
Concordance between the two individuals was 100%. 
 
2.5 Laboratory methods 
 
Upon completion of pulse wave contour analysis venous blood samples were withdrawn from 
the antecubital fossa and samples immediately placed within ice. Thereafter samples for the 
biochemical analysis described below underwent centrifugation (3000 rpm, 4 ºC) prior to 
decanting and storage at -20ºC. 
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For all measurements batch analysis was performed to minimize inter assay variability and 
samples preformed in duplicate. All reagents and samples were allowed to come to room 
temperature prior to use. The inter- and intra-assay coefficients of variation were <10% across 
the range of measured results. Intra-assay coefficients of variation were <7% for all analytes. 
 
Cholesterol, HDL-C and tricylglycerol were measured using commercially available enzymatic 
assay kits from Roche Diagnostics Corporation (Indianapolis, IN, U.S.A.) and a Hitachi 917 
analyser, and LDL-C (low-density lipoprotein cholesterol) was calculated from the Friedewald 
equation 
 
2.5.1 Adiponectin 
 
Adiponectin was analysed using the Quantikine
® Human Adiponectin/Acrp30 Immunoassay 
(Catalog Number DRP300). This is a solid phase ELISA containing recombinant human 
adiponectin and can measure human adiponectin levels within cell culture supernatants, serum 
and plasma. The assay utilises the quantitative sandwich enzyme immunoassay technique. The 
monoclonal antibody specific for adiponectin is recoated onto the micro plate. Standards and 
samples are pipetted into the wells and any adiponectin present is bound by the immobilized 
antibody. Following washing the enzyme linked monoclonal antibody specific for Adiponectin 
is added to the wells. Thereafter following a further wash a substrate solution is added to the 
wells and colour develops in proportion to the amount of Adiponectin bound in the initial step. 
A Multiscan Ascent plate reader and software were used for calculating results  
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2.5.2 Interleukin 6. 
 
IL-6 was analysed using the Quantikine
® Human IL-6 Immunoassay (Catalogue Number 
D6050). This is a solid phase ELISA designed to measure IL6 within cell culture supernates, 
serum and plasma. It contains recombinant human IL-6. The assay employs the quantitative 
sandwich enzyme immunoassay technique. A monoclonal antibody specific for Il-6 is 
precoated upon a microplate.  
 
A dilution series was generated with concentrations of 0pg/ml, 1.56 pg/ml, 3.12 pg/ml, 6.25 
pg/ml, 12.5 pg/ml, 25 pg/ml, 50 pg/ml and 100 pg/ml.  Standards and samples are pipetted into 
the wells and any IL-6 present is bound by the immobilized antibody.  Following washing an 
enzyme linked polyclonal antibody specific for IL-6 is added to the wells. After a further wash 
substrate solution is added to the wells which develops in intensity in proportion to the amount 
of Il6 bound in the initial step. The colour development is stopped and the intensity measured 
using a Multiscan Ascent plate reader and software were used for calculating results. 
 
2.5.3 Soluble ICAM-1 immunoassay. 
 
sICAM-1 was analysed using the Quantikine
® Human sICAM-1 Immunoassay (Catalogue 
Number BBE 1B). The principle stages are as described for adiponectin and IL-6. The 
technique employed is the quantitative sandwich enzyme immunoassay technique. A 
monoclonal antibody specific for sICAM-1 has been precoated onto a micro plate.  
 
A dilution series was generated using 0 ng/ml, 1.86 ng/ml, 10.3 ng/ml, 19.1 ng/ml, 29.8 ng/ml 
and 41.9 ng/ml. Standards, samples, controls and conjugate are pipetted into the wells and any   98 
sICAM-1 present is sandwiched by the immobilised antibody and the enzyme-linked-
monoclonal antibody specific for sICAM-1. After washing a substrate solution is added top the 
wells and colour develops in proportion to the amount of bound sICAM-1. Again the colour 
development is then stopped and the intensity measured using a Multiscan Ascent plate reader 
and software for calculating results.  
 
2.5.4 Highly sensitive C reactive protein. 
 
CRP was measured using a sensitive double-antibody sandwich ELISA with rabbit anti-human 
CRP and peroxidase-conjugated rabbit anti-human CRP (Roche Diagnostics Corporation 
Indianapolis, IN, U.S.A., Catalog No 1972855). The assay is a particle enhanced 
immunoturbidimetric assay. Anti-CRP antibodies coupled to latex microparticles react with 
antigen in the sample to form an antigen/antibody complex. Following agglutination, this is 
measured turbidimetrically. A Hitachi 917 analyzer was used. The assay was linear up to 5 
mg/l and logarithmic thereafter.  
 
2.6 Statistics. 
2.6.1 Reproducibility studies. 
For the reproducibility studies we utilised the technique described by Bland and Altman (Bland 
1996). Bland-Altman plots were derived for to calculate intra-observer bias for C1 and C2 
(Minitab 14).   99 
 
2.6.2 The effect of genotype upon arterial compliance in patients with coronary artery 
disease. 
All data are presented as mean ± SEM unless otherwise stated. Power calculations were 
performed before sample acquisition and 100 subjects were projected to provide 80% power 
for primary analysis based on two sample t-tests to compare mean C2 values between the two 
homozygous groups at each locus. The Chi squared statistic was used to ensure that the 
observed allele frequencies did not differ from that expected under Hardy-Weinberg 
equilibrium. 
 
A two tailed Student‟s t-test was used to analyse differences in phenotype between subjects 
with presence or absence of the T allele for the CYBA C242T SNP, as this has previously been 
reported as being the dominant allele (Cahilly 2000, Cai 1999). One-way ANOVA was used to 
examine the effect of genotype of the NOS3 SNP on vascular parameters as with this SNP there 
has been no documented dominant allele (Hibi 1998). Furthermore a comparison using the 
Student‟s t-test was carried out between patients homozygous for the NOS3T allele and 
possessing the CYBA 242T allele and patients homozygous for the NOS3 G allele and for the 
CYBA C allele. Thereafter multiple regression analysis was preformed to identify the variables 
that independently predicted the relationships. Where a potential confounder was discovered a 
generalised linear model was constructed to ascertain if, adjusting for this variable, the 
relationship remained significant. Statistical significance was defined as p<0.05. Minitab 14 for 
Windows (Minitab Inc) was used for all statistical analysis and PRISM 4 used to generate 
graphs (Graphpad).   100 
2.6.2 The relationship between markers of low grade inflammation and Insulin resistance 
upon arterial compliance in healthy volunteers. 
 
The Kolmogorov Smirnov test for normality was used to establish whether the data sets were 
normally distributed. The data sets for ICAM and adiponectin were normally distributed 
whereas those for IL-6 and CRP were not. For data that did not follow the Gaussian 
distribution, for statistical analysis, the data set was log transformed to create a normal 
distribution. 
 
Simple regression was used to create a model with only one predictor utilizing the least squares 
estimation. Where the data was normally distributed the Pearson correlation was used (ICAM 
and Adiponectin). Where the data did not fit a Gaussian distribution Spearman Rank 
correlation was used, i.e. for CRP and IL 6. Thereafter multiple regression was used to describe 
the statistical relationship between a response and 2 or more predictors. Again this used the 
method of least squares, which determines the equation for the straight line that minimizes the 
sum of the vertical distances between the data points and the line. As before p<0.05 was 
considered significant.   101 
Materials and Methods Appendix 
Manufacturers and Suppliers 
 
Multiscan Ascent Plate Reader and Software. 
Thermo Life Sciences 
Unit 5, The Ringway Centre 
Edison Road, Basingstoke, Hampshire 
RG21 6YN 
Telephone  (01256) 817282) 
Fax     (01256 817292) 
www.thermo.com 
 
Where samples required dilution a Hamilton dilutor was used. 
 
Microlab 500 series. 
 
Scientific laboratory supplies ltd. 
Unit 17. 
Coatbridge business centre, 
204 Main Street 
Coatbridge, Lanarkshire, ML5 3RB 
 
Telephone   (01236) 431857 
Fax     (01236) 431050   102 
Adiponectin 
 
Quantikine
® Human Adiponectin/Acrp30 Immunoassay (Catalog Number DRP300).  
 
Interleukin 6. 
 
Quantikine
® Human IL-6 Immunosassay (Catalogue Number D6050).  
 
sICAM-1 
 
Quantikine
® Human sICAM-1 Immunosassay (Catalogue Number BBE 1B).  
 
Manufactured and distributed by  
R&D Systems Inc. 
614 McKinley Place, NE.  
Minneapolis, MN 55413. 
United States of America 
Tel (0800)  343-7475. 
Fax (612)  379-2956 
 
European Distributors. 
R & D Systems Europe 
19 Barton Lane, Abingdon Lane, Abingdon, 
Oxon, OX14 2NB. 
United Kingdom.   103 
Cholesterol, HDL-C and tricylglycerol 
 
Enzymatic assay kits from  
Roche Diagnostics Corporation 
Indianapolis 
IN 
U.S.A 
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Chapter 3. Baseline subject characteristics and the reproducibility and 
comparison of vascular compliance values. 
 
3.0 Summary. 
This chapter describes the clinical characteristics of the subjects recruited; healthy volunteers 
and patients with coronary artery disease. Thereafter, reproducibility studies examining small 
and large artery compliance values were conducted as there has been some suggestion in the 
medical literature that the reproducibility of DPCA is not optimal (Manning 2002, Rietzschel 
2001, Segers 2001).  
 
3.1 Subject and patient recruitment. 
 
As detailed in section 2.1 the twenty four subjects for reproducibility studies were recruited 
from within the British Heart Foundation Glasgow Cardiovascular Research Centre. The 53 
healthy volunteers for the study of arterial compliance and low grade inflammation were 
recruited from advertisements within Glasgow University and also from the offices of the 
Glasgow Herald. The 103 patients to ascertain the effect of genotype upon arterial stiffness in 
patients with coronary artery disease were recruited from the Coronary Artery Bypass Graft 
operation waiting lists. 
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3.2 Patient Characteristics.  
 
Table 3.1 describes the baseline characteristics of the 103 patients with coronary artery disease. 
The mean age was 61.8 but range included patients as young as 36 and as old as 82. The mean 
BP was 130.94/70.9 mmHg, total cholesterol 4.29 mmol/L and LDL cholesterol 2.34 mmol/L. 
In terms of vascular measurements the mean AIx was 28.89%, mean C1 14.74 ml/mmHg x 10 
and mean C2 4.63 ml/mmHg x 100mmHg. 39(37%) had never smoked cigarettes, 25 (25%) 
had previously been smokers (more than 6 months since their last cigarette) and 40 (38%) were 
current smokers. The cardiovascular medication that the patients were taking is detailed in 
table 3.2. As a group the patients were on the standard regimen with most on a HMG CoA 
Reductase inhibitor (85%), Beta Blocker (72%) and Aspirin (71%). 49% were on an 
Angiotensin converting enzyme inhibitor. 41% were using transdermal or oral nitrate. 
 
3.3 Baseline characteristics of healthy controls.  
 
The characteristics of the healthy controls recruited are detailed in table 3.3. The controls were 
younger with a mean age of 52.74, range 37-72. The mean BP was 124/62 and in terms of 
arterial compliance values the C1 and C2 were higher (15.2 ml/mmHg x 10 and 6.74 ml/mmHg 
x 100 respectively) and AIx lower (23.85%) indicating more compliant arteries. None of the 
controls were taking any medication, 4 were still smoking and 12 were ex smokers.  
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Table 3.1. Baseline Patient Characteristics (n=103). 
 
Variable 
 
 
Mean 
 
Median 
 
SD 
 
SEM 
95% 
CI 
 
Range 
Age (years) 
 
61.84  63.00  8.98  0.86  60.13, 
63.56 
36.00 to 
82.00 
Height (cm)  166.22  168.00  9.42  0.91  164.42, 
168.02 
142.00 
to 
183.00 
Weight (Kg)  81.87  81.00  15.00  1.44  79.01, 
84.74 
47.00 to 
138.00 
BMI  29.69  29.00  5.36  0.52  28.67, 
30.72 
19.33 to 
58.90 
SBP(mmHg)  130.94  129.75  17.30  1.67  127.64, 
134.24 
92.00 to 
185.50 
DBP(mmHg)  70.88  70.625  9.66  0.48  69.03, 
72.73 
47.25 to 
95.00 
PP(mmHg)  60.06  58.00  12.87  1.24  57.60, 
62.51 
40.50 to 
113.50 
AIx(%)  28.89  29.67  11.43  1.16  27.58, 
32.20 
-13.40 to 
59.67 
C1(ml/mmHgx10)  14.74  3.64  5.00  0.48  13.79, 
15.70 
3.70 to 
35.20 
C2(ml/mmHgx100)  4.63  3.64  2.82  0.27  4.09, 
5.17 
1.40 to 
17.20 
CHOL(mmol/l)  4.29  4.25  0.83  0.08  4.13, 
4.54 
2.71 to 
6.94 
LDL(mmol/l)  2.34  2.23  0.74  0.07  2.20, 
2.49 
1.01 to 
4.88 
HDL(mmol/l)  1.07  1.00  0.37  0.04  1.00 to 
1.14 
0.38 to 
2.67 
VLDL(mmol/l)  0.88  0.77  0.51  0.05  0.78, 
0.98 
0.14 to 
3.31 
TRIG(mmol/l)  1.93  1.69  1.12  0.11  1.72, 
2.15 
0.31 to 
7.25 
CRP(mg/l)  4.73  2.00  8.36  0.82  3.11, 
6.35 
0.17 to 
61.55 
Adiponectin(ng/ml)  5053.32  3611.5  4811.90  471.85  4116.40, 
5990.30 
224.06 
to 
28355.00 
ICAM(ng/ml)  374.93  353.38  150.31  14.67  345.81, 
404.05 
164.77 
to 
1296.70 
IL-6 (pg/ml)  4.60  3.45  5.05  0.51  3.59, 
5.61 
0.47 to 
33.98   107 
Table 3.2.  Patient Medication. 
 
Medication   n  % 
Aspirin   75  71 
Aspirin + Clopidogrel  12  11 
Clopidogrel   10  9.5 
ʒeta Blockers   76  72 
Calcium Channel Blockers   55  52 
HMG Co A Reductase Inhibitors   89  85 
Nitroglycerin   43  41 
Angiotensin converting enzyme inhibitors   51  49 
Angiotensin II type-1 receptor antagonist   5  4.8 
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Table 3.3 Healthy Control baseline characteristics (n=53) 
Variable  Mean  Median  SD  SEM  95%  Range 
Age (years) 
 
52.74  52  9.147  1.25  50.21, 
55.26 
37-72 
Height (cm)  171.35  172  10.20  1.40  168.54, 
174.16 
149-194 
Weight (Kg)  77.02  75  13.85  1.90  73.20, 
80.84 
448-113 
BMI  26.14  25.82  3.34  0.46  25.22, 
27.06 
19.40-
35.8 
SBP(mmHg)  124.62  122.25  12.97  1.782  121.03, 
128.19 
106.50, 
168 
DBP(mmHg)  72.42  71.50  7.96  1.09  70.23, 
74.62 
58.25, 
98.250 
PP(mmHg)  52.19  51.00  7.78  1.07  50.05, 
54.34 
40.50, 
81.25 
AIx(%)  23.85  26.00  11.26  1.55  20.74, 
26.85 
-7.50, 
43.50 
C1(ml/mmHgx10)  15.20  15.33  4.14  0.58  14.04, 
16.37 
6.83, 
23.98 
C2(ml/mmHgx100)  6.74  6.85  2.94  0.41  5.91, 
7.57 
2.08, 
14.00 
CHOL(mmol/l)  4.75  4.83  0.78  0.11  4.53, 
4.96 
3.27, 7.25 
LDL(mmol/l)  2.97  3.03  0.81  0.11  2.76, 
3.21 
0.89, 5.73 
HDL(mmol/l)  1.31  1.32  0.30  0.04  1.23, 
1.40 
0.79, 1.99 
VLDL(mmol/l)  0.45  0.38  0.23  0.03  0.38, 
0.51 
0.14, 1.25 
TRIG(mmol/l)  0.98  0.84  0.50  0.07  0.84, 
1.12 
0.30, 2.73 
CRP(mg/l)  2.11  0.85  7.06  0.97  0.16, 
4.06 
0.22, 
51.74 
Adiponectin(ng/ml)  6234.63  4687.2  4824.20  662.66  4903.8, 
7565.5 
159.30, 
19921.00 
ICAM(ng/ml)  298.25  276.11  84.82  11.65  274.85, 
321.65 
169.98, 
703.11 
IL-6 (pg/ml)  3.49  1.75  6.20  0.87  1.75, 
5.24 
0.06, 
37.28 
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3.4 The reproducibility of the Windkessel derived large and small artery compliance 
values. 
 
3.4.1 Background. 
 
The diastolic pulse wave contour analysis method customarily used by Cohn (Cohn 1995) 
uses the 4- element Windkessel model conceptually introduced by Goldwyn and Watt in 
1967 (Goldwyn 1967). McVeigh and Cohn in recent years have described that fitting 
Windkessel model parameters into the diastolic portion of the radial artery pulse 
waveform generating small and larger artery compliance values is useful clinically. In 
particular the small, or oscillatory, compliance value is reduced with age, hypertension 
and diabetes and is sensitive to altered NO bioactivity (McVeigh 1999, McVeigh 1991, 
McVeigh 1993 and McVeigh 2001). There has been criticism in some quarters of this 
technique. Validity and widespread potential clinical utility have been questioned by one 
study finding an absence of correlations between different sites (radial and posterior tibial 
artery sites) as well as frequent uninterpretable values in hypertensive subjects (Manning 
2002). Rietzschel and colleagues found coefficients of variation of 32.8% for C1 and 
33.3% for C2 but only of 6.7% for AIx (Rietzschel 2001). Before conducting larger 
experiments we wished to ensure that, in our hands, C1 and C2 were reproducible 
vascular measurements.  
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3.4.2 Methods.  
 
For the initial reproducibility studies with the aim of producing Bland Altman plots we 
recruited twenty four healthy volunteers who attended twice, more than one week apart, 
fasted between 8am and 10am and having abstained from tea, coffee and nicotine from 
midnight the previous night. The 24 volunteers were all in good health and none had any 
hepatic, endocrine, or renal disease or were on any regular medication. Mean BP in this 
group was 118/72 mmHg.  
 
All subjects gave informed consent prior to enrolment in the study for which ethical 
approval had been granted by the Ethics Committee of the West Glasgow Hospitals 
University NHS trust. Following 60 minutes supine rest non invasive vascular profiling 
were performed as described within sections 2.3.1 and 2.3.2. 
 
Statistical analysis was preformed using Minitab14. Coefficients of variation were 
calculated as the SD of the difference between 2 measurements divided by the mean 
value of the mean of both measurements. Reproducibility data using the method 
described by Bland and Altman (Bland 1996) generates Bland Altman plots depicting 
differences between 2 measurements plotted against the mean of the 2 measurements.  
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3.4.3 Results Reproducibility: Bland Altman Plots.  
 
Using Bland Altman plots the calculated intra-observer bias for C1 was -0.1(SD of bias 
was 0.36, 95% CI -0.8 to 0.6) (Figure 3.1). Likewise for C2 the observed bias was -0.04 
(SD of bias was 0.20, 95% CI -0.44 to 0.36) (Figure 3.2). 
 
 
Figure 3.1 Bland Altman plots for intra observer variation within large artery 
compliance in 24 healthy volunteers. For C1 the calculated intra-observer bias was -0.1 
(SD of bias was 0.36, 95% CI -0.8 to 0.6). 
5 10 15 20 25 30
-1.0
-0.5
0.0
0.5
1.0
+2SD
-2SD
Mean C1 (ml/mmHg)
D
i
f
f
e
r
e
n
e
n
c
e
 
i
n
 
C
1
 
(
m
l
/
m
m
H
g
 
x
1
0
)
   112 
Figure 3.2 Bland Altman plots for intra observer variation within small artery 
compliance in 24 healthy volunteers. For C2 the observed bias was -0.04 (SD of bias 
was 0.20, 95% CI -0.44 to 0.36).  
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3.5 The comparison between systolic and diastolic pulse contour analysis. 
 
3.5.1 Background 
 
Both systolic and diastolic pulse contour analysis have been validated in different 
populations but only a few groups have sought to compare these values in healthy 
volunteers as well as in patients with established vascular disease. Segers et al analysed 
45 human subjects, most of whom had coronary artery disease, simultaneously measuring 
aortic and radial pressure pulse waveforms (Segers 2001). They noted that C2 was 
inversely related to augmentation index (r=-0.36) (Segers 2001). Rietzschel and co 
workers measured AIx and C2 in 100 volunteers, 27 were taking anti hypertensive 
medication but all were free of atherothrombotic disease, and also found a significant 
inverse relation (r=-0.71) (Rietzschel 2001). A much smaller study was recently reported 
by Woodman et al examining 15 men with coronary artery disease and 15 healthy men. 
Their pooled correlation between AIx and C2 was -0.75 (Woodman 2005). The aim of 
this investigation was to compare the 2 methodologically different techniques focusing 
on either the systolic and diastolic portion of the arterial pulse waveform both in patients 
with coronary artery disease and in healthy controls. 
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3.5.2 Subjects and Methods. 
 
The 53 healthy volunteers for the study of arterial compliance and low grade 
inflammation were recruited from advertisements within Glasgow University and also 
from the offices of the Glasgow Herald. The 103 patients to ascertain the effect of 
genotype upon arterial stiffness in patients with coronary artery disease were recruited 
from the Coronary Artery Bypass Graft operation waiting lists. A full description of 
recruitment, general clinical protocol and pulse wave contour analysis are described n 
sections 2.1, 2.2 and 2.3. In each case the volunteer provided informed consent and the 
procedure was tolerated well in each case. Minitab 14 was used as the statistical package 
to construct simple linear correlations. Statistical significance was defined as p<0.05. 
 
3.5.3 Results: Correlations between large and small arterial compliance values in 
patients with coronary artery disease and healthy controls. 
 
Scatter plots of large and small artery compliance values and augmentation index are 
displayed in Figures 3.3 – 3.6. There was a significant correlation between both AIx and 
C1(r=-0.42, p=0.002) and AIx and C2 (r=-0.60, p=<0.0001) in healthy volunteers. While 
there was no association between AIx and C1 in patients with coronary artery disease (r=-
0.17, p=0.009) AIx did correlate with C2 in this population (r=-0.51, p=<0.001). 
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Figure 3.3 Scatter plots of large artery compliance (C1) and augmentation Index in 
healthy volunteers (n=53, r = -0.42, p=0.002).  
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Figure 3.4 Scatter plots small artery compliance (C2) and Augmentation Index in 53 
healthy volunteers. (r = -0.60, p<0.001).  
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Figure 3.5 Scatter plots of large artery compliance (C1) and augmentation index in 
patients with coronary artery disease. (n=103, r = -0.17, p=0.09).  
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Figure 3.6 Scatter plots of small artery compliance (C2) and augmentation index in 
patients with coronary artery disease. (n=103, r = -0.51, p<0.001).  
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3.6 Discussion 
 
The assessment of arterial stiffness is gathering growing recognition as a useful non 
invasive intermediate phenotype. Recently the Conduit Artery Function Evaluation 
(CAFÉ) study showed a SphygmoCor derived central SBP difference between the 2 arms 
of an Anglo-Scandinavian Cardiac Outcomes Trial substudy in spite of similar brachial 
blood pressure changes (Williams 2006). As there is a growing appreciation of the 
clinical utility of the assessment of arterial stiffness the assessment of reproducibility 
becomes of paramount importance. 
 
In essence we have shown that the HDI/Pulsewave 
TM CR-2000 Research Cardiovascular 
Profiling system used to determine Windkessel based diastolic pulse contour arterial 
compliance measurements is reproducible. For C1 the calculated intra-observer bias was -
0.1 (SD of bias was 0.36, 95% CI -0.8 to 0.6). Over 95% of the variability fell within 2 
standard deviations. Furthermore for C2 the observed bias was -0.04 (SD of bias was 
0.20, 95% CI -0.44 to 0.36). Again over 95% of the variability fell within 2 standard 
deviations. 
 
The HDI/Pulsewave 
TM CR-2000 Research Cardiovascular Profiling System has 
previously been proven to be reproducible over both a short and intermediate period of 
observation by Prisant et al (Prisant 2002). This group studied 59 healthy volunteers of 
mean age 36.5 years a mean of 52 days apart finding no significant difference between 
the readings obtained. Previously the reproducibility of this technology had been brought   118 
into question but whereas Rietzschel described coefficients of variation of 32.8% for C1, 
33.3% for C2 and 6.7% for AIx (Rietzschel 2001) suggesting superiority of SPCA 
Woodman found different results with higher coefficient of variation for AIx (22.4%) 
than for C1 (11.3%) or C2 ( 15.6%) suggesting otherwise (Woodman 2005).  
 
The extent of pulse pressure amplification from the aorta to brachial artery varies with 
age, posture and exercise. Pulse pressure amplification as measured by SPCA, but not 
PWV, has been shown to be heart rate dependent (via manipulation of heart rate by 
incremental pacing) both in a group of older subjects with probable left ventricular 
systolic dysfunction and in a younger group with normal unimpaired left ventricular 
function (Wilkinson 2000, Wilkinson 2002c). Hence studies including PWA require 
uniformity in terms of preceding overnight fast and abstinence from strenuous exercise, 
caffeine, nicotine and a period of supine rest. Consensus guidelines have recently been 
published with respect to uniform, optimal conditions such that conclusions obtained 
from studies incorporating PWA may be widely applicable (Laurent 2006). 
 
Large and small artery compliance values, while they lack a discrete anatomical site, are 
associated with changes in arterial stiffness that occur in a predictable fashion with age 
and cardiovascular risk factors; similarly with AIx. We therefore anticipated that there 
would be a significant relationship between these two measurements of arterial stiffness 
as described previously within the medical literature (Segers 2001, Rietzschel 2001, 
Woodman 2005). The significant correlations of -0.60 and -0.51 in healthy controls and 
patients with coronary artery disease are approximate to those described by others (r=-  119 
0.75 Woodman 2005, r=-0.48 Rietzschel 2001) but stronger than those from Segers (r=-
0.36 Segers 2001). This study however does not pool healthy subjects with those with 
coronary artery disease or like those by Woodman and Rietzschel respectively 
(Woodman 2005, Rietzschel 2001) and has a larger number of subjects than that by 
Segers (Segers 2001). It is not clear why there was no correlation (or at best a borderline 
correlation p=0.09) between large artery compliance and AIx in patients with coronary 
artery disease while there was in healthy controls. It is possible that patients with 
increasing arterial stiffness, which is known to correlate with coronary artery plaque load 
(McLeod 2004) the established disease phenotype within the individuals studied with 
coronary artery disease may have precluded the observation of an association.  
 
There is no clear consensus yet as to which means of assessing arterial stiffness may be 
the most appropriate and robust for widespread clinical use. It remains possible that a 
pharmacological challenge may provide more information. Albuterol has been shown to 
produce repeatable changes in the aortic waveform that are substantially inhibited by 
LNMMA and is therefore an endothelium dependent NO mediated vasodilator 
(Wilkinson 2002d).This technique is potentially a simple, repeatable, non invasive means 
of assessing endothelial function in vivo and was blunted in patients with 
hypercholesterolemia (Wilkinson 2002d). It requires validation in other groups of single 
and combined risk factors.  
 
PWV is generally accepted as the most simple, non-invasive, robust and reproducible 
method to assess arterial stiffness and carotid-femoral PWV is currently endorsed as the   120 
current gold standard (Laurent 2006). In healthy individuals a decline in endothelial 
function is associated with increased large artery stiffness, wave reflections and central 
pulse pressure (McEniery 2006). Within patients with coronary artery disease carotid 
radial PWV has been shown to correlate with the extent of coronary artery plaque volume 
(McLeod 2004). The Anglo Cardiff Collaborative Trial, which included 4001 healthy, 
normotensive individuals aged 18 to 90, however noted that while PWV is likely to be a 
better measure in older individuals AIx may be a more sensitive marker of arterial 
stiffness in younger individuals (McEniery 2005). The correlations observed within the 
groups examined suggest that Windkessel based modelling may still have a role although 
there remains, to date, no clinical outcome data utilising this technique. 
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Chapter 4 The NOS3 G894T genotype and arterial compliance in patients 
with coronary artery disease. 
 
4.0 Summary  
This chapter elucidates the effect of the G894T single nucleotide polymorphism of the 
NOS3 gene upon arterial compliance. We found that there was a significant association 
between the number of T alleles and the small artery compliance value as assessed by 
Windkessel based diastolic pulse wave contour analysis. 
 
4.1 Introduction 
 
An accruing body of evidence suggests that oxidative stress, of which reduced NO 
bioactivity is a hallmark, is significantly involved in the pathogenesis of vascular disease 
including hypertension, atherosclerosis, type 2 diabetes mellitus, heart failure and 
hypercholesterolemia (Landmesser 2001, Hamilton 2004).  
 
A previously stated in detail within section 1.6 the NOS3 single nucleotide polymorphism 
(SNP) (894 G T) that encodes a Glu298 Asp amino acid substitution in the eNOS 
protein has been implicated with cardiovascular disorders in which NO bioactivity is 
impaired including coronary artery disease (Hingorani 1999, Hibi 1998, Colombo 2002), 
hypertension (Jáchymová 2001, Miyamoto 1998), stroke (Elbaz 2000) and end stage   122 
renal disease (Noiri 2002). It is also associated with endothelial dysfunction (Leeson 
2002). 
 
A key characteristic of increased vascular oxidative stress is a decrease in the compliance 
of large and small blood vessels. This alteration in vascular stiffness can be measured 
non-invasively using pulse wave analysis for example. We used diastolic pulse wave 
contour analysis utilising the modified Windkessel model as al non invasive intermediate 
phenotype for the assessment of arterial function in patients with coronary artery disease. 
Consistent characteristic changes in the pulse pressure wave shape have been associated 
with ageing and disease states predisposing to vascular events in which NO bioactivity is 
impaired. Small artery compliance has been associated with coronary artery disease in 
post menopausal women (Cohn 1995) and also with impaired NO bioactivity (McVeigh 
2001). 
 
We therefore hypothesised that this functional SNP within an oxidative stress gene, 
which potentially modulates part of its effect on cardiovascular function through altering 
arterial stiffness possibly due to altered eNOS function, would affect the non invasive 
cardiovascular phenotype small artery compliance.  
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4.2 Methods 
 
4.2.1 Subjects  
103 volunteers were recruited from patients attending the Western Infirmary Glasgow for 
coronary artery bypass grafting for coronary artery disease. As detailed in section 2.2 
each volunteer attended the BHF Glasgow Cardiovascular research Unit at the University 
of Glasgow the week prior to surgery fasted and abstinent from tobacco, alcohol, tea and 
coffee from the 10 pm previous night. Each study was performed by myself between 8.00 
am and 11 am. Ethical permission for this study was obtained from the Ethics Committee 
of the West Glasgow Hospitals University NHS trust and each subject gave informed 
consent before a detailed clinical history and examination was performed including an 
ECG to ensure sinus rhythm. 
 
4.2.2 Clinical procedures and laboratory analysis. 
 
Morphological measurements were performed upon the arrival of the subject and then 
following 60 minutes supine rest in a quiet, temperature controlled room the clinical 
protocol outlined in section 2.3 was undertaken. Following pulse wave contour analysis a 
portion of blood was obtained for quantification of IL-6, Adiponectin, sICAM-1 and 
highly sensitive CRP and analysis of the NOS3 G894T genotype. Small and large artery 
compliance values were obtained using a calibrated, proprietary tonometer (model CR 
2000 Hypertension Diagnostics Inc) and used according to manufacturers specifications.   124 
Augmentation Index was measured using the SphygmoCor system (PWV Medical). A 
full description of these techniques is detailed in section 2.3.1 and 2.3.2. IL-6, CRP, 
Adiponectin and sICAM1 were measured using the techniques detailed in 2.5. From the 
portion of blood taken DNA was extracted using the Wizard Genomic DNA Purification 
kit (Promega) and genotyping of the NOS3 G894T SNP was performed by members of 
the BHF Glasgow Cardiovascular Research Centre who were unaware of the patients‟ 
phenotypes. The G894T polymorphism was genotyped by sequencing performed using 
SeqScape (Applied Biosystems) software and two individuals checked all genotypes. 
Concordance between the two individuals was 100%. A full description is detailed in 
section 2.4. 
 
4.2.3 Statistical Evaluation. 
 
All data are presented as mean ± SEM. Power calculations were performed before sample 
acquisition and 100 subjects were projected to provide 80% power for primary analysis 
based on two sample t-tests to compare mean C2 values between the two homozygous 
groups at each locus. The Chi squared statistic was used to ensure that the observed allele 
frequencies did not differ from that expected under Hardy-Weinberg equilibrium. One-
way ANOVA was used to examine the effect of genotype of the NOS3 SNP on vascular 
parameters as with this SNP there has been no documented dominant allele (Hibi 1998). 
Thereafter multiple regression analysis was preformed to identify the variables that 
independently predicted the relationships. Statistical significance was defined as p<0.05. 
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4.3 Results. 
 
4.3.1 Clinical Characteristics 
 
Baseline characteristics of the study population are those displayed in table 3.1. 78 
patients were male and 27 female. The mean age of the patients was 61.84, mean blood 
pressure 131/71 and cholesterol 4.29 mmol/l. In terms of smoking status 37 patients had 
never smoked, 26 patients were ex smokers as defined by more than 6 months of 
abstinence and 40 patients continued to smoke cigarettes. The mean large artery 
compliance (C1) was 14.74 ml/mmHg x 10, mean small artery compliance (C2) 4.63 
ml/mmHg x 100 and Augmentation Index (AIx) 28.89%. 75 patients were on Aspirin, 10 
on Clopidogrel alone and 12 on both Aspirin and Clopidogrel. 76 were taking Beta 
Blockers, 55 on calcium channel blockers, 89 on HMG Co A Reductase Inhibitors, 43 on 
a form of Nitroglycerin, 51 on Angiotensin Converting Enzyme Inhibitors and 5 on 
Angiotensin II type 1 receptor antagonists.  
 
4.3.2 The distribution of the genotypes and frequency of the alleles. 
GG  GT  TT 
43/103  47/103  13/103 
42%  45%  13% 
Table 4.1 The distribution of genotypes and frequency of the alleles of the NOS3 
gene.   126 
 
The distribution of the genotypes and the frequency of the T alleles did not differ 
significantly from that expected under Hardy-Weinberg equilibrium (Chi = 0.007, 
p=0.65, q= 0.35). 
 
4.3.3 The NOS3 G894T genotype and cardiovascular phenotypes.  
 
The effect of the G894T SNP of the NOS3 gene on cardiovascular phenotypes is shown 
in Table 4.2. There was no association observed between this polymorphism and blood 
pressure or large artery compliance (Table 4.2, Figures 4.1, 4.2, 4.3 and 4.4). ANOVA 
revealed a statistically significant association for TT homozygosity and small artery 
compliance (p=0.01, Table 4.2, Figure 4.5). The highest small artery compliance was 
seen in the patients homozygous for the G allele (5.51 ± 0.51 ml/mmHg x 100), an 
intermediate value observed in heterozygotes  (4.21 ± 0.33 ml/mmHg x 100) and the 
lowest value demonstrated in patients homozygous for the T allele (3.18 ± 0.38ml/mmHg 
x 100). No association was evident in this cohort between NOS3 G894T genotype and 
augmentation index (Table 4.2 and Figure 4.6) 
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Table 4.2-.  Associations between the NOS3 G894T genotype and cardiovascular 
phenotypes in patients with coronary artery disease. 
Variable  Genotype  (n)  ANOVA 
  GG 
(43) 
GT 
(47) 
TT 
(13) 
p value 
Age (years)  58.98 ± 1.4  63.17 ± 1.2  63.85 ± 2.5  0.05 
BMI (kg/m
2)  29.85 ± 0.89  29.56 ± 0.80  29.55 ± 0.85  0.97 
SBP (mmHg)  129.9 ± 2.9  132.6 ± 2.3  127 ± 5.2  0.55 
DBP (mmHg)  71.1 ± 1.6  71.11 ± 1.3  69.4 ± 2.8  0.85 
PP (mmHg)  58.9 ± 2.0  61.5 ± 2.0  57.5 ± 2.9  0.51 
HR (beats/min)  61.9 ± 1.6  62.5 ± 1.9  58.33 ± 2.3  0.53 
C1 (ml/mmHg x 10)  15.87 ± 0.89  13.98 ± 0.64  14.47 ± 1.1  0.20 
C2 (ml/mmHg x 100)  5.51 ± 0.51  4.21 ± 0.33  3.18 ± 0.38  0.01 
Augmentation Index (%)  29.48 ± 2.01  28.99 ± 1.74  32.67 ± 2.43  0.61 
CHOL (mmol/l)  4.26 ± 0.11  4.321 ± 0.14  4.43 ± 0.23  0.81 
logTRIG (mmol/l)  0.24 ± 0.03  0.21 ± 0.04  0.21 ± 0.01  0.80 
LDL (mmol/l)  2.30 ± 0.09  2.35 ± 0.12  2.55 ± 0.21  0.57 
HDL (mmol/l)  1.06 ± 0.06  1.07 ± 0.06  1.08 ± 0.10  0.99 
Log CRP (mg/l)  0.34 ± 0.07  0.42 ± 0.08  0.14 ± 0.17  0.21 
Log Adiponectin (ng/ml)  3.49 ± 0.06  3.57 ± 0.05  3.66 ± 0.11  0.32 
Log ICAM (ng/ml)  2.56 ± 0.02  2.55 ± 0.02  2.53 ± 0.05  0.84 
Log IL-6 (pg/ml)  0.52 ± 0.06  0.33 ± 0.09  0.29 ± 0.18  0.19   128 
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Figure 4.1:- The G894T SNP of the NOS3 gene and systolic blood pressure in 
patients with coronary artery disease. 
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Figure 4.2:- The G894T SNP of the NOS3 gene and diastolic blood pressure in 
patients with coronary artery disease. 
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Figure 4.3:- The G894T SNP of the NOS3 gene and pulse pressure in patients with 
coronary artery disease. 
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Figure 4.4:- The G894T SNP of the NOS3 gene and large artery compliance in 
patients with coronary artery disease. 
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Figure 4.5:- The G894T SNP of the NOS3 gene and small artery compliance in 
patients with coronary artery disease. 
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Figure 4.6:- The G894T SNP of the NOS3 gene and augmentation index in patients 
with coronary artery disease. 
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4.3.4 Multiple Regression Analysis. 
 
Multiple regression analysis, examining the possible contribution of age, BMI, SBP, 
DBP, total and LDL cholesterol showed that only small artery compliance was significant 
when NOS3 G894T genotype was assigned as the dependent variable (p=0.01). 
 
Predictor  Regression 
Coefficient 
Standard Error  T value  p value 
Age (years)  0.01  0.01  1.55  0.13 
BMI (kg/m
2)  0.01  0.01  0.68  0.50 
SBP (mmHg)  -0.01  0.01  1.63  0.11 
DBP (mmHg)  0.0001  0.01  0.02  0.99 
C1 (ml/mmHg 
x10) 
-0.02  0.02  1.47  0.15 
C2 (ml/mmHg 
x 100) 
-0.07  0.03  2.64  0.01 
Chol mmol/l  0.04  0.14  0.33  0.74 
LDL mmol/l  0.05  0.15  0.36  0.72 
Table 4.3: Multiple regression analysis of vascular phenotypes with NOS3 G894T 
genotype as the dependent variable. 
 
R
2= 16.11%, adjusted R
2= 16.11%, p=0.03 for the entire study group. 
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6.4 Discussion  
Despite a growing body of evidence that implicates the NOS3 G894T polymorphism in 
both human physiology and pathology there is still no complete consensus as to its role or 
indeed its functional mechanism. This SNP has been associated with altered baseline 
production of nitric oxide (Veldman 2002), blood pressure response to endurance training 
(Rankinen 2000), heamodynamic response to stress (Malhotra 2004), maternal vascular 
adaptation to healthy pregnancy (Savvidou 2001) and flow mediated dilatation and 
carotid intima media thickness in young healthy subjects (Paradossi 2004). There are 
many studies in different populations associating the T allele with susceptibility to 
ischaemic heart disease (Hingorani 1999, Hibi 1998, Colombo 2002, Gardemann 2002, 
Casas 2004). Some controversy remains with negative studies also reported (Rossi 2003, 
Schmoelzer 2003). The G894T SNP, though, has been associated with cerebrovascular 
disease (Elbaz 2000), survival in patients with congestive cardiac failure (McNamara 
2003), coronary in stent restenosis (Gomma 2002) and as previously stated, end stage 
renal disease (Noiri 2002). 
 
There is argument as to whether this SNP is functional. Glutamate and aspartate are both 
conservative substitutions and, indeed, analysis of the crystal structure indicates that 
residue 298 is situated externally away from the active site so that the aspartate 
substitution should have negligible effect on enzyme activity (Fischmann 1999). Though 
the initial experiment by Tesauro and colleagues (Tesauro 2000) suggesting that the 
mutant rather than the wild type enzyme was more amenable to proteolytic cleavage was   133 
discounted as an artefact caused by the acidic pH used (Fairchild 2001), this group did 
suggest, using Chou-Fasman secondary structure predictions, that potentially significant 
structural changes would occur, even with the seemingly small conservative replacement 
(Tesauro 2000). Golser et al (Golser 2003) did not elicit any difference between the 2 
variants with respect to enzyme kinetic parameters, bound cofactors, uncoupled 
NAD(P)H oxidase activity and binding activities for calcium calmodulin and 
tetrahydrobiopterin. Moreover, it has recently been suggested via a series of experiments 
examining the complex intracellular regulation of eNOS that the aspartate variant is 
unlikely to directly modulate eNOS activity (McDonald 2004). However, Noiri et al 
(Noiri 2002) have demonstrated, utilising stably transfected Chinese hamster ovary cells 
for comparing nitric oxide activity, a statistically significant difference in nitric oxide 
production between the 298 glutamate and 298 aspartate variants. This is in keeping with 
our finding that the number of T alleles was associated with small artery compliance, 
which has been found to be altered in parallel with pharmacological manipulation of 
nitric oxide bioavailability (McVeigh 2001).  
 
Measurement of small artery compliance using the modified Windkessel model of 
diastolic pulse contour analysis has been suggested as a useful marker for the non 
invasive detection of vascular abnormalities in disease states where nitric oxide 
bioactivity is known to be impaired (McVeigh 1991, McVeigh 1993, Cohn 1995). Recent 
prospective study suggested possible prognostic (survival) significance for the Asp298 
variant of the NOS3 gene in patients with heart failure (McNamara 2003). One can 
extrapolate from this and our current data that the non-invasive measurements of arterial   134 
compliance (especially C2) might be used as a marker of severity of cardiovascular 
disease and ultimately PWA per se as a non invasive phenotype which would delineate 
those most at benefit of aggressive intervention.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   135 
Chapter 5 The C242T single nucleotide polymorphism of the CYBA gene 
and blood pressure and arterial compliance in patients with coronary 
artery disease. 
5.0 Summary 
 
This chapter describes the effect of the C242T single nucleotide polymorphism upon 
blood pressure and arterial compliance in patients with coronary artery disease. In short 
we found that the 242T allele was associated with elevated systolic and pulse pressure 
and large artery compliance but not diastolic blood pressure nor small artery compliance 
in patients with coronary artery disease. 
 
5.1 Introduction 
 
Oxidative stress is increasingly implicated, as described in sections 1.3 and 1.4, in 
vascular disease. Moreover that induced by O2¯ is especially important as many other 
reactive oxygen species are subsequently derived from it (Taniyama 2003). The 
membrane bound NADPH enzyme system is putatively the major source of vascular O2¯. 
Expression of the p22phox has been found to be more intense in atherosclerotic human 
coronary arteries than non atherosclerotic human arteries, indicating that the p22phox 
might participate in the pathophysiology and pathogenesis of atherosclerotic coronary 
artery disease (Azumi 1999). The gene coding for p22phox, a critical component of the 
NADH/NAD(P)H oxidase enzyme system, a major source of vascular O2¯, is CYBA.   136 
Among the allelic polymorphisms reported in CYBA is C242T, which has been 
demonstrated to affect NADPH oxidase activity (Wyche 2004, Guzik 2000). There have 
been several, contradictory, associations of the C242T SNP with coronary atherosclerosis 
some associating the T allele as being associated with coronary artery disease and others 
indeed suggesting that the T allele may be protective. „Positive‟ associating studies have 
been reported by Cia (Cai 1999), Cahilly (Cahilly 2000) and Nasti (Nasti 2006) within 
European and American populations whereas „negative‟ non associating studies have 
emanated from several groups most recently Finland (Fan 2006, Inoue 1998, Li 1999, 
Saha 1999, Zafari 2002). This SNP has also been associated with cerebrovascular disease 
(Ito 2000), carotid atherosclerosis (Hayaishi-Okano 2003) and susceptibility to diabetic 
nephropathy (Hodgkinson 2003). No relation has been found however with peripheral 
vascular disease (Renner 2000), pre eclampsia (Raijmakers 2002) or with endothelial 
function in patients with hypercholesterolaemia (Schneider 2003).  
 
Consequently given the importance of O2¯ in the generation of vascular disease and the 
association of genetic variation in the p22phox gene with vascular disease we sought to 
ascertain if there was a relationship between vascular compliance measured using systolic 
and diastolic pulse contour analysis and blood pressure and variation of the C242T SNP 
of CYBA in patients with angiographically proven coronary artery disease.   137 
5.2 Methods 
 
5.2.1 Subjects 
 
103 volunteers were recruited from patients attending the Western Infirmary for coronary 
artery bypass grafting for symptomatic, obstructive coronary artery disease. As detailed 
in section 2.2 each volunteer attended the BHF Glasgow Cardiovascular research Unit at 
the University of Glasgow the week prior to surgery fasted and abstinent from tobacco, 
alcohol, tea and coffee from the previous night. Ethical permission for this study was 
obtained from the Ethics Committee of the West Glasgow Hospitals University NHS trust 
and each subject gave informed consent before a detailed clinical history and examination 
was performed including an ECG to ensure sinus rhythm. 
 
5.2.2 Clinical Procedures and laboratory analysis.   
 
Morphological measurements were performed upon the arrival of the subject and then 
following 60 minutes supine rest in a quiet, temperature controlled room the clinical 
protocol outlined in section 2.3 was undertaken. Subsequently a portion of blood was 
taken for quantification of IL-6, Adiponectin, sICAM-1 and highly sensitive CRP and 
analysis of the C242T CYBA genotype. Small and large artery compliance values were 
obtained using a calibrated, proprietary tonometer (model CR 2000 Hypertension 
Diagnostics Inc) and used according to manufacturers specifications. Augmentation   138 
Index was measured using the SphygmoCor system (PWV Medical). A full description of 
these techniques is detailed in section 2.3.1 and 2.3.2. IL-6, CRP, Adiponectin and 
sICAM1 were measured using the techniques detailed in 2.5. From the portion of blood 
taken DNA was extracted using the Wizard Genomic DNA Purification kit (Promega) 
and genotyping of the CYBA C242T SNPs was performed by members of the BHF 
Glasgow Cardiovascular Research Centre who were unaware of the patients‟ phenotypes. 
The C to T substitution, at position 242 in the CYBA was typed by RsaI digestion of 
specific polymerase chain reaction products amplified from genomic DNA as described 
in section 2.4. Analysis was preformed on a 1.5% agarose gel. 
 
5.2.3 Statistical Evaluation 
 
All data are presented as mean ± SEM. Power calculations were performed before sample 
acquisition and 100 subjects, based on pilot data, were projected to provide 80% power 
for primary analysis based on two sample t-tests to compare mean C1 or C2 values 
between the two homozygous groups at each locus. The Chi squared statistic was used to 
ensure that the observed allele frequencies did not differ from that expected under Hardy-
Weinberg equilibrium 
 
A two tailed Student‟s t-test was used to analyse differences in phenotype between 
subjects with presence or absence of the T allele for the CYBA C242T SNP, as this has 
previously been reported as being the dominant allele (Cai 1999, Cahilly 2000 and Nasti 
2006). Thereafter multiple regression analysis was preformed to identify the variables   139 
that independently predicted the relationships. Statistical significance was defined as 
p<0.05. 
 
5.3 Results  
 
5.3.1 Clinical Characteristics. 
 
The baseline characteristics of the study population are those displayed in table 3.1. 78 
patients were male and 27 female. The mean age of the patients was 61.84, mean blood 
pressure 130.94/70.88and cholesterol 4.29 mmol/l. In terms of smoking status 37 patients 
had never smoked, 26 patients were ex smokers as defined by more than 6 months of 
abstinence and 40 patients continued to smoke cigarettes. The mean large artery 
compliance (C1) was 14.74 ml/mmHg x 10, mean small artery compliance (C2) 4.63 
ml/mmHg x 100 and Augmentation Index (AIx) 28.89%. 75 patients were on Aspirin, 10 
on Clopidogrel alone and 12 on both Aspirin and Clopidogrel. 76 were taking Beta 
Blockers, 55 on calcium channel blockers, 89 on HMG Co A Reductase Inhibitors, 43 on 
a form of Nitroglycerin, 51 on Angiotensin Converting Enzyme Inhibitors and 5 on 
Angiotensin II type 1 receptor antagonists.  
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5.3.2 The distribution of the genotypes and frequency of the alleles. 
 
CC  CT  TT 
44/103  51/103  8/103 
43%  50%  7% 
 
Table 5.1 The distribution of genotypes and frequency of the alleles of the p22phox 
CYBA gene. 
 
The distribution of the genotypes and the frequency of the T alleles did not differ 
significantly from that expected under Hardy-Weinberg equilibrium (Chi = 1.69, p=0.67, 
q= 0.33). 
 
5.3.3 The CYBA C242T genotype and cardiovascular phenotypes. 
We sought to examine the influence of the C242T SNP of CYBA upon vascular 
compliance and blood pressure using the dominant allele model. The analysis of all 
measured cardiovascular phenotypes and CYBA C242T genotype are illustrated in Table 
5.2. As displayed in table 5.2 and Figure 5.1 the presence of the 242T allele was 
associated with significantly higher systolic blood pressure. Patients homozygous for the 
C allele had lower systolic blood pressure (125.7 ± 2.3 mmHg) than heterozygotes and 
patients homozygous for the T allele(134.6 ± 2.4 mmHg) (p=0.010). There was no 
statistically significant effect upon diastolic blood pressure (Table 5.2 and Figure 5.2).   141 
There was however a significant association observed between the 242T allele and pulse 
pressure (Table 5.2 and Figure 5.3). Patients that were homozygous for the C allele had a 
PP of 56 ± 1.6 mmHg where as patients heterozygous or homozygous for the T allele had 
a PP of 62.7 ± 1.8 mmHg (p =0.01).  
In terms of arterial stiffness the 242T allele was associated with lower large artery 
compliance (Table 5.3 and Figure 5.4). CC homozygotes had higher large artery 
compliance (17.07 ± 0.82 ml/mmHg x10), than heterozygotes and TT homozygotes 
(13.16 ± 0.53 ml/mmHg x10) ( p = < 0.001). No difference was observed between the 
C242T SNP and small artery compliance nor Augmentation Index in our study 
population (Table 5.3 and Figures 5.5 and 5.6) 
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Table  5.2 -.  Associations between the CYBA C242T genotype and cardiovascular 
phenotypes in patients with coronary artery disease.  
Variable  Genotype  (n)    p value 
  CC 
(44) 
CT 
(51) 
TT 
(8) 
CT + TT 
(59) 
CC vs 
CT+TT 
Age (years)  61.91 ± 1.1  61.6 ± 1.4  58.63 ± 1.3  61.2 ± 1.3  0.68 
BMI (kg/m
2)  28.89 ± 0.69   29.82 ± 0.65  33.2 ± 3.8  30.27 ± 0.76  0.18 
SBP (mmHg)  125.7 ± 2.3  134.4 ± 2.6  135.6 ± 6.3  134.6 ± 2.4  0.01 
DBP (mmHg)  69.6 ± 1.7  71.93 ± 1.2  71.16 ± 2.0  71.82 ± 1.1  0.28 
PP (mmHg)  56 ± 1.6  62.5 ± 2.0  64.5 ± 5.3  62.7 ± 1.8  0.01 
HR (beats/min)  62.2 ± 1.8  61.7 ± 1.7  58.83 ± 3.0  61.3 ± 1.5  0.70 
C1 (ml/mmHg x 10)  17.07 ± 0.82  13.39 ± 0.57  11.71 ± 1.5  13.16 ± 0.53  0.00 
C2 (ml/mmHg x 100)  4.66 ± 0.35  4.74 ± 0.45  3.73 ± 0.69  4.60 ± 0.40  0.91 
Augmentation Index (%)  30.57 ± 1.4  28.3 ± 2.0  32.78 ± 3.0  29.0 ± 1.8  0.49 
CHOL (mmol/l)  4.40 ± 0.12  4.24 ± 0.11  4.28 ± 0.42  4.25 ± 0.11  0.40 
logTRIG (mmol/l)  0.18 ± 0.03  0.26 ± 0.04  0.25 ± 0.09  0.26 ± 0.04  0.12 
LDL (mmol/l)  2.50 ± 0.10  2.21 ± 0.10  2.45 ± 0.36  2.24 ± 0.10  0.07 
HDL (mmol/l)  1.13 ± 0.06  1.04 ± 0.05  0.90 ± 0.10  1.02 ± 0.05  0.14 
Log CRP (mg/l)  0.36 ± 0.08  0.31 ± 0.07  0.57 ± 0.17  0.34 ± 0.07  0.84 
Log Adiponectin (ng/ml)  3.45 ± 0.10  3.59 ± 0.05  3.32 ± 0.14  3.55 ± 0.05  0.34 
Log ICAM (ng/ml)  2.57 ± 0.02  2.54 ± 0.02  2.56 ± 0.03  2.54 ± 0.02  0.32 
Log IL-6 (pg/ml)  0.41 ± 0.09  0.42 ± 0.07  0.27 ± 0.27  0.40 ± 0.07  0.96 
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Figure 5.1:- The C242T SNP of the CYBA gene and SBP in patients with coronary 
artery disease. 
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Figure 5.2:- The C242T SNP of the CYBA gene and DBP in patients with coronary 
artery disease.   144 
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Figure 5.3:- The C242T SNP of the CYBA gene and PP in patients with coronary 
artery disease. 
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Figure 5.4:- The C242T SNP of the CYBA gene and C1 in patients with coronary 
artery disease.   145 
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Figure 5.5:- The C242T SNP of the CYBA gene and C2 in patients with coronary 
artery disease. 
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Figure 5.6:- The C242T SNP of the CYBA gene and AIx in patients with coronary 
artery disease. 
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5.3.4 Multiple Regression Analysis. 
 
Multiple regression analysis, examining the possible contribution of age, BMI, SBP, DBP 
and total cholesterol showed that only large artery compliance was significant when 
CYBA C242T genotype was assigned as the dependent variable (p=0.001). 
 
Predictor  Regression 
Coefficient 
Standard Error  t value  p value 
Age (years)  -0.005  0.006  0.771  0.443 
BMI (kg/m
2)  0.010  0.009  1.138  0.258 
SBP (mmHg)  0.003  0.004  0.647  0.519 
DBP (mmHg)  -0.004  0.007  0.523  0.602 
C1 (ml/mmHg 
x10) 
-0.040  0.012  3.316  0.001 
C2 (ml/mmHg 
x 100) 
0.021  0.019  1.107  0.271 
Chol mmol/l  -0.040  0.057  0.705  0.483 
 
Table 5.3: Multiple regression analysis of vascular phenotypes with CYBA C242T  
genotype as the dependent variable. 
 
R
2= 19%, adjusted R
2= 13.3%, p=0.004 for the entire study group. 
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5.4 Discussion  
 
The p22phox subunit of NAD(P)H oxidase has been associated with vascular disease. 
Azumi and co workers (Azumi 1999) demonstrated increased p22phox expression that 
paralleled increasing disease severity in atherosclerotic coronary artery endothelial cells 
and vascular smooth muscle cells. Guzik et al (Guzik 2002) showed that the p22phox 
protein subunit was significantly increased in human diabetic veins and arteries. 
 
Debate exists as to the role of the common C242T polymorphism of the p22phox gene in 
the pathogenesis of vascular disease. This SNP results in a substitution of histidine-72 
with tyrosine that has been speculated to modulate NAD(P)H oxidase enzyme activity by 
affecting its heme binding site thus influencing the amount of superoxide present and 
consequently nitric oxide bioactivity (Guzik 2000). Some groups have found that this 
single nucleotide polymorphism has no effect upon risk of ischaemic heart disease (Li 
1999, Gardemann 1999, Saha 1999). Others have also suggested that the T allele may 
even be protective in terms of less superoxide generation within human blood vessels and 
less development of carotid atherosclerosis in patients with type 2 diabetes mellitus 
(Hayaishi-Okano 2002). Schächinger et al (Schächinger 2001) suggested that the CC but 
not the TT homozygosity was associated with blunted coronary endothelial 
vasodilatation. 
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On the contrary, and in keeping with the findings of our study, the T allele of the 
p22phox gene has been associated with premature coronary artery disease in an 
Australian population (Cai 1999) and with progression of angiographically determined 
atherosclerosis in an American population in a prospective study (Cahilly 2000). These 
observations were more recently corroborated in an Italian population by Nasti and 
colleagues who noted that in 494 Caucasian Italians undergoing diagnostic coronary 
angiography to ascertain the cause of chest pain that the frequency of the mutant T allele 
was significantly higher in the 276 patients with angiographically documented coronary 
artery disease (Nasti 2006). Furthermore this relationship with the T allele was even 
stronger within patients with early onset coronary artery disease (aged < 55 years) (Nasti 
2006). Within a Japanese population the 242T allele has been associated with ischaemic 
cerebrovascular disease (Ito 2000). Additionally the T allele has been shown to be a 
marker of susceptibility to microvascular disease (nephropathy) in patients with type 1 
diabetes mellitus (Hodgkinson 2003). 
 
This is the first report of an association between the 242T allele of CYBA and the large 
artery stiffness as measured non-invasively. Further more we have shown an association 
between the T allele and higher systolic and pulse pressure. A recent previous report by 
Moreno and coworkers found, conversely, that the prevalence of the CC genotype and the 
C allele were significantly higher in hypertensives than in normotensives (Moreno 2006). 
The disparity between these results is possibly explained by the severity of vascular 
disease displayed in our cohort evidenced by prior diagnostic angiography necessitating 
bypass grafting. The strength of our observation finding an association with non invasive   149 
arterial stiffness is in keeping with recent evidence that suggests that differences in 
central aortic pressures and hence large artery stiffness may be a determinant of differing 
clinical outcomes, as documented in the Conduit Artery Function Evaluation sub study of 
the Anglo-Scandinavian Outcomes Trial (ASCOT) investigators (Williams 2006). A 
prospective study combining pulse contour analysis and p22phox genotype would enable 
a definitive observation regarding the importance of this genotype in cardiovascular 
survival and the strength of the observed associations between the T allele and systolic 
and pulse pressure and large artery stiffness. Though the study was performed blind to 
genotype the weakness of this study is in both the small sample size and small numbers 
of homozygotes and the degree of overlap between each of the groups analysed as 
displayed within the scatter points and hence the results should be interpreted with a 
degree of caution.   150 
Chapter 6 Combined analysis of NOS3 G894T and CYBA C242T 
genotypes upon arterial stiffness. 
 
6.0 Summary 
 
This chapter describes the collated analysis of the NOS3 G894T and CYBA C242T 
genotypes upon arterial stiffness. When the favourable and unfavourable genotypes were 
compared an additive effect was observed such that patients homozygous for the 
„deleterious‟ alleles had lower large and arterial compliance values when contrasted with 
the „favourable‟ alleles. 
 
6.1 Introduction 
 
The involvement of the two SNPs examined in chapters‟ 4 and 5 in vascular disease 
combined with the observations that eNOS protein expression and NO release are 
reduced in human atherosclerosis (Oemar 1998) and augmented p22phox expression in 
atherosclerotic human coronary arteries (Azumi 1999) with the severity of atherosclerosis 
correlating with NAD(P)H oxidase subunit mRNA expression (Sorescu 2002) leads to 
the hypothesis that these two genes may interact. Given that both SNPs have been shown 
to have the potential to be functional, the C242T CYBA polymorphism via the alteration 
of the heme binding site (Guzik 2002) and the G894T NOS3 via altered cleavage at the 
cleavage altering NO generation (Tesauro 1999) we hypothesized that the combination of   151 
the deleterious homozygote alleles of both SNPs may result in reduced arterial 
compliance and hence increased arterial stiffness when compared to the favourable 
alleles. 
 
6.2 Methods 
 
6.2.1. Subjects, clinical procedures and statistical evaluation. 
 
The subjects utilised in the analysis of a possible gene gene interaction were those 
detailed in chapters 4 and 5 and documented in detail in section 2.2. Additionally the 
genotyping of both genes was performed utilising polymerase chain reaction and 
restriction digestion for the CYBA C242T SNP and sequencing for the NOS3 G894T 
SNP. A comparison using the Student‟s t-test was carried out between patients 
homozygous for the NOS3T allele and possessing the CYBA 242T allele and patients 
homozygous for the NOS3 G allele and for the CYBA C allele. Thereafter multiple 
regression analysis was performed to identify the variables that independently predicted 
the relationships. 
 
6.3 Results 
 
The combined analysis of NOS3 G894T and CYBA C242T genotypes are detailed in table 
6.1. There was no difference evident in age, BMI, BP or cholesterol parameters between   152 
the two groups. In order to contrast the arterial stiffness between the favourable versus 
the non-favourable genotypes patients homozygous for the NOS3 G allele and 
homozygous for the CYBA C allele were compared with those homozygous for the 
NOS3T allele and possessing the CYBA 242T allele. Hence the numbers analysed are 
small (18 CYBA CC & NOS3 GG and 8 CYBA CT/TT & NOS3 TT) as only patients with 
the „opposite‟ genotype are included in the analysis. The former displayed higher large 
and small artery compliance than the latter group. Patients with the CC/GG genotype had 
a mean C1 of 19.68 ± 1.3 ml/mmHg x10, with patients with the CT+TT/TT genotype a 
mean C1 13.90 ± 1.6 ml/mmHg x10 (p=0.01, Table 6.1, Figure 6.1). Likewise patients 
with the CC/GG genotype had a mean C2 of 5.48 ± 0.63 ml/mmHg x100, with patients 
with the CT+TT/TT genotype a mean C2 of 3.24 ± 0.52 ml/mmHg x100 (p=0.01, Table 
6.1, Figure 6.2). Using multifactor dimensionality reduction to detect epistasis there was 
no evidence of epistasis between the two genotypes analysed using the constructive 
induction algorithm (Ritchie 2001). 
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Table 6.1. Gene gene interaction. Associations between the CYBA C242T and NOS3 
G894T SNPs and cardiovascular phenotypes. 
Variable  Genotype(n)  p value 
  CYBA CC 
NOS3 GG 
(18) 
CYBA CT/TT 
NOS3 TT 
(8) 
CC+GG vs 
CT/TT + TT 
Age(years)  59.44 ± 1.5  60.13 ± 3.3  0.85 
BMI (Kg/m2)  28.79 ± 0.92   29.50 ± 1.00  0.61 
SBP (mmHg)  122.6 ± 4.00  126.8 ± 8.00  0.64 
DBP (mmHg)  69.7 ± 2.5  69.6 ± 4.2  0.98 
PP (mmHg)  52.81 ± 2.1  57.2 ± 4.4  0.39 
HR (beats/min)  60.7 ± 2.9  55.79 ± 2.5  0.21 
C1 (ml/mmHg x10)  19.68 ± 1.3  13.90 ± 1.6  0.01 
C2 (ml/mmHg x100)  5.48 ± 0.63  3.24 ± 0.52  0.01 
CHOL (mmol/l)  4.13 ± 0.15  4.51 ± 0.35  0.34 
logTRIG (mmol/l)  0.17 ± 0.04  0.262 ± 0.06  0.20 
LDL (mmol/l)  2.28 ± 0.14  2.58 ± 0.93  0.33 
HDL (mmol/l)  1.12 ± 0.09  1.04 ± 0.13  0.13 
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Figure 6.1 Combined analysis of the CYBA C242T and NOS3 G894T genotypes and 
large artery compliance.  
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Figure 6.2 Combined analysis of the CYBA C242T and NOS3 G894T genotypes and 
small artery compliance.    155 
6.3.4 Multiple Regression Analysis. 
Multiple regression analysis, examining the possible contribution of age, BMI, SBP, 
DBP, total, ldl cholesterol and triglyceride concentration showed that only the 
large(p=0.02) and small(p=0.05) artery compliance values contributed significantly when 
genotype was assigned as the dependent variable. 
Predictor  Regression 
Coefficient 
Standard Error  t value  p value 
Age (years)  0.014  0.01  1.04  0.32 
BMI (kg/m
2)  0.0004  0.02  0.02  0.99 
SBP (mmHg)  0.002  0.01  0.16  0.87 
DBP (mmHg)  -0.02  0.02  1.18  0.26 
C1 (ml/mmHg 
x10) 
-0.04  0.02  2.65  0.02 
C2 (ml/mmHg 
x 100) 
-0.07  0.03  2.14  0.05 
Chol mmol/l  -0.06  0.25  0.23  0.82 
LDL mmol/l  0.34  0.26  1.33  0.20 
Log Trig 
mmol/l 
0.19  0.51  0.36  0.72 
Table 6.2: Multiple regression analysis of vascular phenotypes with combined NOS3 
G894T - CYBA C242T  genotype as the dependent variable. 
R
2= 61.9%, adjusted R
2= 69.2%, p=0.03 for the entire study group.   156 
6.4 Discussion 
 
This chapter outlines the potentially additive effects of two common allelic variants 
within oxidative stress genes that potentially modulate the action of the gene products 
and are both implicated in the pathogenesis of vascular disease.  
 
Other groups have also attempted to look at the association of cardiovascular phenotypes 
with combinations of allelic variants. A large meta analysis was undertaken by Zintzaras 
et al (Zintzaras 2006) looking at the meta analysis of all the available studies relating the 
G894T, eNOS VNTR 4 b/a, -786T/C and G23T polymorphisms and their associations 
with hypertension. They preformed cumulative and recursive cumulative meta analyses 
which supported an association between hypertension and the eNOS VNTR 4 b/a 
polymorphism such that under a recessive model the allele b provided evidence of 
protection, especially when the analysis was confined to whites. Notably they found no 
detectable influence of the G894T, -786T/C nor G23T polymorphisms (Zintzaras 2006). 
A sib-pair study analysis and haplotype study was carried out by Persu and co workers 
who examined for linkage and association of the three commonly reported di allelelic 
polymorphisms (G894T, -786T/C, eNOS VNTR 4 b/a) and the intron 13 CA-repeat of 
NOS3 with blood pressure as a continuous trait (Persu 2005). The NOS3 haplotypes 
which associated with ambulatory blood pressure recordings all harboured the 894T 
allele (Persu 2005).  
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Other studies looking to ascertain the influence of combinations of allelic variants have 
been Casas et al (Casas 2004) have previously reported that individuals homozygous for 
the NOS3 894T and the NOS3 intron-4a allele are at increased risk of ischemic heart 
disease (Casas 2004). Further more a gene-gene interaction has also been documented 
between another NOS3 SNP (-786T/C) and the angiotensin converting enzyme gene 
insertion/deletion polymorphism in patients with early coronary artery disease (Álvarez).  
 
Sampians et al (Sampians 2007) investigated the relationship with the three commonly 
reported di allelelic polymorphisms (G894T, -786T/C, eNOS VNTR 4 b/a) and 
endothelial dysfunction in a population of 128 patients with an acute myocardial 
infarction aged less than 40. They found that a NOS3 -786TT/894 GT haplotype was 
associated with increased flow mediated dilatation than the other haplotypes. 
 
The observed interaction between the SNPs studied in this study and arterial compliance 
is the first to concentrate on a non invasive cardiovascular phenotype. It is the first study 
additionally to attempt to combine the effect of the CYBA C242T SNP with the NOS3 
G894T SNP. Chapter 4 describes that the 894T allele of the NOS3 gene is associated with 
attenuated small artery compliance and chapter 5 that the 242T allele of the CYBA gene is 
associated with high large artery stiffness. When the 2 alleles coincide the negative effect 
could be further potentiated. The limitations are naturally the small number of patients 
that were involved in the analysis as well as that the subjects are drawn from a single 
geographic are and all have established vascular disease. The fact that both genes are 
involved in ROS generation and implicated, as described, in the pathophysiology of   158 
atherosclerotic vascular disease lends further weight to the potential usefulness of PWA 
as an intermediate phenotype for cardiovascular clinical functional genomics.   159 
Chapter 7 Chronic low grade inflammation and insulin resistance and 
arterial compliance in healthy volunteers. 
 
7.0 Summary 
 
This clinical study was designed to ascertain whether, in healthy individuals free of 
vascular disease, markers of chronic low grade inflammation and insulin resistance were 
associated with arterial compliance. Fifty three healthy volunteers attended the clinical 
research unit to have a non invasive vascular profile performed and serum taken for 
biochemical analysis. In multiple regression analysis there was an association between 
vascular compliance and some, but not all markers of low grade chronic inflammation 
and insulin resistance. 
 
7.1 Introduction 
 
The advent of both non invasive vascular and biochemical surrogate markers for 
cardiovascular disease has provided intermediate phenotypes that may guide the clinician 
in treatment and risk stratification before established vascular disease is present (Davies 
2003, Oliver 2003, McVeigh 2003, Cohn 2004).  Cardiovascular disease is complicit with 
alterations in the structure, properties, and function of wall and endothelial components 
of blood vessels (Gibbons 1994). This study examines biochemical compounds which are 
either markers of, or pathophysiologically involved in, the genesis of vascular disease and   160 
compares them to the non-invasively obtained large and small artery compliance values 
and augmentation index. Plasma levels of CRP are strong independent predictors of 
atherosclerotic events in apparently healthy individuals (Ridker 1997, Ridker 1998). Its 
association with aortic and brachial PWV and augmentation index has been examined 
previously (Yasmin 2004, Kampus 2004). IL-6 plasma levels within the highest quartile 
of the „normal‟ range have been associated with future cardiovascular events (Harris 
1999, Ridker 1999). Lower levels of Adiponectin are associated with insulin resistance, 
type 2 diabetes mellitus, hypertension and ischaemic heart disease (Matsuzawa 2004, 
Mallamaci 2002, Kumada 2003). There has also been an association of levels of 
Adiponectin with endothelial function (Lawlor 2005). Increasing levels of ICAM1 are 
associated with dyslipidaemia, hypertension and ischaemic heart disease (Hackman 1996, 
Chae 2001, Ridker 1998). Changes in the pulse pressure wave shape have been described 
in all these entities both in terms of AIx and small and large compliance values 
(Wilkinson 2000, Wilkinson 2002, Cohn 1995, McVeigh 1999). As with each marker 
studied statistical strength does not imply causality as confounding factors or reverse 
causality offer alternative explanations for the association (Schunkert 2008). An 
association thus between arterial stiffness and these biochemical markers would perhaps 
strengthen their relative associations with vascular disease and putatively add to their 
potential role in risk stratification. 
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7.2 Methods 
 
7.2.1 Subjects 
 
Fifty three healthy normotensive volunteers were recruited via advertisements within 
Glasgow University and local newspapers. This clinical study was approved by the Ethics 
Committee of the West Glasgow University NHS trust. No subjects were taking any 
medication and all abstained from alcohol, nicotine, tobacco, food and strenuous activity 
overnight before the study day. All subjects attended fasted in the morning between 7.00 
and 9.00 am depending on availability. Physical health was confirmed by screening with 
history, a full physical examination, ECG and supine blood pressure measurement in 
triplicate (Dinamap Critikon, Johnson and Johnson Professional Products Ltd.). Ninety 
volunteers were screened and those with raised blood pressure, an antecedent history of 
vascular disease or an abnormal ECG excluded. Of the 53 patients recruited the mean age 
was 52.74 years (range 37-72) years. Mean systolic blood pressure was 125 ±13 mmHg 
and diastolic blood pressure 72 ± 8 mmHg. The mean BMI was 26.14 ± 3.34 kg/m
2 and 
total cholesterol 4.75 ± 0.78 mmol/l. 4 subjects were smokers and 12 were ex smokers 
with more than 6 months since their last cigarette. Of the ex smokers 8 had more than a 
10 pack year history. Table 3.3 details the baseline characteristics of the healthy 
volunteers.    162 
7.2.2 Clinical Procedures 
 
Following screening morphometric parameters were taken as detailed in section 2.3. 
Thereafter 60 minutes supine rest was taken before vascular phenotyping and then blood 
obtained for quantification of IL-6, Adiponectin, sICAM-1 and highly sensitive CRP. 
Small and large artery compliance values were obtained using a calibrated, proprietary 
tonometer (model CR 2000 Hypertension Diagnostics Inc) and used according to 
manufacturers specifications. Similarly Augmentation Index was measured using the The 
SphygmoCor system (PWV Medical). A full description of these techniques is detailed in 
section 2.3.1 and 2.3.2. IL-6, CRP, Adiponectin and sICAM1 were measured using the 
techniques detailed in 2.5.  
 
7.2.3 Statistical Evaluation. 
 
The package used for analysis was Minitab for Windows (Minitab Inc). P value of <0.05 
was considered significant. 
 
Using the Kolmogorov Smirnov test for normality with the Dallal and Wilkinson 
approximation to Lilliefors' method the data sets for sICAM-1 and adiponectin were 
normally distributed whereas those for IL-6 and CRP were not. For data that did not 
follow the Gaussian distribution, for statistical analysis, the data set was log transformed 
to create a normal distribution.   163 
 
Simple regression was used to create a model with only one predictor utilizing the least 
squares estimation. Where the data was normally distributed the Pearson correlation was 
used (sICAM-1 and Adiponectin). Where the data did not fit a Gaussian distribution 
Spearman Rank correlation was used, i.e. for CRP and IL-6. Thereafter multiple 
regression was used to describe the statistical relationship between a response and 2 or 
more predictors. Again this used the method of least squares, which determines the 
equation for the straight line that minimizes the sum of the vertical distances between the 
data points and the line. Augmentation Index has been shown to vary with heart rate 
(Wilkinson 2002b) hence AIx was corrected for a mean heart rate of 75. 
 
7.3 Results  
 
In the fifty three volunteers without vascular disease the procedures were completed 
without complication and were well tolerated.  
 
7.3.1 Arterial stiffness.  
 
The mean Large artery compliance value (C1) in this group was 15.20 ± 4.14 ml/mmHg 
x 10. The mean small artery compliance (C2) was 6.74 ml/mmHg x 100. This is 
comparable to previous work undertaken using this technique (McVeigh2001). Similarly   164 
the mean augmentation index measurement of 23.85 ± 11.26 % was akin to 
measurements obtained by other groups (Kampus 2004).  
7.3.2 Interleukin 6. 
 
IL-6 was measured with a commercial assay kit (Quantikine human
 IL-6, R and D 
System).The mean IL 6 level in this group was 3.49 ± 6.2 pg/ml. While in the normal 
range for this assay (1-10 pg/ml) our results are slightly higher than those from Chae et al 
from the United States who observed correlations across quartiles of systolic blood 
pressure of less than 3pg/ml although exact means are not detailed in their publication 
(Chae 2001).    165 
 
Table 7.1 Linear Correlation of IL6 Using Spearman Rank Correlation 
 
Parameter  Spearman r  95% CI  p value 
Age(years)  0.343  0.072 to 0.567  0.011 
Height(m)  -0.076  -0.347 to 0.206  0.588 
Weight(kg)  -0.003  -0.280 to 0.276  0.986 
BMI  0.035  -0.245 to 0.310  0.802 
Smoking Status  0.011  -0.268 to 0.288  0.939 
SBP(mmHg)  0.356  0.0860 to 0.576  0.009 
DBP(mmHg)  0.258  -0.021 to 0.500  0.062 
PP(mmHg)  0.366  0.0979 to 0.584  0.007 
HR  0.177  -0.107 to 0.433  0.206 
C1(ml/mmHgx10)  -0.325  -0.557 to -0.045  0.020 
C2(ml/mmHgx100)  -0.527  -0.705 to -0.286  < 0.0001 
AIx(%)  0.361  0.093 to 0.581  0.008 
AIx(%)/HR75  0.429  0.172 to 0.632  0.001 
CHOL(mmol/l)  -0.201  -0.453 to 0.082  0.150 
Log TRIG(mmol/l)  -0.036  -0.311 to 0.245  0.799 
LDLChol(mmol/l)  -0.201  -0.454 to 0.081  0.148 
HDL(mmol/l)  -0.134  -0.397 to 0.149  0.338 
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The spearman rank associations are detailed in table 7.2. We found in our group a 
significant correlation with age (p=0.011) as has been found previously (Bermudez 
2002). Spearman rank correlation with only IL 6 levels as the predictor also showed that 
IL 6 was correlated positively with AIx (p=0.008). When AIx was adjusted for heart rate 
the relationship persisted (p=0.001). Higher levels of IL6 within the normal range were 
therefore associated with increased arterial stiffness. Akin to this was the finding that 
higher levels of IL 6 were associated with lower levels of arterial compliance, i.e. stiffer 
arteries with a significant correlation for both C1 (p=0.02) and C2 (p=<0.001). 
Associations were also seen with both SBP (p=0.009) and PP (p=0.007) but not DBP. 
 
7.3.3 Multiple regression analysis: IL 6 in healthy volunteers. 
 
Multiple regression analysis with C1 as the dependent variable showed significant 
associations for height, BMI, smoking and systolic blood pressure but not IL-6 (table 
7.3). The „good of the fit‟ for this multiple regression analysis was a R
2 of 61.5%, and 
highly significant with p value <0.001. Incorporating pulse pressure into any of the 
analysis generated, as would be expected, redundant information. Table 7.4 shows that 
when C2 was taken as the dependent variable only log normalized IL 6 remained 
significant (p=0.05). Therefore even in healthy individuals where vascular disease is not 
apparent small artery compliance is associated with mediators of low grade chronic 
inflammation. With augmentation index corrected for heart rate of 75 age and systolic 
blood pressure were significant but not IL 6 (table 7.5) 
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Table 7.2 Results for the multiple regression analysis of IL 6 with Large Artery 
Compliance as the dependent variable. 
Predictor  Regression 
Coefficient 
Standard Error  tvalue  p value 
Age (years)  0.07  0.05  1.35  0.18 
Gender  -0.70  1.15  -0.60  0.55 
Height (m)  0.22  0.06  3.71  0.001 
BMI (kg/m
2)  0.22  0.12  1.88  0.07 
Smoking  -1.92  0.60  -3.18  0.003 
SBP  -0.18  0.03  -5.73  0.000 
Log IL6  -1.15  0.87  -1.31  0.20 
 
R
2= 66.9%, adjusted R
2= 61.5%, p=0.000 for the entire study group (n=53).  
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Table 7.3 Results for the multiple regression analysis of IL 6 with Small Artery 
Compliance as the dependent variable. 
 
Predictor  Regression 
Coefficient 
Standard Error  tvalue  p value 
Age (years)  -0.03  0.04  -0.58  0.57 
Gender  -0.79  1.05  -0.76  0.45 
Height (m)  0.04  0.05  0.83  0.41 
BMI (kg/m
2)  0.14  0.10  0.39  0.17 
Smoking  -0.23  0.53  -0.43  0.67 
SBP  -0.07  0.05  -1.47  0.15 
DBP  -0.08  0.07  -1.04  0.31 
Log IL6  -1.59  0.77  -2.05  0.05 
R
2= 51.0%, adjusted R
2= 41.7%, p=0.000 for the entire study group (n=53).  
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Table 7.4 Results for the multiple regression analysis of IL 6 with Augmentation 
Index as the dependent variable. 
 
Predictor  Regression 
Coefficient 
Standard Error  t value  p value 
Age (years)  0.34  0.17  2.07  0.04 
Gender  3.48  3.92  0.89  0.38 
Height (m)  -0.34  0.19  -1.76  0.09 
BMI (kg/m
2)  -0.19  0.40  -0.48  0.64 
Smoking  1.66  2.05  0.81  0.42 
SBP  0.30  0.11  2.81  0.01 
Log IL6  3.35  3.00  1.12  0.27 
R
2= 49.5%, adjusted R
2= 41.7%, p=0.000 for the entire study group (n=53).  
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7.3.4 CRP in healthy volunteers 
 
CRP was measured using a sensitive double-antibody sandwich ELISA with rabbit anti-
human CRP and peroxidase-conjugated rabbit anti-human CRP. The assay was linear up 
to 5 mg/l and logarithmic thereafter. The inter- and intra-assay coefficients of variation 
were <10% across the range of measured results. Intra-assay coefficients of variation 
were <7% for all analytes. Mean CRP levels in this group were 2.11 ± 7.06 mg/L. The 
mean levels are lower than those in a recent similar study where mean level of 4.0 ± 5.6 
were found (Yasmin 2004). 
 
Linear correlations of hsCRP are displayed in table 7.6. As the data did not follow 
Gaussian distribution Spearman Rank correlations were used and thereafter for further 
analysis the data was log transformed. As with previous work we found that highly 
sensitive CRP correlated with BMI and hence weight. Moreover in accordance with 
Abramson et al we found that CRP correlated with pulse pressure (Abramson 2002). 
There was a trend, but not statistically significant, between small artery compliance and 
hs CRP (p=0.097). Additionally CRP correlated with HDL (p=0.005). 
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Table 7.5 Linear Correlation: hsCRP Using Spearman Rank Correlation 
 
Parameter  Spearman r  95% CI  p value 
Age(years)  0.199  -0.084 to 0.452  0.154 
Height(m)  -0.018  -0.295 to 0.261  0.897 
Weight(kg)  0.397  0.133 to 0.608  0.003 
BMI  0.521  0.284 to 0.698  < 0.0001 
Smoking Status  0.159  -0.124 to 0.419  0.254 
SBP(mmHg)  0.242  -0.038 to 0.487  0.081 
DBP(mmHg)  0.117  -0.166 to 0.383  0.403 
PP(mmHg)  0.292  0.015 to 0.527  0.034 
HR   0.018  -0.262 to 0.294  0.900 
C1(ml/mmHgx10)  -0.165  -0.429 to 0.124  0.246 
C2(ml/mmHgx100)  -0.235  -0.486 to 0.052  0.097 
AIx(%)  0.181  -0.103 to 0.437  0.196 
Aix(%)/HR75  0.184  -0.099 to 0.439  0.188 
CHOL(mmol/l)  0.066  -0.216 to 0.337  0.641 
Log TRIG(mmol/l)  0.202  -0.080 to 0.455  0.146 
LDLChol(mmol/l)  0.159  -0.125 to 0.418  0.256 
HDL(mmol/l)  -0.378  -0.594 to -0.112  0.005 
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7.3.5 Multiple Regression Analysis: CRP  
 
In multiple regression analysis with C1 as the dependent variable (table 7.7, adjusted R
2= 
48.2, p=0.000) correlated with gender (p=<0.01), BMI (p=0.05) and SBP (p=0.004). 
Though a tendency existed with log normalized CRP it did not reach clinical significance. 
Where the dependent variable was C2 (table 7.8, adjusted R
2=39.8%, p=0.000) a 
significant correlation existed with gender (p=0.03), BMI (p=0.02), and log CRP 
(p=0.02). Table 7.9 shows multiple regression analysis with AIx corrected for heart rate 
as the dependent variable (adjusted R
2= 44%, p=0.000). Age (p=0.007), Gender (0.000) 
and DBP (p=0.01) but not log CRP ( 0.43) were significant correlates. The lack of 
association between CRP and Aix mirrors that of Yasmin  et al (Yasmin 2004) but is at 
odds with the work of Kampus and co workers ( Kampus 2003). Given that the same 
technology was utilized in each study technical differences are unlikely to explain the 
different findings. That C2 and AIx are not analogous is further strengthened by the 
disparity in the associations described. 
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Table 7.6 Multiple Regression Analysis of log CRP in healthy volunteers with large 
artery compliance as the dependent variable.  
Predictor  Regression 
Coefficient 
Standard Error  tvalue  p value 
Age (years)  -0.03  0.05  -0.51  0.61 
Gender  -3.95  0.974  -4.17  0.00 
BMI (kg/m
2)  0.31  0.15  2.02  0.05 
Smoking  -1.29  0.70  -1.86  0.07 
SBP  -0.18  0.06  -3.02  0.004 
DBP  0.04  0.10  0.45  0.65 
Chol mmol/l  0.13  0.55  0.23  0.82 
HDL mmol/l  0.62  1.66  0.37  0.71 
Log CRP   -2.38  1.27  -1.87  0.07 
R
2= 57.6%, adjusted R
2= 48.2%, p=0.000 for the entire study group (n=53).  
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Table 7.7 Multiple Regression Analysis of log CRP in healthy volunteers with small 
artery compliance as the dependent variable.  
 
Predictor  Regression 
Coefficient 
Standard Error  tvalue  p value 
Age (years)  -0.06  0.04  -1.44  0.16 
Gender  -1.67  0.73  -2.29  0.03 
BMI (kg/m
2)  0.28  0.12  2.34  0.02 
Smoking  0.003  0.53  0.01  0.99 
SBP  -0.07  0.05  -1.43  0.16 
DBP  -0.08  0.08  -1.07  0.29 
Cholesterol  0.12  0.42  0.27  0.79 
HDL mmol/l  1.30  1.27  1.02  0.31 
Log CRP  -1.93  0.97  -1.98  0.05 
R
2= 50.7%, adjusted R
2= 39.8%, p=0.000 for the entire study group (n=53).  
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Table 7.8 Multiple Regression Analysis of log CRP in healthy volunteers with 
Augmentation Index as the dependent variable.  
 
Predictor  Regression 
Coefficient 
Standard Error  tvalue  p value 
Age (years)  0.43  0.15  2.82  0.007 
Gender  10.54  2.69  3.93  0.000 
BMI (kg/m
2)  -0.28  0.44  -0.64  0.53 
Smoking  0.50  1.99  0.25  0.80 
SBP mmHg  -0.09  0.17  -0.54  0.60 
DBP mmHg  0.72  0.28  2.56  0.01 
Chol mmol/l  -1.49  1.59  -0.94  0.35 
HDL mmol/l  -5.55  4.78  -1.16  0.25 
Log CRP  2.95  3.67  0.80  0.43 
R
2= 53.7%, adjusted R
2= 44.0%, p=0.000 for the entire study group (n=53).  
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7.3.6 ICAM in healthy volunteers 
 
sICAM-1 was measured, as described in section 2.5 by ELISA. The mean level was 
298.25 ± 84.82 which is comparable with levels found elsewhere in the literature (Chae 
2001). Simple linear regression, as detailed in table 7.10 highlighted positive correlations 
with age (p=0.01), weight (p=0.04), BMI (p=0.02), smoking status (p=0.004), HDL 
(p=0.01). A positive correlation was seen for augmentation index when corrected for 
heart rate (p=0.006) and a negative relationship was seen between ICAM and small artery 
compliance (p=0.05). No relationship was seen with large artery compliance however (p= 
0.112). 
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Table 7.9 ICAM and Vascular Parameters: Simple Linear Regression 
 
Parameter  Pearson r  95% CI  r
2  p value 
Age(years)  0.335  0.071 to 0.555  0.112  0.014 
Height(m)  0.090  -0.185 to 0.352  0.008  0.521 
Weight(kg)  0.290  0.021 to 0.520  0.084  0.035 
BMI  0.328  0.064 to 0.550  0.108  0.016 
Smoking Status  0.385  0.128 to 0.594  0.148  0.004 
SBP(mmHg)  0.228  -0.045 to 0.469  0.052  0.101 
DBP(mmHg)  0.182  -0.0926 to 0.431  0.033  0.191 
PP(mmHg)  0.194  -0.0811 to 0.441  0.038  0.165 
HR   0.192  -0.0830 to 0.439  0.037  0.169 
C1(ml/mmHgx10)  -0.225  -0.472 to 0.054  0.051  0.112 
C2(ml/mmHgx100)  -0.278  -0.515 to -0.003  0.077  0.048 
AIx(%)  0.279  0.010 to 0.511  0.078  0.043 
AIx(%)/HR75  0.376  0.117 to 0.586  0.141  0.006 
CHOL(mmol/l)  -0.120  -0.378 to 0.155  0.015  0.391 
Log TRIG(mmol/l)  -0.027  -0.295 to 0.245  0.001  0.849 
LDLChol(mmol/l)  0.023  -0.249 to 0.292  0.001  0.870 
HDL(mmol/l)  -0.352  -0.568 to -0.090  0.124  0.010 
r
2 = Coefficient of determination 
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7.3.7 Multiple regression analysis: ICAM  
 
Multiple regression analysis with large artery compliance as the dependent variable 
confirmed the lack of association between large artery compliance (p=0.07) and ICAM in 
our study population (table 7.11, adjusted R
2=31.6%, p=0.001). Only weight was 
significant in this analysis (p=0.00). The significant associations seen within simple 
linear analysis with small artery compliance and augmentation index were corroborated 
with multiple regression analysis.  With small artery compliance as the dependent 
parameter only ICAM remained a significant correlate (p=0.05) (table 7.12 adjusted R
2 
20.9%, p=0.01). No other significant correlates were observed. With augmentation index, 
multiple regression analysis (table 7.13 adjusted R
2 38.9%, p=0.000) correlates were seen 
no only with ICAM (p=0.01) but also with age (p=0.01) and weight (p=0.001). The 
finding that the intracellular adhesion molecule ICAM, a cellular mediator of 
inflammation with a role in atherogenesis is associated with arterial stiffness is a novel 
finding. It didn‟t matter whether either SPCA or DPCA was used. These results would 
certainly be in keeping with those of Ridker (Ridker 1998) who found that plasma 
concentrations of ICAM was associated with risks of future myocardial infarction in 
apparently healthy men.  
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Table 7.10 Multiple Regression Analysis of ICAM in healthy volunteers with Large 
Artery Compliance as the dependent variable.  
Predictor  Regression 
Coefficient 
Standard Error  tvalue  p value 
Age (years)  -0.02  0.06  -0.30  0.76 
Weight (kg)  0.25  0.06  4.35  0.00 
BMI (kg/m
2)  -0.37  0.23  -1.60  0.12 
Smoking  -0.89  0.85  -1.05  0.30 
ICAM (ng/ml)  -0.01  0.01  -1.87  0.07 
HDL (mmol/l)  1.18  1.90  0.62  0.54 
R
2= 39.8%, adjusted R
2= 31.6%, p=0.001 for the entire study group (n=53) 
 
 
 
 
 
 
 
 
   180 
Table 7.11 Multiple Regression Analysis of ICAM in healthy volunteers with Small 
Artery Compliance as the dependent variable.  
Predictor  Regression 
Coefficient 
Standard Error  tvalue  p value 
Age (years)  -0.09  0.05  -1.87  0.07 
Weight (kg)  0.08  0.04  1.87  0.07 
BMI (kg/m
2)  0.06  0.18  0.31  0.76 
Smoking  0.45  0.65  0.70  0.49 
ICAM (ng/ml)  -0.01  0.01  -1.99  0.05 
HDL (mmol/l)  1.47  1.45  1.01  0.32 
R
2= 30.4% adjusted R
2= 20.9% p=0.01 for the entire study group (n=53) 
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Table 7.12 Multiple Regression Analysis of ICAM in healthy volunteers with 
Augmentation Index(%) as the dependent variable.  
Predictor  Regression 
Coefficient 
Standard Error  tvalue  p value 
Age (years)  0.42  0.15  2.79  0.01 
Weight (kg)  -0.50  0.14  -3.57  0.001 
BMI (kg/m
2)  0.74  0.58  1.29  0.20 
Smoking  -1.09  2.19  -0.50  0.62 
ICAM (ng/ml)  0.05  0.02  2.71  0.01 
HDL (mmol/l)  -3.81  4.97  -0.77  0.45 
R
2= 45.9% adjusted R
2= 38.9 % p=0.000 for the entire study group (n=53) 
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7.3.8 Adiponectin in healthy volunteers 
 
Adiponectin measurements were quantified using commercially available ELISA (R&D 
Systems, Minneapolis, MN, USA). The mean levels were 6234 ± 4824.2 ng/ml – 
comparable with the work of others (Lawlor 2005). The data were normally distributed so 
simple linear regression was performed. As table 7.14 show adiponectin was positively 
correlated with sex (p=0.002), SBP (p=0.04), DBP (p=0.04), HDL (p=0.05) as well as 
augmentation index corrected for heart rate. Inverse correlations were observed with 
height (p=0.02), weight (p=0.0001), BMI (p=0.02) and large artery compliance (p=0.02).    183 
 
Table 7.13 Adiponectin and Vascular Parameters: Simple Linear Regression 
 
Parameter  Pearson r  95% CI  r
2  p value 
Age(years)  0.138  -0.138 to 0.393  0.019  0.325 
Height(m)  -0.329  -0.550 to -0.064  0.108  0.016 
Weight(kg)  -0.440  -0.635 to -0.193  0.194  0.001 
BMI  -0.314  -0.539 to -0.048  0.099  0.022 
Smoking Status  -0.051  -0.317 to 0.223  0.003  0.717 
SBP(mmHg)  0.279  0.009 to 0.511  0.078  0.043 
DBP(mmHg)  0.283  0.014 to 0.514  0.080  0.040 
PP(mmHg)  0.176  -0.099 to 0.426  0.031  0.208 
HR   0.085  -0.190 to 0.347  0.007  0.547 
C1(ml/mmHgx10)  -0.325  -0.551 to -0.054  0.106  0.020 
C2(ml/mmHgx100)  -0.269  -0.507 to 0.007  0.073  0.056 
AIx(%)  0.427  0.178 to 0.626  0.183  0.001 
AIx(%)/HR75  0.434  0.186 to 0.631  0.189  0.001 
CHOL(mmol/l)  -0.128  -0.385 to 0.147  0.017  0.360 
Log TRIG(mmol/l)  -0.352  -0.569 to -0.091  0.124  0.010 
LDLChol(mmol/l)  -0.131  -0.388 to 0.144  0.017  0.349 
HDL(mmol/l)  0.275  0.005 to 0.508  0.076  0.046 
r
2 = Coefficient of determination   184 
7.3.9 Multiple Regression Analysis. Adiponectin in Healthy Volunteers. 
 
Once more multiple regression analysis was preformed for large artery compliance (table 
7.15, adjusted R
2 55.9%, p = 0.000), small artery compliance (table 7.16, adjusted R
2 
37.3%, p = 0.001) and augmentation index corrected for heart rate (table 7.17, adjusted 
R
2 46.4%%, p = 0.000). No association was documented between either of the non 
invasive pulse contour measurements although correlations were seen with large artery 
compliance and height, SBP and log normalized triglyceride levels; small artery 
compliance and weight; and augmentation index corrected for heart rate and age and 
DBP. Although pulse contour analysis generated arterial stiffness measurements are not 
synonymous with endothelial function both are dependent up on structure and function of 
the arterial wall and hence potentially affected by atherogenesis. The lack of association 
seen in relation to DPCA and SPCA is therefore in keeping with the findings of Singhal 
and colleagues who found that whereas plasma adiponectin levels were associated with 
Insulin resistance they were not with endothelial function in young, healthy adolescents 
(Singhal 2005)  
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Table 7.14 Multiple Regression Analysis of Adiponectin in healthy volunteers with 
Large Artery Compliance as the dependent variable.  
 
Predictor  Regression 
Coefficient 
Standard Error  T value  p value 
Age  0.02  0.05  0.43  0.67 
Gender  -0.87  1.41  -0.62  0.54 
Height  0.15  0.08  2.00  0.05 
Weight  0.07  0.05  1.54  0.13 
SBP  -0.22  0.06  -3.92  0.00 
DBP  0.07  0.09  0.80  0.43 
Log Trig  4.76  2.22  2.14  0.04 
HDL mmol/l  2.03  1.56  1.30  0.20 
Adiponectin(ng/ml)  0.0001374  0.0001086  1.27  0.21 
R
2= 63.8% adjusted R
2= 55.9 % p=0.000 for the entire study group (n=53) 
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Table 7.15 Multiple Regression Analysis of Adiponectin in healthy volunteers with 
Small Artery Compliance as the dependent variable.  
 
Predictor  Regression 
Coefficient 
Standard Error  T value  p value 
Age  -0.05  0.05  -1.16  0.25 
Gender  -1.18  1.20  -0.98  0.33 
Height  -0.02  0.06  -0.31  0.76 
Weight  0.08  0.04  2.04  0.05 
SBP  -0.09  0.05  -1.92  0.06 
DBP  -0.07  0.08  -0.86  0.40 
Log Trig  -0.09  1.88  -0.05  0.96 
HDL mmol/l  1.37  1.32  1.04  0.30 
Adiponectin(ng/ml)  0.00008  0.00009  0.88  0.38 
R
2= 48.6% adjusted R
2= 37.3 % p=0.001 for the entire study group (n=53) 
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Table 7.16 Multiple Regression Analysis of Adiponectin in healthy volunteers with 
Augmentation Index as the dependent variable.  
 
Predictor  Regression 
Coefficient 
Standard Error  T value  p value 
Age  0.33  0.16  2.11  0.04 
Gender  3.98  4.33  0.92  0.36 
Height  -0.27  0.22  -1.24  0.22 
Weight  -0.04  0.15  -0.29  0.77 
SBP  -0.03  0.17  -0.18  0.86 
DBP  0.58  0.28  2.06  0.05 
Log Trig  -3.02  6.77  -0.45  0.66 
HDL mmol/l  -7.20  4.77  -1.51  0.14 
Adiponectin(ng/ml)  0.0003  0.0003  1.03  0.31 
R
2= 55.7% adjusted R
2= 46.4 % p=0.000 for the entire study group (n=53) 
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7.4 Discussion 
In brief we have described an association between parameters of low grade inflammation 
and vascular compliance in healthy volunteers. Similar analysis was performed in the 
cohort of patients with coronary artery disease but no statistical association was found in 
patients with the established phenotype. By multiple regression analysis there were 
significant associations between small artery compliance and IL-6, high sensitivity CRP 
and sICAM-1. There was also an association between augmentation index and ICAM. 
The importance of these results rests upon firstly what a change in arterial compliance 
may represent and secondly whether there is a link between this and biochemical markers 
of low grade inflammation. In short C2 and augmentation index are both sensitive to 
decreased NO bioactivity, a scenario common to atherosclerotic risk factors and low 
grade chronic inflammation.   
 
Alterations in arterial compliance mirror the functional and structural changes that 
accompany the progression of atherosclerosis, a process that these molecules are either 
risk markers for or indeed themselves culprit vehicles. The relationships that are shown 
further lend utility to pulse contour analysis as a useful tool for non invasive vascular 
assessment both physiologically and in risk assessment.  
 
The small artery compliance value does not represent a specific arterial bed or anatomical 
localization but reflects function (endothelial NO dependent) and structural changes 
(McVeigh 2001, Cohn 2004). While both are age dependent large artery compliance   189 
reflects structural alterations in the conduit arteries that are accelerated by hypertension 
and atherosclerosis. This parameter has not been found to be sensitive to pharmacological 
manipulation of NO (McVeigh 2001). Augmentation index has also been found to be 
sensitive to inhibition of NO synthase with L-NMMA (Wilkinson 2002) but that C2 is 
not analogous to Aix is sufficient to explain why the correlations between C2 and CRP, 
IL6 and ICAM were significant but only an association existed only between ICAM and 
AIx. In studies comparing the two AIx and C2 were related  in part but not completely 
related to small artery compliance (r
 = -0.487, Rietzschel 2001, r= -0.36, Segers 2001). 
 
Inflammation constitutes an important role within the development of atherosclerosis 
(Ross 1996, Libby 2002). The series of ensuing events involves recruitment of leukocytes 
to the arterial wall promoting development of atherosclerotic lesions. The vascular 
endothelium contributes to the inflammatory response by, following activation by 
proinflammatory cytokines or „classical cardiovascular risk factors, expressing leukocyte 
adhesion molecules which themselves promote adhesion of monocytes and T 
lymphocytes to the endothelial surface (Libby 2002, Widlansky 2003). The phenotypic 
changes in the endothelium induced by cardiovascular disease risk factors, cytokines and 
inflammatory markers including CRP, IL-6 and sICAM-1 in turn promotes a decrease in 
the production and/or biological activity of NO (Widlansky 2003,Verma 2002). 
Decreased NO activity promotes leukocyte adhesion, thrombosis, vasoconstriction and 
cellular proliferation; the principal components of atherogenesis (Vita 2002). CRP 
decreases expression of eNOS and NO synthesis in part by reducing the half life of eNOS 
(Verma 2002) and has been demonstrated to decrease eNOS expression and bioactivity in   190 
human aortic endothelial cells (Venugopal 2002). These observed effects may also 
account form the relationship between IL-6 and small artery compliance as IL 6 is a 
potent stimulus for hepatic CRP production (Pearson 2003).  Other vascular phenotypes 
which associate with NO bioactivity have been shown to correlate with low grade 
inflammation. Vita et al (Vita 2004) examined the cross sectional relationship between 
vasodilator function in the forearm (both in terms of brachial artery flow-mediated 
dilatation and reactive hyperaemia) and CRP, IL-6 and sICAM-1 in the Framingham 
Offspring Study. They found that there was an incremental contribution of CRP, IL-6 and 
sICAM-1 to reactive hyperaemia above and beyond traditional risk factors (Vita 2004). 
Other groups have suggested that there is a correlation between CRP and brachial artery 
flow mediated dilatation (Tan 2002, Brevetti 2003) and CRP and coronary circulation 
endothelial dysfunction via the cold pressor test (Tomai 2001). Chapter 4 described how, 
in a group of patients with CAD, small artery compliance was lower in patients 
homozygous for the 894T allele of the NOS3 gene. The T allele has also been found to 
not only increase the risk for premature MI by Antoniades and coworkers (Antoniades 
2005) but also to be associated with a modified response of the vascular endothelium 
during the acute phase of the MI by affecting the release of IL-6. IL- 6 triggers an acute 
phase reaction in the liver, regulating the release of acute phase reactants such as CRP, 
and up regulating the expression of adhesion molecules in endothelial cells and 
depressing NO production by inhibiting eNOS (Cardaropoli 2003). A genome wide 
linkage scan for arterial stiffness was undertaken within 204 families from the 
Framingham Offspring study with tonometry data by Mitchell and colleagues (Mitchell 
2005). They found 4 regions of suggestive linkage for carotid femoral PWV including a   191 
peak on chromosome 7 at 29 cM which includes IL-6. Not only does this implicate 
arterial stiffness as heritable but also that IL-6 may account for a proportion of the 
heritability.  
 
The lack of association between adiponectin and any of the pulse contour analysis 
variables given recent investigations are not surprising. Though the association between 
adiponectin and insulin resistance, diabetes mellitus and hypertension (Stefan 2002, Hotta 
2000, Iwashima 2004) has been clearly established the association with vascular 
phenotypes remains more obtuse.  Adiponectin did not predict endothelial function in 294 
adolescents (Singhal 2005) and most recently high molecular weight Adiponectin was not 
associated with incident coronary heart disease within the British Women‟s Heart and 
Health Study (Sattar 2008).   192 
Chapter 8 General Discussion, Conclusions and Future Work. 
 
The cardiovascular disease epidemic continues to advance and increase both 
geographically to developing countries and numerically such that the projected increase 
in the proportion of all deaths attributable to cardiovascular causes increasing from 
approximately 25% in 1990 to more than 40% by 2020 (Reddy 2004). The „post genome 
era‟ permits the ability to study gene function and gene gene relationships which has been 
critical to the investigation of complex cardiovascular traits. The ultimate clinical 
dividend of this approach will include mechanistic classification of the common cardiac 
phenotypes, diagnostic markers and improved clinical therapy in terms of prevention and 
intervention on the basis of a putative risk assessment based upon an individual's 
cardiovascular risk haplotype (Dominiczak 2005). While others have utilised case-control 
association studies, i.e. the occurrence of a particular allele of a polymorphism in a group 
of subjects more frequently than expected by chance, as a process of the evaluation of 
two candidate genes in cardiovascular disease this project focused upon a non invasive 
cardiovascular phenotype, pulse wave analysis.  
 
The pathogenesis of vascular disease including hypertension, atherosclerosis, type 2 
diabetes mellitus, heart failure and hypercholesterolemia is, at least in part driven by 
oxidative stress (Landmesser 2001, Hamilton 2004). The relation of oxidative stress to 
atherosclerotic vascular disease is one where reactive oxygen species modulate the 
accumulation of sub endothelial LDL particles (Sorescu 2002). The principle reactive 
oxygen species are •O2
-  and NO of which the associated genes CYBA and NOS3 have   193 
been implicated in vascular disease where NO bioactivity is impaired (Hingorani 2000) 
which is associated with a decrease in the compliance of large and small blood vessels.  
 
The objective of this thesis was to investigate the effect of single nucleotide 
polymorphisms of oxidative stress genes and low grade inflammation upon pulse wave 
contour analysis which has emerged as a useful non invasive, intermediate vascular 
phenotype. In this way the continuum from gene to protein to function has been 
paralleled by the examination of genotype, oxidative stress markers and arterial stiffness. 
 
8.1 The reproducibility of diastolic pulse wave contour analysis and its relation to 
systolic pulse contour analysis. 
 
Using Bland Altman plots the calculated intra-observer bias for C1 was -0.1(SD of bias 
was 0.36, 95% CI -0.8 to 0.6) and for C2 the observed bias was -0.04 (SD of bias was 
0.20, 95% CI -0.44 to 0.36). Moreover over 95% of the variability fell within 2 standard 
deviations. Furthermore there was a significant correlation between both AIx and C1and 
AIx and C2 in healthy volunteers and though there was no association between AIx and 
C1 in patients with coronary artery disease AIx did correlate with C2 in this population. 
 
Non invasive measures of assess the arterial pulse, while not a new arterial phenotype 
(Sharpey 1866), is becoming increasingly popular as measures of central aortic pulse 
pressure is recognized as providing additional information beyond that given by 
conventionally measured brachial pulse pressure (Williams 2006). PWV remains pre-  194 
eminent as the current gold standard (Laurent 2006) especially as it has been shown to 
correlate with coronary arterial plaque load (McLeod 2004) and has been shown to be an 
independent predictor of clinical outcome, albeit in high risk patient groups (Blacher 
1999, Blacher 1999, Blacher 2003, Guerin 2001). Systolic and diastolic pulse pressure 
pulse contour analysis also has its advocates. The former also has outcome data 
(Kingwell 2002, London 2001) and the recent Anglo Cardiff Collaborative Trial in 4001 
healthy, normotensive individuals aged 18-90 has not only provided „normal reference 
values‟ but also suggested that while PWV may be a better assessment of arterial stiffness 
in older individuals AIx might be a more sensitive marker of arterial stiffness and risk in 
younger individuals who potentially have more to gain from a biological marker driven 
treatment regimen (McEniery 2005). Moreover endothelial function, characterized by 
impaired NO bioactivity and oxidative stress has, within healthy individuals, been shown 
to be inversely associated with aortic PWV and AIx (McEniery 2006). The correlations 
observed in this thesis between C2 and AIx suggests that this may also be the case with 
the Windkessel derived arterial compliance measurement. Consistent characteristic 
changes in the pulse pressure wave shape have been associated with ageing and disease 
states predisposing to vascular events and application of the four element 3
rd order 
modified Windkessel model has been shown to generate useful information pertaining to 
hypertension and diabetes (C1) (McVeigh 1991, McVeigh 1993) and increasing age, 
coronary artery disease in post menopausal women and diabetes (C2) (McVeigh 1999, 
Cohn 1995, McVeigh 1993). Additionally the consistent and predictable changes found 
with pharmacologically impaired NO bioactivity suggest that C2 may be sensitive to 
conditions underpinned by oxidative stress (McVeigh 2001).   195 
 
8.2 The effect of the G894T SNP of the NOS3 gene upon arterial stiffness in patients 
with coronary artery disease. 
 
There was no association observed between this polymorphism and blood pressure or 
large artery compliance however ANOVA revealed a statistically significant association 
for TT homozygosity and small artery compliance (p=0.01). The highest small artery 
compliance was seen in the patients homozygous for the G allele (5.51 ± 0.51 ml/mmHg 
x 100), an intermediate value observed in heterozygotes  (4.21 ± 0.33 ml/mmHg x 100) 
and the lowest value demonstrated in patients homozygous for the T allele (3.18 ± 
0.38ml/mmHg x 100). Multiple regression analysis, examining the possible contribution 
of age, BMI, SBP, DBP, total and LDL cholesterol showed that only small artery 
compliance was significant when NOS3 G894T genotype was assigned as the dependent 
variable (p=0.01). 
 
Arterial stiffness measures and mean and pulsatile components of blood pressure are 
heritable and appear to have genetic determinants that are postulated to be linked to 
separate genetic loci in humans (Mitchell 2005). Durier  et al investigating the 
physiological genomics of human arteries in an elegant study by examining gene 
expression of human aortic specimens and correlating the results with PWV found 
patterns of expression correlating with arterial stiffness including genes which may 
mediate, in part NO dependent vasodilatation (Durier 2003). The observations therefore 
that a common allelic variation is associated with an arterial stiffness parameter   196 
associated with impaired NO bioactivity is consistent with these previous studies. This 
gene variant has been shown to be associated with survival in patients with heart failure 
(McNamara 2003) and the ultimate determinant of potential clinical utility of our finding 
would be a survival or treatment effect that would modulate clinical decision making in 
terms of risk stratification and treatment. 
 
8.3 The C242T single nucleotide polymorphism of the CYBA gene and blood pressure 
and arterial compliance in patients with coronary artery disease. 
 
We sought to examine the influence of the C242T SNP of CYBA upon vascular 
compliance and blood pressure using the dominant allele model. The presence of the 
242T allele was associated with significantly higher systolic blood pressure. Patients 
homozygous for the C allele had lower systolic blood pressure (125.7 ± 2.3 mmHg) than 
heterozygotes and patients homozygous for the T allele(134.6 ± 2.4 mmHg) (p=0.010). 
There was no statistically significant effect upon diastolic blood pressure but there was 
however a significant association observed between the 242T allele and pulse pressure. 
Patients that were homozygous for the CC allele had a PP of 56 ± 1.6 mmHg where as 
patients heterozygous or homozygous for the T allele had a PP of 62.7 ± 1.8 mmHg (p 
=0.01).  
 
In terms of arterial stiffness the 242T allele was associated with lower large artery 
compliance. CC homozygotes had higher large artery compliance (17.07 ± 0.82   197 
ml/mmHg x10), than heterozygotes and TT homozygotes (13.16 ± 0.53 ml/mmHg x10) ( 
p = < 0.001). No difference was observed between the C242T SNP and small artery 
compliance nor Augmentation Index in our study population. Multiple regression 
analysis, examining the possible contribution of age, BMI, SBP, DBP and total 
cholesterol showed that only large artery compliance was significant when CYBA C242T 
genotype was assigned as the dependent variable (p=0.001). 
 
The p22phox subunit is a common component of all types of NADPH oxidases and is the 
reputed redox centre of the enzyme system. The allelic variant C242T of the enzyme 
system has been demonstrated to affect enzyme activity (Guzik 2000, Wyche 2004) but 
as has been detailed there have been case control candidate gene association studies 
which have provided incongruous results as to which allelic variant is deleterious or 
advantageous (Cai 1999, Cahilly 2000, Nasti 2006, Inoue 1998, Saha 1999, Fan 2006). 
The strength of this thesis is thus in seeking to establish whether a gene function 
relationship is present. The finding that large artery stiffness, associated with 
hypertension (McVeigh 1991), is associated with the 242T allele is in keeping with the 
recent findings of Moreno et al who found a relationship between the C242T 
polymorphism in a case control study (Moreno 2006). They found however, that the CC 
genotype was associated with higher blood pressure levels and also NADPH oxidase 
activity and p22phox expression quantified from phagocytic cells by chemiluminescence 
and by northern and western blots (Moreno 2006). A larger study combining protein 
expression with arterial phenotype is therefore required before the relationship of this 
polymorphism and vascular disease is clearly delineated.   198 
 
8.4 Combined analysis of NOS3 G894T and CYBA C242T genotypes upon arterial 
stiffness. 
 
In order to contrast the arterial stiffness between the favourable versus the non-favourable 
genotypes patients homozygous for the NOS3 G allele and homozygous for the CYBA C 
allele were compared with those homozygous for the NOS3T allele and possessing the 
CYBA 242T allele. The former displayed higher large and small artery compliance than 
the latter group. Patients with the CC/GG genotype had a mean C1 of 19.68 ± 1.3 
ml/mmHg x10, with patients with the CT+TT/TT genotype a mean C1 13.90 ± 1.6 
ml/mmHg x10 (p=0.01). Likewise patients with the CC/GG genotype had a mean C2 of 
5.48 ± 0.63 ml/mmHg x100, with patients with the CT+TT/TT genotype a mean C2 of 
3.24 ± 0.52 ml/mmHg x100 (p=0.01). There was no difference evident in age, BMI, BP 
or cholesterol parameters between the two groups. Multiple regression analysis, 
examining the possible contribution of age, BMI, SBP, DBP, total, ldl cholesterol and 
triglyceride concentration showed that only the large(p=0.02) and small(p=0.05) artery 
compliance values contributed significantly when genotype was assigned as the 
dependent variable. 
 
The interplay of these two enzyme systems may be hypothesized to modulate the 
oxidative milieu within vascular cells and the observed gene gene interaction adds weight 
to this theory. Most previous studies examining combinations of polymorphisms have 
concentrated on one gene such as the meta analysis by Zintzaras and co workers   199 
(Zintzaras 2006). The combination of two genes that are associated with diminished NO 
bioactivity may therefore provide useful information. NO is a potent anti atherogenic 
molecule and endothelial dysfunction has been established as determining all cause 
mortality in coronary heart disease (Schächinger 2000). The interplay of two genes 
which, implicated in the genesis of oxidative stress and associated therefore with 
impaired NO bioactivity and consequently potentially endothelial dysfunction, and an 
observed gene gene interaction is entirely in keeping with prior studies examining 
reactive oxygen species vascular biology. 
 
8.5 Chronic low grade inflammation and insulin resistance and arterial compliance 
in healthy volunteers. 
 
Within healthy volunteers multiple regression analysis showed that small artery 
compliance was significantly associated with IL 6 (p=0.05), CRP (p=0.02) and ICAM 
(p=0.01). Augmentation index showed only an association with ICAM (p=0.01). There 
was no significant correlation between Adiponectin levels and either of the arterial 
stiffness parameters studied. 
 
Inflammation plays a critical role in all stages of atherosclerosis from the nascent lesion 
to the acute coronary syndrome (Libby 2002). There has been considerable interest and 
speculation about the interrelation between vascular inflammation and atherosclerosis 
(Ross 1999). The link with endothelial function and consequently arterial stiffness has 
been explored and CRP, IL-6 and sICAM-1 have previously been shown to associate   200 
with endothelial function (Vita 2004). The observation that Windkessel derived pulse 
contour analysis is also related to these markers of low grade inflammation is hence 
consistent with these observations. Additionally CRP has also been reported to be 
associated with coronary microvascular endothelial function (Teragawa 2004). This 
thesis describes that in patients with CAD, small artery compliance is lower in patients 
homozygous for the 894T allele of the NOS3 gene. The T allele has also been shown to 
modulate the response of the vascular endothelium during the acute phase of the MI by 
affecting the release of IL-6 (Antoniades 2005). IL- 6 triggers an acute phase reaction in 
the liver, regulating the release of acute phase reactants such as CRP, and up regulating 
the expression of adhesion molecules in endothelial cells and depressing NO production 
by inhibiting eNOS (Cardaropoli 2003). Furthermore Mitchell and colleagues utilized 
tonometry within the Framingham Offspring study and discovered 4 regions of 
suggestive linkage for carotid femoral PWV including a peak on chromosome 7 which 
includes IL-6 (Mitchell 2005) This suggests that arterial stiffness may not only be 
heritable but also that IL-6 may account for a proportion of the heritability and also links 
these two non invasive phenotypes. CRP itself has been demonstrated to decrease eNOS 
expression, enzymatic activity and bioactivity within human aortic endothelial cells 
further supporting its role in atherogenesis. The observations in this thesis associating 
arterial stiffness with low grade chronic inflammation are hence in keeping with current 
knowledge and extends the robustness of diastolic pulse contour analysis as a vascular 
phenotype. The lack of association with adiponectin is congruent with that of Iwashima 
and co workers (Iwashima 2004). 
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8.6 Conclusions 
a) Diastolic pulse wave contour analysis is a reproducible assessment of arterial stiffness 
with the potential to represent a high fidelity non invasive vascular phenotype. 
 
b) Small artery compliance is correlated with Augmentation Index and although the 
measurements are not analogous they both represent useful means of acquiring 
quantitative data concerning arterial stiffness. 
 
c) The 242T allele of the p22phox gene, CYBA, is associated with decreased large but not 
small artery compliance and increased systolic and pulse pressure. 
 
d) Homozygosity for a common NOS3 polymorphism (894 G T) was associated with 
decreased small artery compliance but not with large artery compliance or blood 
pressure. 
 
e) The markers of chronic inflammation Interleukin 6, ICAM and hsCRP but not 
Adiponectin, a marker of Insulin resistance, predict small artery compliance in healthy 
individuals apparently free of vascular disease. 
 
8.7 Future work 
 
There are several important considerations which relate to future investigations regarding 
the relation of genotype and phenotype in cardiovascular disease. Firstly the sample size   202 
required must be sufficient to detect small genetic effects and gene-gene and gene-
environment interactions. Secondly standardized high-fidelity phenotyping methods are 
required and in terms of the applicability of pulse wave analysis the current gold standard 
remains carotid femoral pulse wave velocity (Laurent 2006). Thirdly the use of proteomic 
markers to link the gene function relationship would add weight to conclusions. 
 
In terms of diastolic pulse waveform analysis the next step in assessing the clinical utility 
of this technology is to ascertain whether it represents an independent predictor of 
clinical outcome much in the way that has been established with pulse wave velocity 
(Blacher 1999, Blacher 1999, Blacher 2003, Guerin 2001) and Augmentation Index 
(Kingwell 2002, London 2001). Only then would small and large artery compliance 
values form comparable clinical parameters alongside other measurements of arterial 
stiffness or markers of low grade chronic inflammation such as CRP which although 
popular have also not always generated encouraging results (Danesh 2004). 
 
This thesis describes what is in essence a small gene function candidate gene study and 
the clinical relevance of the C242T CYBA and G894T NOS3 SNPs will only be fully 
clarified when an appropriately powered study allowing inclusion of other potentially 
involved loci to form a full haplotype analysis. As stated there have been discrepant case 
control association studies which such a study would provide a definitive answer to. The 
completion of the Human Genome Project in 2003 has conferred upon researchers the 
ability to find the genetic contributions to human disease phenotypes for genetic 
variations that contribute to their onset. Such a genome wide association study would   203 
hence allow definitive associations with vascular phenotypes and genetic variation 
including pulse wave analysis and biochemical markers associated with vascular disease. 
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